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 Abstract 
Inorganic polyphosphate (polyP) is a linear chain of three to around one thousand orthophosphates 
linked by phosphoanhydride bonds. Not only is polyP considered as a “molecular fossil” that 
existed on the primordial earth, but it is also universally found in all living species tested so far. 
Yet, unlike many other conserved molecules in biology, the pathways by which polyP is 
metabolized are not conserved, and the polyP synthesizing and degrading machineries in 
mammalian cells are still completely unknown. This lack in knowledge substantially hampers 
progress in polyP research since it renders reverse genetics powerless in deciphering the 
physiological functions of polyP in these species. Moreover, it raises two very important questions 
in the field: 1) why did evolution give rise to vastly different mechanisms to generate such a 
conserved molecule, and 2) what are the roles of this ancient polymer in modern species and time? 
In my thesis work, I used a multipronged approach to address these questions. First of all, I detected 
an enrichment of polyP in the nucleolus of HeLa cells using an immunofluorescence probe derived 
from the polyP-binding domain of Escherichia coli exopolyphosphatase. This fraction of polyP is 
highly dynamic to environmental stress – it rapidly accumulates and relocates to distinct foci in 
the nucleolus during cisplatin-mediated apoptosis. The extent of polyP accumulation in such foci 
positively correlates with the intrinsic susceptibility of different ovarian cancer cells to cisplatin. 
And indeed, when we supplemented HeLa cells and ovarian cancer cells with exogenous polyP, 
they became significantly albeit slightly sensitized to the chemotherapeutic drug. 
To take this one step further, I revealed the identities of cisplatin-triggered polyP foci with 
fluorescence colocalization analysis and reported polyP in the light nucleolar cap, fibrillar cap and 
Cajal body. Formation of these polyP-rich compartments is inflicted by impaired ribosome RNA 
synthesis, which underlies cisplatin toxicity. Intriguingly, I also discovered inositol 
hexakisphosphate kinase, a polyP-related protein, as a novel component of the light nucleolar cap. 
These results prompted me to hypothesize that polyP, a highly negatively charged polymer, might 
play a role in regulating the structural dynamics of this phase-separated compartment. 
However, to illustrate the molecular mechanisms of polyP functions relies on the identification of 
 xv 
polyP metabolizing enzymes, in particular, polyphosphate kinase in mammalian cells. Therefore, 
I conducted a whole genome siRNA screen for genes involved in the up- and down-regulation of 
polyP, using cisplatin-induced polyP accumulation as a reporter. I proposed several promising 
candidates, GRIN3B, P2RY1, ATP5F1E, PANK4 and AP3M1, which might be responsible for 
signaling polyP synthesis or catalyzing the reaction itself. Furthermore, I discovered a potential 
connection between inositol phosphate metabolism and polyP regulation. Meanwhile, I also 
uncovered genes involved in the following pathways: nucleotide excision repair, the ubiquitin-
proteasome system, and cell cycle progression, to be essential regulators of cisplatin toxicity and 
potential targets for optimizing the current platinum-based therapeutic interventions. 
In summary, my work has revealed an important aspect of polyP function in nucleolar stress 
response and begun to explore the molecular mechanisms of this phenomenon. Moreover, I have 
laid the foundation for future work aimed at characterizing the polyP regulatory network in 
mammalian cells, especially the long-sought polyphosphate kinase.
 1 
Chapter 1 The Subcellular Localizations, Functions and Regulation of Inorganic 
Polyphosphate 
This chapter is partially adapted from the following review article: “Inorganic polyphosphate, a 
multifunctional polyanionic protein scaffold” (1) written as part of my thesis work. 
Inorganic polyphosphate (polyP) consists of minimally three and maximally up to one thousand 
phosphates, connected via high-energy phosphoanhydride bonds (Fig. 1.1). Originally emerged 
during volcanic eruptions, polyP is thought to be one of the first energy-rich molecules on earth 
(2). Early work revealed that some microorganisms accumulate polyP in dense metachromatic 
granules that can be visualized with methylene blue staining (3). However, few studies reported 
the potential physiological role(s) of polyP in bacteria or any other organism, causing the polyP 
field to lie dormant for much of the 20th century. This situation changed, however, once polyP 
caught the attention of Sylvy Kornberg and later that of her husband Arthur Kornberg, who spent 
the last 15 years of his career investigating the “forgotten polymer” (4). Kornberg and his team 
developed many of the currently available polyP detection and quantification methods (5,6), and, 
most importantly, identified the enzymes responsible for polyP synthesis in bacteria (7,8). This 
breakthrough discovery enabled them, for the first time, to genetically manipulate polyP synthesis 
in a living organism and hence systematically evaluate the physiological consequences of polyP 
depletion. As it turns out, polyP fulfills a number of different functions in bacteria; polyP 
production was found to increase stress resistance, motility, and biofilm formation as well as 
contribute to sporulation, quorum sensing, and virulence (6,9-14). In eukaryotes, polyP appears to 
play an equally large number of diverse roles, ranging from stimulating blood clotting through the 
activation of factor XII to chelating calcium for bone mineralization, stabilizing mTOR, and 
triggering apoptosis (15-18). This amalgam of seemingly unrelated functions (Fig. 1.1) poses new 
and even more intriguing questions as to how such a simple polyanion like polyP can fulfill all 
these different roles (Table 1.1). Furthermore, the field urges the discovery of the polyP 
biosynthetic pathways in the mammalian species, which not only possesses a far-reaching impact 
on the physiological activities of the organisms but may also be exploited to regulate the 
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progression of pathological conditions. 
 
Figure 1.1 PolyP, a simple, universal, and multifunctional polyanion. The linear polyP chain consists of minimally three and 
maximally up to about 1,000 orthophosphates linked by high-energy phosphoanhydride bonds. PolyP has been identified in all the 
organisms tested so far, where it fulfills an astonishing array of different functions. This figure was adapted from the review article 
“Inorganic polyphosphate, a multifunctional polyanionic protein scaffold” (1). 
1.1 PolyP biosynthesis and regulation in bacteria 
Many bacteria, including numerous pathogens, encode the non-essential enzyme polyphosphate 
kinase (PPK1), which catalyzes the reversible transfer of the terminal γ-phosphate of ATP to polyP 
(the in vivo starting molecule is not yet known) (7). In addition to PPK1, some microorganisms 
encode a second, structurally unrelated kinase, PPK2, which catalyzes the transfer of terminal Pi 
from polyP to GDP to form GTP (8,19,20). Most if not all of these bacteria also encode the 
exopolyphosphatase PPX, which hydrolyzes polyP into individual phosphates, thereby indirectly 
utilizing the cellular ATP pool to maintain phosphate homeostasis (21). 
Steady state concentrations of polyP in the bacterial cytosol are typically in the low micromolar 
range, even in the mutant strains that lack the polyphosphatase PPX (22). These results suggest 
that the levels and/or activity of PPK must be tightly regulated, a conclusion that makes energetic 
sense given that polyP synthesis draws from the cellular ATP pool. Yet, upon nutrient shift (5,23) 
or exposure to osmotic changes (5), acidic pH (24), oxidants such as hypochlorous acid (25) or 
very high temperatures (26), bacteria rapidly accumulate high levels of polyP. In fact, under some 
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of these stress conditions, bacteria have been shown to convert millimolar amounts of ATP into 
extremely long chains of polyP (>1,000 Pi), decreasing their cellular ATP pool by up to 30-50% in 
the process (25). Not surprisingly, preventing bacteria from synthesizing polyP (i.e., by deleting 
ppk1) makes them exquisitely sensitive to nutrient deprivation, oxidants or high temperature (25-
29). In addition, deletion of the ppk1 gene has been shown to decrease bacterial pathogenicity in a 
comprehensive manner, i.e., by reducing motility, colonization, virulence factor production and 
biofilm formation (28,30) (Table 1.1). 
Much of Kornberg’s research focused on how bacterial polyP synthesis is regulated and which 
potential transcriptional regulators might control ppk1 gene expression (5,6,23). These studies 
revealed that the ppk1 gene is a direct target of sigma38, the master transcriptional regulator for 
late stationary phase genes (31). PolyP, in turn, induces transcription of rpoS (the gene encoding 
sigma38) and further amplifies its own synthesis (23,28,32). While these results nicely explained 
the increased PPK1 and polyP levels in the bacteria during the stationary growth phase, they failed 
to reveal how polyP synthesis is regulated during rpoS-independent stress conditions, such as 
oxidative or heat stress. As it turns out, in contrast to many stress-induced transcriptional responses, 
polyP-synthesis appears to be primarily regulated on a posttranscriptional and/or posttranslational 
level. In Pseudomonas fluorescens, for instance, mRNA transcripts of the ppk1 gene have been 
shown to be targeted by antisense RNA, which finetunes PPK1 synthesis and hence regulates polyP 
abundance (33). Our study in HOCl-treated Escherichia coli cells revealed that polyP 
accumulation is, at least in part, mediated by the reversible inactivation of PPX. In this case, 
reversible oxidation of a critical cysteine, located in the polyP binding site, directly inactivates 
PPX until reducing conditions are restored (25). Despite these insights, it is clear that inactivation 
of PPX is only part of the polyP accumulation story. Since ppx deletion strains do not accumulate 
polyP in the absence of stress and PPK1 levels do not seem to significantly increase upon nutrient 
shift or other stress conditions in E. coli (22,34,35), it is highly likely for PPK1 to be post-
translationally regulated, either directly or through stress-sensitive regulators. Once PPK1 is 
activated and polyP is synthesized, however, transient inactivation of PPX will guarantee that 
polyP levels remain high until non-stress conditions are restored. 
1.2 PolyP localizations and functions in eukaryotic cells 
The earliest studies on the distribution of polyP in mammalian cells used subcellular fractionation 
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and biochemical quantification assays. They reported that polyP is present in the nucleus, plasma 
membrane, cytoplasm and intracellular organelles (36). Recently developed polyP-specific probes, 
including DAPI (whose excitation and emission spectra shift significantly when bound to polyP 
instead of DNA) (37), EcPPXc fusion proteins (38,39) or JC-D7 and JC-D8 (40) supported these 
results, but they also demonstrated that polyP is particularly enriched in the nucleolus, 
acidocalcisomes (a conserved organelle rich in protons, calcium and phosphorous) and 
mitochondria. Moreover, polyP was found to be secreted from astrocytes and subsequently taken 
up by neurons, suggesting that it is present both inside and outside of the cell (41,42) (Fig. 1.2). 
1.2.1 Nucleus 
The proximity of polyP and nucleic acids has been first reported in prokaryotic species and yeast. 
Traditionally, PolyP-RNA complexes, held together by divalent cations, such as Mg2+ and Ca2+, 
were purified (43,44). Later on, studies in E. coli postulated that polyP-RNA interactions might be 
crucial to control RNA stability in vivo, as PPK1 was identified as a component of the RNA 
degradation machinery (i.e., the degradosome) (45). In cyanobacteria, on the other hand, polyP 
granules were predominantly observed around the nucleoid (46), where ribosomes are enriched 
under normal growth conditions. Hence, despite the fact that polyP and nucleic acids are both 
negatively charged, polyP might be associated with DNA and/or RNA, not only physically but also 
functionally. 
Contrary to the primitive nucleoid, which largely contains naked DNA, the nucleus of eukaryotic 
organisms has a highly compact organization of genetic information and a sophisticated 
compartmentalization of biochemical reactions. Therefore, it is not surprising that polyP exhibits 
a more precise arrangement in the nucleus. Notably, several lines of evidence established that 
polyP resides in the nucleolus (38,47-49), a prominent membraneless structure and the birthplace 
of ribosomes. In situ labeling of polyP with an immunofluorescence probe pinpointed polyP to the 
dense fibrillar component and the fibrillar center, but not the granular component of the nucleolus 
(38) (Fig. 1.2). To this date, the molecular details of nucleolar polyP await further characterization. 
Yet, a novel posttranslational (non-enzymatic) modification, namely polyphosphorylation, which 
involves the covalent attachment of polyP chains to the lysine residues of selected nucleolar and 
glycosomal proteins (47,48,50), could in part explain the specific targeting of polyP to the 
nucleolus. 
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Figure 1.2 Subcellular localizations of polyP in the eukaryotic cell. PolyP (represented by a dashed line) was found in the nucleus 
(specifically, in the fibrillar center and dense fibrillar component of the nucleolus), on the plasma membrane and inner 
mitochondrial membrane, in the mitochondrial matrix, lysosome or vacuole lumen, cytoplasmic vesicles (including 
acidocalcisomes and secretory vesicles) and on the outer and inner surfaces of matrix vesicles. Organelles in which polyP have not 
been detected are omitted, and the sizes of different organelles are not drawn to scale. 
1.2.2 Plasma membrane and inner mitochondrial membrane 
Mammalian cells have evolved a robust membranous system. Embedded within the plasma 
membrane and the inner mitochondrial membrane are various channels made up of polyP, Ca2+, 
and a second biopolymer, polyhydroxybutyrate (PHB) (Fig. 1.2). PHB-Ca2+-polyP complexes 
were first observed in the plasma membrane of E. coli, where they were proposed to serve as an 
entrance channel for foreign DNA during transformation (51). The architecture of the PHB-Ca2+-
polyP complex has been deduced from the biochemical features of the three constituents (51). In 
this model, the periphery of the channel is lined with PHB, whose methyl group extends outwards 
and anchors the macromolecule in the surrounding lipid bilayer. Meanwhile, the ester oxygen of 
PHB is posed to the interior of the channel, where it is bridged to the phosphoryl oxygen of polyP 
by a calcium ion. Altogether, PHB, Ca2+, and polyP form a channel of 2.4 nm diameter (externally) 
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with an approximate molar ratio of 1: 0.5: 1. However, both the gating mechanism and the 
selectivity of the PHB-Ca2+-polyP complex remain elusive thus far. 
Intriguingly, as evolution takes place, the PHB-Ca2+-polyP unit is incorporated into a number of 
proteinaceous assemblies which dwell in a variety of intracellular compartments and hence impose 
a multifaceted impact on the cell. 
One category of such complexes includes, but is not limited to, the K+ channel of streptomyces A 
(KcsA) in Streptomyces Lividans (52), the cold-sensing transient receptor potential melastatin 8 
(TRPM8) channel (53) in the peripheral neurons, and the Ca2+-ATPase in erythrocytes (54). The 
functional roles of these assemblies are far from clear. Whereas removal of polyP by 
exopolyphosphatase greatly alters the voltage-gating properties of TRPM8 (53), the erythrocyte 
calcium pump is postulated to catalyze polyP synthesis and degradation (54). Taken together, these 
observations suggest that polyP is not only a structural scaffold but also a dynamic regulator that 
governs the functional states of these ion-conducting complexes. 
A less well-characterized PHB-Ca2+-polyP assembly was identified in the inner mitochondrial 
membrane as part of the mitochondrial permeability transition pore (mPTP) (55,56). In spite of the 
critical roles that are played by mPTP in energy homeostasis and cell death, the molecular 
composition of this channel is still enigmatic. In addition to PHB, Ca2+, and polyP, subunits of the 
FoF1-ATPase are compelling candidates for configuring mPTP (57-59), albeit with conceivable 
differences from the classic ATP-producing engine. In accordance with this idea, an FoF1-ATPase 
dimer resembles mPTP in the electrophysiological properties (59). In addition, the transmembrane 
and pore-forming element of the Fo rotor, namely the c subunit was found to interact with the PHB-
Ca2+-polyP complex (57,58). Hence, it is plausible that mitochondria, regarded as the powerhouse 
of the cell, engage cognate machineries to coordinate energy production, stress response, and cell 
survival. Being an energetic biopolymer itself, polyP could be a direct or indirect product of the 
ensemble, an ingenious switch between the two facets of FoF1-ATPase activities, or both. 
1.2.3 Mitochondrial matrix 
In contrast to the membrane-bound polyP fractions, the mitochondrial matrix contains an 
alternative polyP reserve, which adopts a ‘free’ form (Fig. 1.2). There, the negatively charged 
polymer made up of 15 to 25 phosphates is likely to interact with Ca2+ (60), a crucial messenger 
for metabolic and proapoptotic stimuli. PolyP depletion by an ectopic expression of yeast 
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exopolyphosphatase in the mitochondrial matrix profoundly impacts the metabolomic landscape 
of the cell, shifting the major source of ATP production from oxidative phosphorylation to 
glycolysis (61). Given the reliance of tumor cells on glycolysis for sustained proliferation, it is 
plausible that free mitochondrial polyP may play a role during tumorigenesis and the progression 
of cancer. 
1.2.4 Lysosome 
The unicellular eukaryotic species Saccharomyces cerevisiae differs from the vast majority of 
other eukaryotes in that it contains a known polyphosphate kinase – the vacuolar transporter 
chaperone 4 (Vtc4) (62). Vtc4 is part of an elaborate ring-like structure, which couples polyP 
synthesis with its translocation into the vacuole where polyP is stored (63) (Fig. 1.2). Vacuolar 
polyP is a central player in the phosphate homeostasis.  The vacuole appears to sequester phosphate 
when cells are actively growing (62) and releases it to supply the building blocks for DNA 
replication during the S phase (64). Moreover, vacuolar polyP chelates heavy metals, such as 
manganese and cadmium, to prevent cellular damage caused by toxic environmental pollutants 
(65,66). In addition, polyP increases nitrogen storage by complexing arginine without disturbing 
the osmolarity of the cell (67). For these reasons, it is crucial to synchronize polyP production and 
its translocation to the vacuolar lumen. Otherwise, excess polyP in the cytoplasm will not only 
distort the morphology of the cell but also interfere with the growth rate of this organism (68). 
Compared to a wealth of knowledge about vacuolar polyP in yeast, little is known about lysosomal 
polyP in mammalian cells. This is largely due to the fact that lysosomes do not contain Vtc4, or 
any other functional equivalent known to date. Only a few studies have addressed the presence of 
polyP in the lysosome, using human fibroblasts and cultured mouse astrocytes (41,42,69) At a 
minimum, part of the lysosomal polyP in astrocytes can be mobilized by an exocytic signal and 
contributes to gliotransmission and neuronal firing (41,42). 
1.2.5 Cytoplasmic vesicle 
The most prominent polyP deposit in mammalian cells is the acidocalcisome (39,70-72) (Fig. 1.2), 
an acidic, calcium-rich organelle, which is conserved from bacteria to humans (73). Historically, 
acidocalcisomes were first identified in the unicellular parasites, i.e., Trypanosoma (74). Yet, more 
detailed molecular analysis rendered this structure analogous to ancient volutin granules in bacteria 
(75) as well as to electron-dense granules in human platelets, mast cells, and basophils (39,71). 
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The commonality of volutin granules, acidocalcisomes, and platelet dense granules is that they all 
contain an extraordinary amount of polyP. In platelets, for example, the intragranular polyP 
concentration can reach levels of up to 130 mM (in phosphate unit) (71), nearly 1000-fold more 
than the average polyP level in other mammalian cells and tissues (36). This unique feature makes 
physiologic sense as acidocalcisome polyP is readily secreted and executes extracellular tasks in 
the organism, including acting in the blood clotting cascade and eliciting proinflammatory 
responses (16,39,76-79). 
PolyP secretion and uptake have also been documented in the brain, despite the fact that neurons 
and other nerve cells do not contain acidocalcisomes. The most prominent polyP storage appears 
to be in the synaptic vesicles in neurons and the postulated ATP-containing vesicles in astrocytes 
(41,80) (Fig. 1.2). Both structures are responsive towards environmental cues. Neuronal polyP is 
released upon membrane depolarization (80), and polyP vesicles in astrocytes are released upon 
elevated cytoplasmic Ca2+ levels, which are characteristic of many physiological and pathological 
conditions (41,42). Once secreted, polyP exerts at least two functions on nearby cells: 1) polyP 
substantially enhances the firing rate of neurons via a direct modulation of the voltage-gated 
sodium, potassium, and calcium channels (80) and 2) polyP functions as a gliotransmitter by 
activating the purinergic receptor P2Y1 found in astrocytes (42). Intriguingly, the G protein-
coupled receptor P2Y1 incurs a Ca2+ release from the ER, setting into motion a subsequent polyP-
induced polyP release (42), which serves to amplify the signal via a feed forward mechanism. 
PolyP signaling is prevalent among all astrocytes and selected neurons (42). Furthermore, it is 
endowed with a critical role in overseeing the autonomic behaviors in mice (42). 
1.2.6 Matrix vesicle 
An alternative polyP-rich vesicle, namely the matrix vesicle buds from the apical membrane of 
osteoblast, creating a platform for calcium and phosphate condensation into hydroxyapatite (81), 
the basic material of cartilage, bone, and teeth. As its name suggests, matrix vesicle floats in the 
extracellular environment and exhibits an opposite membrane topology to the aforementioned 
cytoplasmic polyP enclosures. Electron microscopy revealed that polyP populates the outer and 
inner surfaces of the vesicle, less so the lumen (81) (Fig. 1.2). Once hydrolyzed, for example, by 
the alkaline phosphatase on the plasma membrane of osteoblast, polyP is converted to phosphate 
and shifts the equilibrium towards hydroxyapatite formation (17,82). Hence, mobilization of polyP 
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on the matrix vesicle is programmed to support the continuous development of the skeleton. 
Table 1.1 The subcellular localizations and physiological functions of polyP in different species 
Species Subcellular localization (if described) Function Reference 
E. coli 
 Stringent response (5,6) 
 Stationary phase survival (10,27) 
 
Stress resistance 
(heat, oxidants, osmotic shock, acidic pH, and heavy 
metal) 
(10,25-28,83) 
 Biofilm formation (28,84) 
 Persistence (28,85) 
 Transcription (23,28,32) 
Ribosome Translation (86) 
Plasma membrane DNA entry (87) 
P. aeruginosa 
 Cellular structures (nucleoid and cell envelope) (30) 
 Motility (11,12,30) 
 Stress resistance (oxidants and desiccation) (29,30) 
 Biofilm formation (13,30) 
 Virulence (13) 
 Quorum sensing (13) 
 Colonization (28) 
S. cerevisiae 
Nucleoplasm, nucleolus Posttranslational modification (47,48,50) 
Vacuole Phosphate homeostasis (62,64) 
Vacuole Arginine sequestration (67) 
Cytoplasm Stress resistance (heavy metal) (65,66) 
 DNA synthesis and repair (64,88) 
Dictyostelium 
discoideum 
 Development and germination (89,90) 
 Predation (90) 
 Cytokinesis (91) 
T. brucei and 
T. cruzi 
Nucleolus, glycosome Posttranslational modification (50) 
 Stress resistance (osmotic shock) (92-94) 
 Cytokinesis (92) 
 Infection (93,95) 
Homo sapiens 
Plasma membrane, 
cytoplasm Ion channel activation (53,96) 
Plasma membrane, 
cytoplasm Signaling (mTOR, FGF2, and integrin 1) (18,97,98) 
Mitochondria 
Mitochondrial activity (mPTP opening, Ca2+ homeostasis, 
and energy metabolism) 
(15,60) 
Nucleolus rRNA transcription (38,48) 
 DNA repair (88) 
Acidocalcisome Blood clotting and inflammation (16,39,71,76-79) 
Synaptic vesicles, 
putative ATP-containing 
vesicles, lysosomes 
Neurotransmission and gliotransmission (41,42,80) 
Matrix vesicles Bone mineralization (17,81) 
1.2.7 Regulation of polyP levels and chain lengths 
Due to a lack of feasible tools for polyP detection, it is very challenging even nowadays to monitor 
polyP dynamics in situ and in real time. Nonetheless, an immense knowledge has accumulated in 
the past two decades when discrete, static snapshots of polyP were spliced to reflect the differential 
regulation and constant mobilization of this molecule by intra- and extracellular signals. 
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Apart from certain cell types such as thrombocytes, mast cells, and basophils, which store up to 
130 mM polyP (in Pi unit) in the form of medium-sized polyP chains in the dense granules (71), 
eukaryotic polyP levels are generally in the micromolar range, and their chain lengths vary between 
50 and 800 Pi (36). Based on tissue-wide studies in rats and mice, the heart and the brain appear 
to contain the highest amounts of polyP (~100 µM), followed by the lung, the kidney and the liver 
(36,99). On the organellar level, nucleus accommodates almost twice as much polyP as the plasma 
membrane, overtaking the cytoplasm and the mitochondrion by several folds (36). Taken together, 
these observations evince a convoluted program of polyP localization and abundance possibly 
determined by the developmental cues of an organism. 
So far, no conditions have been reported in mammalian cells that would cause such a massive 
increase in polyP levels as what has been observed in nutrient-shifted or oxidatively-stressed 
bacteria. That being said, substantial polyP fluctuations accompany a handful of physiological and 
pathological processes in the eukaryotic species. For instance, brain polyP levels seem to decline 
with age and Alzheimer’s disease state (84,100), alluding to the role of polyP in amyloidogenesis 
not only in vitro but also in vivo. Furthermore, at the onset of apoptosis, human leukemia cell line 
HL60 exploits an ingenious design that the quantity of polyP levels off while the proportion of 
long vs. short chain polyP markedly reduces (100). Hence, polyP level and chain length might 
represent two independent tiers of a seemingly multi-dimensional network for polyP regulation. 
As the field continues to search for conditions which allow polyP accumulation, it will shed light 
on the conundrum whether mammalian cells have inherited the capacity to upregulate polyP in the 
face of stress from their bacterial ancestors. And if so, is it conducted by transcriptional, 
translational or post-translational changes? Undoubtedly, this endeavor will gain momentum once 
the long-sought mammalian polyphosphate kinase(s) and polyphosphatase(s) are unearthed, or 
vice versa. 
1.2.8 A proposed mechanism for the versatile functions of polyP 
Based on the previous description, polyP is an unfathomable biopolymer whose primordial origin 
and simplistic structure clearly defy its sophisticated arrangements and diverse functions in the 
eukaryotic cell (Figure 1.1, Fig. 1.2 and Table 1.1). Ample evidence corroborates the roles of polyP 
in a wide range of biological processes, which include stress response, apoptosis, 
neurodegeneration, inflammation, blood clotting, and so on (101-105). Conceivably, this amalgam 
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of polyP activities directly reflects and results from the intricate local environment where polyP is 
effective. Although it is plausible that the phosphate- and energy-rich nature of polyP is due to 
alter organismal physiology in certain aspects, it is the interaction between polyP and those 
molecules located to the same subcellular compartments that is mostly likely to underpin the 
versatility of polyP functions. 
In full agreement with this view, polyP acts as a promiscuous protein scaffold with a broad 
spectrum of clients (25,26,84,106,107). Essentially, this negatively-charged polymer is capable of 
discerning a folding intermediate and remodeling it to an amyloid-like, β-sheet-rich structure 
(25,26,84). Such conformational rearrangement is the staple of all polyP-client complexes studied 
to date. However, in stark contrast, the physiological outcome of polyP-client interaction is utterly 
dependent on the intrinsic property of the client. For non-amyloidogenic proteins, such as 
luciferase and citrate synthase, association with polyP shields the client from aggregation under 
proteotoxic stress and primes it for refolding once a permissive environment is restored (25,26). 
And for the amyloidogenic counterparts, exemplified by Aβ, α-synuclein, and tau, polyP 
accelerates fibril formation and alters fibril morphology so profoundly as to modify the stability 
and hence the seeding capacity of these macromolecules (84,106,107). Overall, research from our 
lab infers that polyP is a cytoprotective agent whose fundamental working mechanism(s) involve 
dictating the folding pathways of its clients (25,26,28,29,84) and furthermore orchestrating the 
downstream cellular responses in a physiological or pathological setting. 
1.3 PolyP kinase – in the past and on the horizon 
The biggest remaining puzzle in the field is the question how polyP is synthesized in mammalian 
species. Unlike many other conserved molecules that are known in biology, polyP is not 
synthesized via the same conserved pathway but derived from seemingly unrelated ATP-fueled 
engines that show no sequence homology and have no homologues in higher eukaryotes. Even if 
one focuses only on the prokaryotic branch of the phylogenetic tree, clear homologues of E. coli 
PPK1 are absent in a large number of polyP-synthesizing species (108). Therefore, in lieu of a 
homology-based quest for mammalian PPK, divergent paths are taken to 1) deepen our 
understanding of the known polyP kinases in other organisms in an attempt to seek undercover 
connections to their mammalian parallels; 2) scrutinize the proteomes of endogenous polyP-rich 
organelles; and 3) resolve the conjunction of polyP and inositol pyrophosphates, whose regulation 
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and perhaps even biosynthesis are evidently entwined. 
1.3.1 E. coli PPK1 
In the early 1990s, the biggest breakthrough in the polyP field came as the Kornberg group 
successfully purified E. coli PPK1 and cloned its gene (ppk1) (7,109), marking the transition from 
a descriptive observation of polyP to a mechanistic investigation of its activities. In-depth 
bioinformatic analyses failed to recognize any homologues of ppk1 in 40 % of all taxa in the 
prokaryotic kingdoms (110). Furthermore, this gene was adopted by only a few eukaryotic species, 
such as Caenorhabditis remanei, Candida humicola and Dictyostelium discoideum through 
horizontal gene transfer (91,105,111). An unexpected structural similarity manifests in the catalytic 
domains of PPK1 and phospholipase D (PLD), which lack any perceptible sequence homology or 
functional overlap (112). As a lipid phosphatase, PLD hydrolyzes phosphatidylcholine to 
phosphatidic acid and choline, thereby remodeling the lipid composition of the plasma membrane 
and partaking in signal transduction (113). Due to the fundamental differences of the reactions that 
PPK and PLD catalyze, perturbation of PLD has not been studied specifically in the context of 
polyP. Yet, with PPK being the predominant source of polyP biosynthesis in bacteria, it might be 
fruitful to inspect the obscure connections between the structures, activities and evolution of these 
two enzymes. 
1.3.2 P. aeruginosa PPK2 
As researchers readily expanded polyP research to a pathogenic bacterium P. aeruginosa, they 
unveiled a parallel pathway for polyP generation and utilization centered on a nucleoside 
diphosphate kinase called PPK2 (8,19). In line with the fact that P. aeruginosa PPK1 (a close 
homologue of E. coli PPK1) and PPK2 are not related, there are rudimentary disparities pertaining 
to the substrates, metal cofactors, velocities and chain length preferences of the two enzymes (8). 
Most strikingly, PPK2 exhibits a 75-fold higher specific activity for replenishing GTP with polyP 
and GDP than building polyP chains via the reverse reaction (8,19). Essentially, 80 % of polyP in 
P. aeruginosa is synthesized by PPK1 (8), turning PPK2 into an auxiliary mechanism for 
maintaining polyP levels in this organism. Mapping ppk2 in the phylogenetic tree evinced a 
coexistence of ppk1 and ppk2 genes in around 90 % of all species with ppk2 (110). This finding 
strengthens the idea that the energetically-favored ATP pathway is more prominent for making 
polyP in bacteria and archaea. Still, the discovery of P. aeruginosa PPK2 is instrumental. Not only 
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did it reveal an unexplored avenue in bacterial activities, but it also enlightened the field on a form 
of polyP-consuming enzyme(s) which may harness the energy of nucleoside triphosphates and 
give rise to polyP chains in a designated environment. 
1.3.3 D. discoideum PPK2 
The perhaps most disputable polyP kinase, D. discoideum PPK2, is thought to consist of three 
actin-related proteins: ERpA, ArpD, and ACT28 (114). This tripartite protein complex was purified 
(with highly-enriched specific activity) from the ppk1 null strain of D. discoideum and considered 
to be a backup polyP kinase until recent evidence in vivo raised doubt on this claim. The leading 
argument was made by the Saiardi group who observed a complete depletion of polyP by solely 
knocking out ppk1 (89). This result challenged the disposition that actin-related proteins might 
take charge of manufacturing polyP in an enormous number of species where no other polyP 
kinases have been discovered (110). 
1.3.4 S. cerevisiae Vtc4 
The feasibility of doing high throughput genomic screenings led to the unanticipated discovery of 
yeast polyP kinase – Vtc4, which traverses the vacuolar membrane (62). The cytoplasmic domain 
of Vtc4, which contains the catalytic site, entrains the γ-phosphate of ATP into a growing polyP 
chain (63). The newly synthesized polymer is simultaneously deposited to the vacuolar lumen 
through a membrane channel formed by the VTC complex and presumably driven by an 
established electrochemical gradient across the vacuolar membrane (68). 
While the mammalian lysosome is reminiscent of the yeast vacuole, no Vtc4 homologues have 
been identified in the mammalian structure. Nonetheless, fluorescence labeling of polyP traces it 
in the lysosomes of glial cells in mice (41,42), opening up questions whether de novo synthesis of 
polyP takes place in the lysosome or whether polyP is merely a cargo of the vesicular transport 
system. The former conjecture is supported by the observation that isolated lysosomes from human 
fibroblasts actively incorporate [32P]Pi into long-chain [32P]polyP (69). This finding brings about 
an exciting opportunity to isolate the polyP synthesizing enzyme(s) from the lysosome proteome. 
1.3.5 Are mitochondria the origin of polyP? 
Emerging evidence now proposes mitochondria as the most promising location of mammalian 
polyP kinase(s). The rationale appears to be several-fold. From an endosymbiotic perspective, 
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mitochondria arose from engulfed bacteria which possibly enveloped the oldest polyP-related 
enzymes on earth. While immense adaptations ensued to define the traits of a eukaryotic cell, 
mitochondria remain one of the hotspots for polyP deposit and function even after two billion years. 
More importantly, abrogation of mitochondrial membrane potential by either drugs or membrane 
permeabilization diminishes polyP signal in this compartment (115), which signifies the action of 
proton motive force in sustaining normal polyP levels. To take this one step further, Baev et al. 
reported what seems to be a polyP synthesis event in isolated mitochondria, namely an increase of 
mitochondrial polyP signal with the addition of substrates for the electron transport chain, but not 
ATP itself, and a prompt inhibition of this activity by oligomycin, a widely-used toxin for FoF1-
ATPase (116). Surely, this finding raises an intriguing question whether the ATP-producing engine 
is designated to making another extremely energetic molecule in mammalian cells. 
1.3.6 The conjunction of polyP and inositol pyrophosphate (PP-IP) synthesis 
Apart from polyP, there is another class of energy-rich molecules, PP-IP, which bear 
phosphoanhydride bond-linked diphosphate groups at one or more positions of the six-carbon 
inositol ring. The first steps of PP-IP synthesis can be executed by two families of enzymes, inositol 
hexakisphosphate kinases (IP6Ks) and inositol hexakisphosphate and diphosphoinositol 
pentakisphosphate kinases (PPIP5Ks). IP6K1 and PPIP5K recognize specific forms of IP5 and IP6 
and convert them to IP7, or even IP8, by phosphorylating selected phosphate groups attached to 
inositol (117,118). Genetic manipulation of IP6K1 or PPIP5K interferes with numerous biological 
processes, including haemostasis, carcinogenesis, inflammation, cell migration, signaling, and etc. 
(119). Notably, the activities of PP-IP largely overlap with those of polyP – an expected outcome 
based on the fact that polyP synthesis itself is superintended by PP-IP. Ample evidence in yeast, 
Trypanosoma and mice corroborates an abrupt decrease of polyP when PP-IP production is 
impeded by knocking out Ip6k1 or KCS1 (the gene that encodes yeast IP6K1), VIP1 (the gene that 
encodes yeast PPIP5K) or other critical genes in the inositol phosphate and PP-IP pathways (120-
123). Mechanistically, IP6, IP7, and IP8 (which contains two pyrophosphate groups instead of a 
triphosphate chain) potentiate polyP synthesis with increasing efficacies by directly binding to the 
SPX domain of the VTC complex (124,125). Since the levels of PP-IP fluctuate with that of 
phosphate (125), PP-IP might therefore serve as a messenger between phosphate profusion in the 
cytoplasm and polyP accumulation in the vacuole. On a slightly different tangent, IP8 in the form 
of triphosphoinositol pentakisphosphate (PPP-IP5) is a genuine product of IP6K1 in vitro and in 
 15 
vivo (117), which ratifies an underappreciated role of IP6K in assembling short phosphate chains. 
Hitherto, it is unclear whether there are any limits on the length of phosphate stretches emanating 
from the inositol core and to which enzymes these decisions are delegated. However, it is certainly 
appealing to conceptualize a model for polyP synthesis where PP-IP acts as the root for alternating 
polyP elongation and release. 
1.3.7 PolyP-consuming enzymes 
In the search for novel polyP-synthesizing machineries, a few enzymes were recognized for their 
ability to use polyP as a phosphate donor. Such examples include glucokinase, NAD kinase, 
dolichyl diphosphate-polyphosphate phosphotransferase, and so on (108,126). Although their 
reactions may be reversed by excess substrates, it is unknown whether such conditions can ever 
be reached in vivo. 
In summary, polyP biosynthetic pathways have diverged so profoundly that homology-based 
approaches can hardly connect the “dots” (i.e., known polyP kinases in a few model organisms) 
and restore the full evolutionary picture of this activity. The fact that polyP itself is so well-
conserved while its metabolism is so versatile suggests an irreplaceable yet highly adaptive role of 
polyP in the cell. Focusing on the mammalian species, there are two outstanding features of this 
polymer: 1) the scarcity of polyP under normal growth condition as well as stress conditions tested 
so far and 2) the complexity of polyP localizations and functions. On one hand, these 
characteristics imply that polyP is tightly regulated in vivo; on the other hand, they set the 
bottleneck towards identifying the key players of the polyP regulatory network. Therefore, both 
conceptual and technical innovations are urged to overcome these barriers. After all, finding the 
enzyme(s) that synthesize and regulate polyP synthesis in mammals is key – once this is achieved, 
many of the remaining doors will open and hopefully reveal how this ancient biomolecule works 
today.
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Chapter 2 Accumulation of Inorganic Polyphosphate Is a Cellular Response to 
Cisplatin-Induced Apoptosis 
This work has been published as a research article (127) in the journal Frontiers in Oncology. I 
designed and performed the following experiments: 1) visualization of time- and dose-dependent 
polyP accumulation in the nucleoli of HeLa cells and ovarian cancer cells after cisplatin treatment; 
2) colocalization analysis of polyP and cleaved caspase-3; 3) assessment of ovarian cancer cell 
proliferation in response to cisplatin challenge; and 4) establishment and characterization of a 
stable HeLa cell line which overexpressed yeast exopolyphosphatase in the nucleus. I wrote part 
of the draft and revised the full manuscript. Other coauthors, Daniela Knoefler, Asavari Rajpurkar, 
Nicole Taube, Akash S. Rai, Jake Erba, Benjamin Sliwinski and Moses Markowitz acquired and 
analyzed data for the rest of the experiments, and Ellen Quarles contributed to data analysis. 
Daniela Knoefler and Ellen Quarles performed the statistical analysis. Daniela Knoefler wrote the 
first draft of the manuscript, and Ellen Quarles wrote sections of it. 
2.1 Introduction 
About 1,600 patients die of cancer each day, making cancer the disease with the second highest 
mortality rate in the United States (128). Platinum-containing drugs such as cisplatin, one of the 
oldest approved chemotherapeutic agents, are used in about 50% of chemotherapies administered 
to cancer patients (129). Nevertheless, treatment with cisplatin is associated with significant 
problems. As a DNA-damaging agent, cisplatin kills not only cancer cells but also healthy cells. 
Off-target effects can be irreversible and include hearing loss and neuropathy (130). Moreover, 
while cisplatin treatment has been shown to be effective in reducing the mortality of testicular, 
bladder, cervical, and head and neck cancer, other tumors such as lung cancer are innately resistant 
towards cisplatin (131,132). Finally, many cancer types have been reported to develop cisplatin 
resistance coinciding with long term treatment. For example, ovarian cancer cells may respond 
well during initial chemotherapy treatment but commonly become resistant when the cancer 
reoccurs (131). Thus, the non-specific toxicity of cisplatin and the resistance of some cancers 
restrict the therapeutic use of the drug. To increase the treatment options for cancer patients, it is 
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therefore of crucial importance to understand how mammalian cells respond to cisplatin-mediated 
toxicity and hence identify targets that might increase cisplatin sensitivity specifically in cancer 
cells. 
The toxicity of cisplatin is attributed primarily to its interaction with DNA and the cisplatin-
induced formation of DNA adducts and double strand breaks (133,134). This DNA damage, if not 
properly mended by the cellular DNA repair machinery, blocks cell cycle progression and induces 
apoptosis (135). However, induction of apoptosis has also been observed in cells lacking a nucleus 
(136), implying that cisplatin might target other cellular components in addition to nuclear DNA. 
Based on recent work which showed that cisplatin also interacts with mitochondrial DNA, proteins, 
and small molecules such as glutathione (137-140), it was proposed that mitochondrial dysfunction 
and/or oxidative stress contribute to cisplatin toxicity. These unexpected results emphasize the 
need to further elucidate the mechanism of cisplatin action. 
Our lab has recently discovered that bacteria respond to oxidative stress treatment with the 
accumulation of large amounts of inorganic polyphosphates (polyP), linear chains of 
phosphoanhydride bond-linked phosphates, which serve to protect proteins and cells against 
irreversible oxidative damage (25). Mammalian cells also synthesize polyP, but functional studies 
focused primarily on its roles in cell proliferation, apoptosis, angiogenesis, metastasis, blood 
clotting, and inflammation (18,77,79,98,141-143). Here we set out to test whether polyP plays a 
role during cisplatin-induced stress in mammalian cells. Our studies revealed that several cancer 
cell lines respond to cisplatin treatment with a robust upregulation and redistribution of 
endogenous polyP, leading to the formation of distinct nucleolar polyP foci. Instead of the expected 
cytoprotective function of polyP, however, we discovered that the levels of endogenous polyP 
directly correlate with the levels of caspase-mediated apoptosis induction, suggesting that polyP 
plays a role in cisplatin-mediated apoptosis. Indeed, by administrating exogenous polyP, we were 
able to increase cisplatin-induced toxicity, suggesting that altering cellular polyP levels might 
represent a potential novel mechanism to modulate the therapeutic efficacy of cisplatin. 
2.2 Materials and methods 
2.2.1 Reagents, plasmids, and proteins 
Polyphosphates with chain lengths of 14, 60, 130 and 300 Pi were kindly provided by T. Shiba 
(Regenetiss, Japan) and aliquoted in smaller volumes to avoid repeated freeze-thaw cycles. A cis-
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Diammineplatinum(II) dichloride (Sigma-Aldrich) stock solution (3 mM) was prepared in double 
distilled water. The plasmid pETM41-EcPPXc, which encodes the Maltose Binding Protein 
(MBP)-EcPPXc was a kind gift from Florian Freimoser (Addgene plasmid #38329; 
http://n2t.net/addgene:38329; RRID:Addgene_38329) (144). To generate the mCherry-EcPPXc 
fusion protein, EcPPXc was cloned into the mCherry-containing pTEV5 vector between BamHI 
and NotI sites. To generate the alternative GFP-EcPPXc probe, GFP was amplified from the 
pEGFP-N2 vector with flanking regions containing NdeI and BamHI recognition sequences and 
inserted to replace mCherry in the mCherry-EcPPXc construct. The purification of His-tagged 
mCherry-EcPPXc, GFP-EcPPXc, and their respective His-tagged control proteins, mCherry and 
GFP, was done using a Ni-NTA column (Qiagen, Hilden, Germany). All reagents were purchased 
from Thermo Fisher Scientific (Waltham, MA, USA), Sigma-Aldrich (St. Louis, MO, USA) or 
New England Biolabs (Ipswich, MA, USA) unless specified otherwise. 
2.2.2 Cell lines 
HeLa EM2-11ht cell line (145) was a generous gift of Dr. J. Nandakumar, University of Michigan. 
HeLa EM2-11ht and HeLa (ATCC® CCL-2™, ATTC, Manassas, VA, USA) cells were grown in 
DMEM (#11995065, Thermo Fisher Scientific). The ovarian cancer cell lines OVCAR3 and 
OVCAR8 (a generous gift of Dr. K. McLean, University of Michigan) were cultured in DMEM 
(ATCC® 30-2002™) from ATTC (Manassas, VA, USA). All media were supplemented with 10% 
Fetal Bovine Serum (#F4135, Sigma-Aldrich) and 1% Penicillin-Streptomycin (#15140122, 
Thermo Fisher Scientific). Cells were grown at 37°C with 5% CO2. 
2.2.3 Cisplatin treatment 
Cells grown to ~ 80% confluence were detached from the flask using 0.25% Trypsin-EDTA 
(#25200056, Thermo Fisher Scientific). 1.2×105 cells were seeded in each well of a 24-well plate 
and 104 cells were plated in each well of a 96-well plate. After the cells were allowed to attach 
overnight, they were treated with a range of cisplatin concentrations for the indicated period of 
time. 
2.2.4 Proliferation and cell death assays 
All microplate reader-based assays were performed in 96-well cell culture plates (#3596, Corning, 
Inc., Corning, NY, USA). The WST-1 Cell Proliferation Assay Kit (#10008883, Cayman Chemical, 
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Ann Arbor, Michigan, USA) was used to assess proliferation. Briefly, medium containing cisplatin 
was removed from the 96-well plate, and the mixture of the WST-1 Developer Reagent and the 
Electron Mediator Solution was first diluted in fresh medium to the working concentration and 
then added to the treated cells. Absorbance was measured in a BMG FLUOstar Omega microplate 
reader (Ortenberg, Germany) at a wavelength of 450 nm. Using the average of three technical 
replicates, the absorbance readings of the treated samples were normalized to those of the untreated 
cells. 
To determine the fraction of cells with compromised cell membranes as a readout for cell death, 
the SYTOXTM Green Nucleic Acid Stain (#S7020, Thermo Fisher Scientific) was used (146). All 
cisplatin treatments were set up in duplicates in a 96-well plate. Following the treatment, one set 
of samples were permeabilized with 120 µM Digitonin (#D141, Sigma-Aldrich) while the other 
remained unperturbed. Then, 5 µM SYTOXTM Green Nucleic Acid Stain was added to all the wells, 
and the samples were incubated for 30 minutes at 37°C. The fluorescence of incorporated 
SYTOXTM Green Nucleic Acid Stain was measured in a Tecan Infinite M1000 microplate reader 
(Männedorf, Switzerland) using an excitation wavelength of 504 nm and an emission wavelength 
of 523 nm. With the fluorescence from the digitonin-treated samples serving as the readout for 
total cell number, the percentage of dead cells was calculated by normalizing the fluorescence of 
the unperturbed wells to the fluorescence of the corresponding digitonin-treated wells. 
The percentage of dead cells was also determined using Trypan Blue, which stains cells with 
disrupted membranes. Treated cells were detached from the wells using 0.25% Trypsin-EDTA, and 
an aliquot of cells was mixed and incubated shortly with Trypan Blue Solution (#15250061, 
Thermo Fisher Scientific). Stained (i.e., dead) cells and unstained (i.e., live) cells were counted in 
a light microscope and the percentage of dead cells was calculated. 
To determine the extent of apoptosis induction, a luminescence-based activity assay for the 
executioner caspases, caspase-3 and caspase-7, was utilized. Cells were seeded at a density of 104 
cells per well in a white 96-well plate with clear bottom (#CLS3610, Corning, Inc.). The Caspase-
Glo® 3/7 assay (#G8090, Promega Corporation, Madison, WI, USA) was used to measure the 
activity of caspase-3 and caspase-7. The manufacturer’s instructions were followed with the 
exception that only 70 µl of the Caspase-Glo 3/7 Reagent was added to 70 µl of fresh medium to 
each well. After incubating the plate for 30 minutes at room temperature, luminescence was 
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measured at 23°C in a BMG FLUOstar Omega microplate reader (Ortenberg, Germany). Each 
treatment was performed with three technical replicates and the average was calculated. 
2.2.5 Flow cytometry 
Following cisplatin treatment, cells were detached using 0.25% Trypsin-EDTA and combined with 
the supernatant, which contained dead, floating cells. Then, all cells were spun down at 300 g at 
room temperature for 5 minutes, and the pellet was washed with Cell Staining Buffer (#420201, 
BioLegend, San Diego, CA, USA). For the labeling of apoptotic and necrotic cells, the FITC 
Annexin V Apoptosis Detection Kit with PI (#640914, BioLegend, San Diego, CA, USA) was 
used, following the manufacturer’s protocol. In short, the cell pellet was resuspended in Annexin 
V Binding Buffer. Then, Annexin V and Propidium iodide (PI) were added to the cell suspension. 
The percentage of Annexin V- and PI-positive cells (i.e., late apoptotic or necrotic cells) was 
measured in an Attune NxT Flow Cytometer (Thermo Fisher Scientific, Waltham, MA, USA; 
courtesy of the Buttita Lab, University of Michigan, Ann Arbor, MI, USA). Annexin V was 
measured in the BL1 channel while PI was measured in the BL3 channel. Gating was done using 
Annexin V-single stained cells, PI-single stained cells, and a double positive control. 
2.2.6 Immunofluorescence staining 
For fluorescence microscopy, cells were seeded onto 12 mm cover slips (#CLS-1760-012, 
Chemglass Life Sciences, Inc., Vineland, NJ, USA) placed in a 24-well plate (#3526, Corning, 
Inc.). Following cisplatin treatment, cells were fixed in 4% v/v freshly prepared paraformaldehyde 
(#1578100, Electron Microscopy Sciences, Hatfield, PA, USA) at room temperature for 15 minutes, 
washed with PBS and permeabilized in 0.3% Triton X-100 (#0219485480, MP Biomedicals, Solon, 
OH, USA) for 10 minutes. Triton X-100 was prepared in blocking solution, which contained 1% 
bovine serum albumin (#A3059, Sigma-Aldrich) in PBS. After a brief wash, cells were incubated 
in blocking solution for 1 h at room temperature. For the visualization of endogenous polyP, 
mCherry-EcPPXc or GFP-EcPPXc, and the respective control protein mCherry or GFP, were used 
at a concentration of 10 µg/ ml in blocking solution and incubated overnight at 4°C, protected from 
light. For the staining of apoptotic cells, a rabbit cleaved caspase-3 (Asp175) monoclonal antibody 
(#MAB835, R&D Systems, Minneapolis, MN, USA) was used at a concentration of 8 µg/ ml in 
blocking solution. For the staining of p53, a mouse p53 antibody (#DO-1, Santa Cruz 
Biotechnology, Dallas, TX, USA) was used at a concentration of 4 µg/ ml. To stain RNA 
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polymerase I, a rabbit anti-PAF49 IHC antibody (#IHC-00474, Bethyl Laboratories, Montgomery, 
TX, USA) was used at a concentration of 8 µg/ ml. To label nucleophosmin (NPM1), an anti-
NPM1 antibody (#32-5200, Thermo Fisher Scientific) was used at a concentration of 2 µg/ ml. 
Incubation of these primary antibodies was performed overnight at 4 °C together with polyP 
staining. The next day, cells were washed with PBS and then incubated with the respective 
secondary antibody for 1 h at room temperature, protected from light. Secondary antibodies used 
in this study were obtained from Abcam, Cambridge, United Kingdom and included goat anti-
rabbit IgG-Alexa Fluor® 488 (#ab150077), donkey anti-mouse IgG-Alexa Fluor® 488 (#ab150105), 
and goat anti-rabbit IgG-Alexa Fluor® 647 (#ab150079). After washing with PBS, cells were 
incubated with DAPI (#D1306, Thermo Fisher Scientific) at a concentration of 2.5 µg/ ml for 10 
minutes at room temperature to stain the nucleus. Cells were washed five times with PBS before 
the coverslips were mounted on microscope objective slides using Citiflour AF1 mounting medium 
(#19470, Ted Pella, Inc., Redding, CA, USA). 
Fluorescence images for mCherry-EcPPXc staining were acquired with a 40× objective on an 
Olympus BX61 upright microscope (Olympus, Center Valley, PA, USA) equipped with a 
Photometrics Coolsnap HQ2 cooled CCD camera and a quad filter set (DAPI/ FITC/ TRITC/ CY-
5). A closed feedback loop was enabled to keep the illumination of the X-Cite® exacte mercury 
lamp consistent. GFP-EcPPXc labeling and colocalization analysis of polyP, RNA polymerase I, 
and NPM1 were performed with a Leica SP8 laser scanning confocal microscope (Leica GmbH, 
Mannheim Germany) on a DMI8 microscope base using LAS X software, 100× oil objective 
(#11506378, Leica GmbH) and a 405 nm diode laser, in addition to a multi-line white light laser, 
set to 488, 594, and 647 nm excitation wavelengths. Spectral detection using a PMT from 410 to 
480 nm was utilized for DAPI, a HyD detector from 493 to 560 nm for GFP and Alexa Fluor® 488, 
and a HyD detector from 653 to 800 nm for Alexa Fluor® 647. 
2.2.7 Uptake of fluorescently labeled polyP 
PolyP300 was end-labeled with Alexa Fluor™ 647 Cadaverine (#A30679, Thermo Fisher Scientific, 
Waltham, MA, USA) as described in (84). A labeling efficiency of 10-15% was obtained. HeLa 
cells were seeded on coverslips as described above. After washing the cells with PBS, they were 
incubated with 200 µM labeled polyP (in Pi units) overnight in the absence or presence of 25 µM 
cisplatin. Staining for endogenous polyP was performed as described above using the GFP-
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EcPPXc probe.  
2.2.8 Image quantification 
Immunofluorescence images of DAPI and mCherry-EcPPXc (or GFP-EcPPXc) were used to 
define the puncta regions and quantify their signals using Fiji (ImageJ) software. Briefly, nuclear 
regions of interest (ROIs) were defined in the DAPI channel, using Thresholded Blur, Make Binary, 
and Fill Holes followed by hand segmentation to ensure accurate ROIs, and applied to the 
mCherry-EcPPXc (or GFP-EcPPXc) channel. Total nuclear signal was measured. Then the nuclear 
ROIs were separated into distinct files, and each nuclear ROI was used to define puncta ROIs. 
Puncta ROIs were found by applying several ImageJ plugins in order: Median and Thresholded 
Blur to reduce background noise and maintain puncta edges, Subtract Background with a rolling 
ball radius of 5 pixels to define areas that are brighter than nucleoplasm signal, and finally Make 
Binary, Fill Holes, and Watershed to define the puncta ROIs. These puncta ROIs were then applied 
to the original mCherry-EcPPXc (or GFP-EcPPXc) channel to record size and pixel intensity 
information. Finally, nucleoplasm signal was measured by defining a nucleoplasm ROI: Nuclear 
ROI with holes for all the puncta ROIs found in that nucleus. This was measured as for the puncta 
ROIs. Image background signal was determined by defining five non-cellular ROIs per image and 
averaging the pixel intensity. This background was subtracted from all ROI data. R Studio was 
used to analyze puncta data and produce the dot plot in Figure 2.1 and the histograms and dot plot 
in Supplementary Figure 2.1. (https://www.rstudio.com). 
2.2.9 Generation of stable ScPPX-expressing cells 
ScPPX, with an N terminal Nuclear Localization Sequence (NLS) followed by three FLAG tags, 
was cloned into pBI-4 vector using NotI and SalI and subsequently inserted into pBI-F3 vector 
using SarI and StuI. HeLa EM2-11ht cells were seeded in a 6-well plate with the density of 3×105 
cells/ well and transfected the next day with 1 µg pCAGGS-IRES-Puro plasmid and 1 µg NLS-3× 
FLAG-ScPPX plasmid using Lipofectamine™ 3000 (#L3000008, Thermo Fisher Scientific), 
following the manufacturer’s protocol. After 12 hours of incubation with the transfection mix, cells 
were transferred to a 10 mm culture dish and grown in the presence of 5 µg/ ml puromycin 
dihydrochloride (#P8833, Sigma-Aldrich). After 36 hours, puromycin was removed, cells were 
rinsed with PBS and then grown in medium supplemented with 40 µM ganciclovir (#G2536, 
Sigma-Aldrich) for 8 to 10 days until single colonies appeared. Single colonies were picked and 
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grown in the absence or presence of 200 ng/ ml doxycycline hyclate (#D9891, Sigma-Aldrich) to 
induce ScPPX protein expression. The expression of NLS-3× FLAG-ScPPX was verified with 
Western Blotting using a mouse anti-FLAG M2 antibody (#F3165, Sigma-Aldrich). All vectors 
were kind gifts of Dr. J. Nandakumar, University of Michigan. 
2.2.10 Ex vivo ScPPX activity assay 
NLS-3× FLAG-ScPPX transgenic HeLa EM2-11ht cells were seeded in a 6-well plate at the 
density of 1.5×105 cells/ well. The next day, expression of ScPPX was induced with 200 ng/ ml 
doxycycline for 48 hours, after which 25 μM cisplatin was added, and cells were incubated for 
another 24 hours. Cells were detached using 0.25% Trypsin-EDTA, collected with PBS and spun 
down at 300 g at room temperature for 5 minutes. The pellet was washed once with 100 µl lysis 
buffer: 20 mM Tris-HCl pH 7.5, 50 mM NaCl, 2 mM EDTA, 1% IGEPAL® CA-630 (#I8896, 
Sigma-Aldrich), cOmplete™, EDTA-free Protease Inhibitor Cocktail (#5056489001, Sigma-
Aldrich), 12.5 units/ ml Pierce™ Universal Nuclease for Cell Lysis (#88702, Thermo Scientific) 
and spun down at 300 g at 4°C for 5 minutes. The pellet was resuspended in 100 µl lysis buffer, 
and cells were lysed by sonication at 4°C. The activity of ScPPX was measured using the 
EnzChek® Phosphate assay kit (#E6646, Thermo Fisher Scientific) following the manufacturer’s 
instructions. As substrate for ScPPX, 150 µM polyP130 was added to the reaction mix, and the 
release of phosphate was monitored by absorbance reading in a Synergy HTX multi-mode 
microplate reader (BioTek, Winooski, VT, USA). For the normalization of input, the protein 
amount of each sample was measured using the DCTM protein assay (#5000112, Bio-Rad 
Laboratories, Hercules, CA, USA) following the manufacturer’s instructions, and absorbance was 
determined at 700 nm in a BMG FLUOstar Omega microplate reader (Ortenberg, Germany). The 
specific activity of ScPPX was calculated from the initial rate of polyP130 degradation and the 
protein concentration of the cell lysate. 
2.2.11 Statistics 
If not noted otherwise, the average of N > 3 biological replicates and the s.e.m. are plotted. 
Graphing and statistics were performed using GraphPad Prism 7 (San Diego, CA, USA). Number 
of replicates and significance level are found in each figure legend. 
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2.3 Results 
2.3.1 Cisplatin treatment triggers polyP accumulation in cancer cells 
To study the effects of cisplatin treatment on the levels and distribution of polyP in cancer cells, 
we treated the cervical cancer cell line HeLa EM2-11ht (from here on referred to as HeLa) with 0, 
5, 15, and 25 µM cisplatin for 12 and 24 hours, and visualized endogenous polyP using the specific 
probe GFP-EcPPXc. This fusion protein consists of the C-terminal polyP-binding domain of 
Escherichia coli exopolyphosphatase (EcPPXc) (144,147) and the fluorescent protein GFP. 
Staining of fixed cells with GFP lacking the EcPPXc domain revealed a negligible background 
signal in both untreated and cisplatin-treated cells (Fig. S2.1A). In contrast, however, staining with 
the polyP-specific probe GFP-EcPPXc revealed polyP signals in the nucleus of unstressed HeLa 
cells (Fig. 2.1A). These signals dramatically increased upon cisplatin treatment in a dose- and time-
dependent manner and presented themselves as distinct and bright nuclear foci (Fig. 2.1A). The 
apparent cisplatin-induced accumulation of endogenous polyP was significant and consistent 
across experiments (Fig. 2.1B) as well as in another HeLa clone obtained from the American Type 
Culture Collection (Fig. S2.1B). In-depth quantification of the distribution and intensity of nuclear 
polyP puncta of four experiments revealed that following cisplatin stress (red symbols and bars) 
the number of polyP puncta per cell drastically decreased (Fig. S2.1C, top panel) while the size of 
the puncta (Fig. S2.1C, middle panel) and their fluorescence intensity (Fig. S2.1C, bottom panel) 
significantly increased. These results indicate that the cellular polyP pool not only increases but 
significantly rearranges its subcellular localization upon cisplatin exposure. 
To characterize the viability of the cells following the treatment, we focused on treatment 
conditions which led to the most profound changes in cellular polyP in HeLa cells, that is, 25 µM 
cisplatin treatment for 24 hours. We observed that this treatment was sufficient to significantly 
impair the proliferation of HeLa cells, causing a 60% reduction in cell numbers compared to the 
untreated control (Fig. 2.1C). Cisplatin-treated cells also displayed, on average, a 5-fold induction 
of cell death as measured by the percentage of Annexin V and Propidium Iodide-positive cells (Fig. 
2.1D) as well as Trypan Blue-positive cells (Fig. S2.1D). Moreover, treatment with cisplatin 
caused a 3-fold increase in both caspase-3 and caspase-7 activities (Fig. 2.1E), doubled the amount 
of cleaved caspase-3 (Fig. S2.1E), and elevated the levels of the tumor suppressor p53 when 
compared to the untreated control (Fig. 2.1F). Based on these results, we concluded that the 
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cisplatin treatment we used to trigger a robust polyP response concomitantly inhibits proliferation 
and induces cell death through caspase activation and p53 stabilization in HeLa cells. 
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Figure 2.1 Cytotoxic cisplatin treatment triggers formation of nuclear polyP foci. (A) Visualization of endogenous polyP levels 
and distribution in HeLa cells treated with 0, 5, 15, and 25 μM cisplatin for 12 and 24 hours, respectively. The overlay of GFP-
EcPPXc signal (magenta) and DAPI signal (blue) reveals the nuclear localization of polyP. Representative images of projected z 
series are displayed. Scale bar: 50 μm. (B) Quantification of polyP levels following the same cisplatin treatments as those described 
in (A). Left: Four replicate experiments are shown, color coded by experiment. (Mean GFP-EcPPXc signal increased as [cisplatin] 
increased: p = 0.0367 at 24 hours by repeated measures ANOVA. Measurements at 12 hours were not significantly different. Right: 
From one representative experiment, the mean GFP-EcPPXc signal of the puncta regions is plotted against the mean value of the 
non-puncta regions of each nucleus. (C-F) Evaluations of cell viability after 25 μM cisplatin treatment for 24 hours (red bars). (C) 
Proliferation was determined by WST-1 assay (N= 6, mean + s.e.m., unpaired t-test, **: p=0.0011). (D) Percentage of Annexin V 
and PI-positive cells was measured by flow cytometry (N= 4, mean + s.e.m., unpaired t-test, ****: p<0.0001). Apoptosis induction 
was monitored by (E) activity of caspases 3 and 7 (N=3, mean + s.e.m., unpaired t-test, *: p=0.0147), and (F) p53 level (N= 6, 
mean + s.e.m., unpaired t-test, *: p=0.0241). 
2.3.2 Cisplatin treatment leads to nucleolar polyP foci formation 
By using the nuclear DNA stain DAPI as reference, we found that cisplatin-induced polyP foci 
mainly localized to the nucleoli of HeLa cells (Fig. 2.1A). To further investigate the subcellular 
localization of polyP following cisplatin treatment, we co-stained control and cisplatin-treated 
HeLa cells with GFP-EcPPXc and an antibody against nucleophosmin (NPM1), a protein localized 
to the granular component of the nucleoli (148). In untreated HeLa cells, we did not observe any 
significant overlap of GFP-EcPPXc fluorescence with NPM1 antibody signal (Fig. 2.2A, left panel, 
and Fig. S2.2A for controls). Upon cisplatin exposure, NPM1 re-localizes within the nucleus, like 
polyP. However, in contrast to polyP, NPM1 diffuses into the nucleoplasm and hence does not co-
localize with polyP (Fig. 2.2A, right panel). These results excluded the possibility that polyP is 
enriched in the granular component of the nucleoli. To test whether polyP localizes to the fibrillar 
center or dense fibrillar component, sub-compartments of the nucleolus in which rDNA 
transcription and early processing take place (148), we conducted similar co-staining experiments 
but used an antibody against RNA polymerase I (Pol I), a component of the fibrillary center of 
nucleoli instead (149). As shown in Fig. 2.2B (and Fig. S2.2B for controls), we found a significant, 
albeit partial overlap between polyP (magenta) and RNA Pol I (cyan) fluorescence upon cisplatin 
treatment. These results were consistent with previous studies which showed co-localization of 
polyP and RNA Pol I in myeloma cells (38). Interestingly, the authors also observed a direct 
inhibition of RNA Pol I activity by polyP in vitro. Given that cisplatin is known to halt rRNA 
transcription in the concentration range of 25 to 100 μM in vivo (150), our finding that polyP and 
RNA Pol I are in close proximity after cisplatin treatment suggests that polyP and RNA Pol I might 
be physically interacting and/or functionally related. Yet, more vigorous biochemical analyses are 
needed to test this hypothesis. 
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Figure 2.2 Cisplatin-induced polyP foci are adjacent to RNA Pol I in the nucleolus. Co-staining of untreated and cisplatin-
treated HeLa cells with GFP-EcPPXc and (A) an NPM1 antibody or (B) an RNA Pol I antibody. The overlay of polyP (magenta) 
and the respective nucleolar marker (cyan) is shown to illustrate the localization of polyP foci in the nucleolus. Representative 
images of projected z series are displayed. Scale bar: 50 μm. The corresponding control images labeled with GFP and the fluorescent 
secondary antibodies are shown in Fig. S2.2, A and B. 
2.3.3 Cisplatin-induced polyP response positively correlates with cellular toxicity 
Microscopic analysis of cisplatin-treated cells revealed a significant cell-to-cell variation in polyP 
staining after treatment with 25 µM cisplatin for 24 hours. Intriguingly, we also observed 
significant cell-to-cell variation in the cleaved caspase-3 signal, suggesting a potential correlation 
between polyP levels and cleaved caspase-3 signal (and hence initiation of apoptosis). To 
investigate whether a correlation between polyP levels and cleaved caspase-3 levels exists, we 
determined the amount of cleaved caspase-3 signal and that of mCherry-EcPPXc signal after 
cisplatin treatment in four independent experiments using between 12 and 46 individual cells per 
experiment. These measurements revealed that, on average, cells with higher polyP levels have 
increased levels of cleaved caspase-3 (Fig. 2.3A). It is of note that cisplatin-induced cleaved 
caspase-3 and polyP do not co-localize to the same cellular compartment after 24 hours of cisplatin 
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exposure (Fig. S2.2C), rendering a direct interaction between the two molecules very unlikely. 
 
Figure 2.3 Correlation between cisplatin-induced polyP accumulation and cellular toxicity. (A) Correlation of polyP levels 
and cleaved caspase-3 levels in individual HeLa cells treated with 25 μM cisplatin for 24 hours. Four different experiments were 
conducted, and symbols of the same color represent cells from the same experiment. (B) A positive correlation between nuclear 
polyP levels and cisplatin-triggered proliferation inhibition in ovarian cancer cells. Cisplatin-sensitive cell line OVCAR3 and 
cisplatin-resistant cell line OVCAR8 were treated with 30 μM cisplatin for 8 hours. Cisplatin toxicity was indicated by reduced 
viability of cisplatin-treated cells with the WST-1 assay (left panel). P-values were derived from two-tailed T-tests. And average 
nuclear polyP levels, normalized to untreated controls, were measured by GFP-EcPPXc fluorescence intensity (right panel). (C) 
Visualization of endogenous polyP in ovarian cancer cells with varying degrees of cisplatin sensitivity. OVCAR3 and OVCAR8 
cells were subject to the same treatment as that in (B). Images from a representative experiment are shown to demonstrate the 
distinct polyP responses of OVCAR3 and OVCAR8 cells to cisplatin, revealed by the different intensities and distribution of GFP-
EcPPXc signals (magenta). Nuclear DNA was labeled with DAPI. Representative images of projected z series are displayed. Scale 
bar: 50 μm. 
The observed positive correlation between cisplatin-mediated polyP accumulation and apoptosis 
initiation in HeLa cells prompted us to explore other cancer cells with intrinsically different 
sensitivities to cisplatin and compare their polyP responses after the drug treatment. Based on IC50 
values reported in the literature, ovarian cancer cell line OVCAR3 is 1.4 to 2-fold more susceptible 
to cisplatin than the ovarian cancer cell line OVCAR8 (151,152). We confirmed these results with 
WST-1 proliferation assays, which showed that OVCAR8 cells are indeed more resistant to 
cisplatin treatment compared to OVCAR3 cells (Fig. 2.3B, left panel). Similar to HeLa cells, both 
ovarian cancer cell lines responded to cisplatin treatment with a dose- and time-dependent increase 
in nuclear polyP levels as well as the formation of distinct nucleolar polyP foci (Fig. S2.3, A and 
B). However, and in agreement with our previous results, the extent to which OVCAR8 cells 
responded to cisplatin treatment with the upregulation and redistribution of polyP was much less 
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pronounced compared to OVCAR3 cells (Fig. 2.3B, right panel and Fig. 2.3C).  In fact, at least 
twice the amount of cisplatin was necessary to trigger a response in OVCAR8 cells that was 
comparable to what we observed in OVCAR3 cells (Fig. S2.3, A and B). These results supported 
our previous conclusion that cisplatin-mediated polyP accumulation and rearrangement positively 
correlate with the level of apoptosis induction and hence cisplatin sensitivity. Although the 
underlying mechanism remains elusive, the dynamic changes of nuclear polyP appear to be a bona 
fide response to cisplatin-induced toxicity in various carcinomas and related to the susceptibilities 
of cancer cells to the chemotherapeutic agent. 
2.3.4 Exogenous polyP administration increases cisplatin sensitivity of selected cancer cells 
Based on our observation that the accumulation of endogenous polyP correlates with the induction 
of apoptosis upon cisplatin exposure (Fig. 2.3), we investigated whether manipulating cellular 
polyP levels would alter cisplatin sensitivity. Unfortunately, the genetic manipulation of in vivo 
polyP levels in mammalian systems is hampered by the fact that the polyP producing and 
decomposing enzyme(s) are still unknown (1). In an attempt to decrease endogenous polyP levels, 
we expressed the S. cerevisiae exopolyphosphatase (ScPPX) under a doxycycline-inducible 
promoter (145) specifically in the nucleus of HeLa cells.  Similar strategies to decrease cellular 
polyP have been used previously albeit with variable success (18,48,50). We confirmed the 
doxycycline-induced expression of ScPPX in the stable cell clones (Fig. S2.4A), and subsequently, 
we measured the enzymatic activity of ScPPX in cell lysates by monitoring the degradation of 
chemically synthesized polyP. Comparing ScPPX specific activity in cell lysates of untreated cells 
(370 mmol Pi·min-1·g-1) versus cisplatin-treated cells (449 mmol Pi·min-1·g-1) revealed that the 
yeast enzyme was fully functional in the presence of cisplatin. However, we failed to observe a 
greater than 10% reduction in the amount of polyP that accumulated in the ScPPX-expressing cells 
following cisplatin treatment (Fig. S2.4B). As a result, there was no significant difference in the 
cisplatin-induced proliferation deficiency between the ScPPX-expressing cells and their parent 
cells either (Fig. S2.4C). 
Being unable to significantly decrease endogenous polyP levels, we employed the opposite 
approach and determined whether increasing endogenous polyP levels might alter the cisplatin 
sensitivity of HeLa cells. We and others have previously shown that mammalian cells readily take 
up exogenous polyP (Fig. S2.4D) (42). We therefore exposed HeLa cells simultaneously to 
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cisplatin and exogenous polyP and determined whether polyP supplementation affects the 
sensitivity of cells toward cisplatin. Indeed, HeLa cells treated with 5 µM cisplatin in combination 
with either 200 µM polyP130 or polyP300 showed a more severe growth defect compared to those 
treated with cisplatin alone (Fig. 2.4A). Cytotoxicity assays confirmed these results and showed 
that the presence of physiologically relevant chain lengths of polyP, that is, polyP130 and polyP300 
significantly increased the efficacy of a higher cisplatin dose, i.e., 25 μM, in triggering apoptosis 
and eventually cell death (Fig. 2.4, B and C). Notably, we did not observe any effect when we 
supplemented cisplatin treatment with shorter polyP chains (polyP14 and polyP60), a finding that 
was fully consistent with previous reports that physiological chain lengths of polyP (>60 Pi units) 
are disproportionally more effective than short polyP chains in a variety of polyP functional assays 
(84). Moreover, we excluded that incubation of cells with polyP in the absence of cisplatin affects 
cell growth or survival (Fig. 2.4, A-C). To test whether polyP enhances cisplatin efficacy also in 
other cell lines, we co-treated OVCAR3 cells with both polyP and cisplatin (Fig. 2.4D). Again, we 
observed a significantly increased toxicity of cisplatin when the treatment was combined with 
polyP. These results strongly suggest that non-toxic, physiologically relevant polyP levels and 
chain lengths are able to synergistically increase the cytotoxicity of cisplatin in cancer cells. 
 31 
 
Figure 2.4 Exogenous polyP increases cisplatin-induced cellular toxicity. (A) Proliferation of HeLa cells treated with 5 μM 
cisplatin in the absence (red bars) or presence of polyP (green bars) or exposed to 200 μM polyP130 or polyP300 only (blue bars) (N 
= 5, mean + s.e.m). A one-way ANOVA followed by a Tukey multiple comparison test was performed (*: p<0.05; **: p<0.01). (B) 
Percentage of Annexin V and PI-positive HeLa cells following the combined treatment of 25 μM cisplatin and 200 μM exogenous 
polyP14-300 (shades of green) compared to cisplatin only treatment (red bar) and polyP alone control (blue bars) (N=7, mean + s.e.m., 
one-way ANOVA with Dunnett’s multiple comparison, *: p<0.05; ****: p<0.0001). (C) Percentage of SYTOX Green-permeable 
(i.e., dead) HeLa cells simultaneously treated with 25 μM cisplatin and 200 μM polyP130 or polyP300 (green bars). Treatment with 
25 μM cisplatin alone is shown in red and the polyP only control is shown in blue (N = 3; mean + s.e.m.). A one-way ANOVA 
followed by a Tukey multiple comparison test was performed (*: p<0.05; **: p<0.01). (D) Percentage of SYTOX Green-permeable 
(i.e., dead) ovarian cancer cell line OVCAR3 simultaneously treated with 25 μM cisplatin and 200 μM polyP130 or polyP300 (green 
bars), or exposed to either 25 μM cisplatin (red bar) or polyP only (blue bars) (N = 3; mean + s.e.m.). A one-way ANOVA followed 
by a Tukey multiple comparison test was performed (**: p<0.01; ***: p<0.001). 
2.4 Discussion 
In this study we discovered that several different cancer cell lines respond to cisplatin treatment 
with the accumulation of endogenous polyP (Fig. 2.1 and Fig. S2.3), whose relative cellular levels 
appeared to directly correlate with apoptosis induction and cell death. Cisplatin treatment seemed 
to trigger both new polyP synthesis as well as subcellular reorganization of polyP pools into distinct 
nucleolar foci, coinciding with a general cisplatin-induced reorganization of the nucleoli. These 
membraneless compartments, which are the birthplace of the ribosomes, have previously been 
shown to be sensitive to perturbations in metabolic rates, cellular stress, and DNA damage 
(148,153). Here, we report the identification of cisplatin-induced polyP foci primarily in the 
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fibrillar center and dense fibrillar component, the regions of rDNA transcription and early 
processing (148). These results suggested that polyP might be involved in the process and/or 
regulation of ribosomal RNA synthesis, a conclusion that was further supported by our findings 
that polyP partially co-localizes with RNA Pol I upon cisplatin stress (Fig. 2.2). Intriguingly, 
previous unrelated studies showed 1) that polyP directly inhibits RNA Pol I activity in vitro (38) 
and 2) that cisplatin treatment inhibits the activity of RNA Pol I in vivo (154). Based on our results 
and the finding that cisplatin-induced polyP levels and apoptosis induction are directly linked, it is 
now tempting to speculate that cisplatin-induced polyP accumulation affects the activity of RNA 
Pol I, thereby activating the apoptotic program. It is of note that reduction of RNA Pol I-mediated 
transcription triggers p53-mediated apoptosis in lymphoma cells but not in non-tumor cells (155). 
This specificity raises the intriguing possibility that polyP might affect RNA Pol I activity and 
enhance cisplatin toxicity specifically in cancer cells. In support of this notion, a recent report 
found that the administration of polyP triggered apoptosis in human colon cancer but failed to 
induce apoptosis in primary cultures of murine small intestinal epithelial cells (156). 
In support of our hypothesis that polyP plays a role in inducing and/or regulating the progression 
of apoptosis following cisplatin stress, we found that cells with higher levels of endogenous polyP 
had, on average, higher levels of apoptosis (Fig. 2.3). Cleaved caspase-3 and cisplatin-induced 
polyP puncta, however, do not localize to the same compartment (Fig. S2.2C), raising the question 
whether polyP acts on other steps in this pathway. The nucleolus has long been implicated to 
partake in the execution of apoptosis (157). Intriguingly, many nucleolar proteins, including 
topoisomerase I (Top1), a potential substrate of caspase-3 (158,159), have recently been found to 
be polyphosphorylated, a novel post-translational modification characterized by the addition of 
polyP chains to lysines (47). Functioning as a molecular switch, polyphosphorylation not only 
appears to mediate the translocation of substrates in and out of the nucleolus but also governs their 
functional activities. Hence it will be of interest to determine whether accumulation of 
polyphosphorylated components lead to the observed puncta formation and contribute to the 
mechanism by which polyP modulates the course of apoptosis. 
Our observation that cleaved caspase-3 and endogenous polyP levels positively correlate now 
raises the fundamental question whether cells that innately generate more polyP are more sensitive 
to cisplatin (i.e., polyP being a mediator of apoptosis), or whether cells that are more sensitive to 
cisplatin accumulate more polyP (i.e., polyP being a “by-product” of apoptosis induction). A key 
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experiment that would help to answer this question is to test the cisplatin sensitivity of polyP-
depleted cells. However, the process of how polyP is generated in mammalian cells has yet to be 
discovered (1). Unable to manipulate the mammalian players of polyP synthesis, we therefore 
attempted to modulate endogenous polyP by expressing a polyP-degrading enzyme from yeast 
(18). This approach, however, was unsuccessful in reducing endogenous polyP levels or affecting 
cisplatin sensitivity in our study (Fig. S2.4). Since the inability to reduce cellular polyP levels was 
not due to potential inhibitory effects of cisplatin on the enzymatic activity of ScPPX, we now 
speculate that cisplatin-induced polyP might either not be accessible to exopolyphosphatases in 
vivo (160), or that the spatial confinement of polyP in the interior of the nucleolus might protect 
polyP from ScPPX (50). Indeed, when we probed the subcellular localization of polyP and ScPPX, 
we found that the two molecules did not partition to the same region in the nucleus. While 
endogenous polyP was highly enriched in the nucleolus, ScPPX was most abundant in the cytosol 
and nucleoplasm (Fig. S2.4E). Furthermore, we cannot rule out the possibility that the polyP-
degrading enzyme, ScPPX, and the polyP-binding probe, EcPPXc, recognize different fractions of 
polyP in the cells. The former might be capable of scavenging soluble polyP (exemplified by polyP 
in the mitochondrial matrix) (15), whereas the latter might selectively bind complexed polyP 
retained in the protein network after paraformaldehyde fixation. 
We then took the opposite approach and increased polyP levels by incubating cells with exogenous 
polyP chains, which are routinely taken up by mammalian cells. These experiments revealed that 
increasing the levels of polyP in cells did indeed increase cisplatin-mediated toxicity in a chain 
length-dependent manner (Fig. 2.4). While the polyP-mediated augmentation of cisplatin toxicity 
was highly reproducible and significant, the relative increase in cytotoxicity was considered 
modest and ranged between 5-10%.  However, we would like to emphasize that supplementation 
of exogenous, synthetic polyP is an imperfect approach to modify intracellular polyP distribution 
and/or abundance. In fact, when we monitored the subcellular localization of fluorescently labeled 
polyP300 chains, it was evident that they did not fully recapitulate the nucleolar localization of 
endogenous polyP fractions (Fig. S2.4D). Hence, we expect much more pronounced enhancement 
of cisplatin potency by polyP once we will be able to genetically manipulate endogenous polyP 
levels.  Nevertheless, our results are supported by published reports, which showed that 
supplementation of lung cancer cells with exogenous polyP increased radiation-induced DNA 
double strand breaks and decreased cell survival (161). Moreover, the pro-metastatic protein h-
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Prune, whose expression correlates with lung cancer progression, has been shown to be a short-
chain exopolyphosphatase in vitro (143,162).  Taken together, these findings suggest that 
mammalian cancer cells might have acquired mechanisms to regulate their cellular polyP levels 
and hence their drug resistance. Therefore, a strategy to increase polyP levels might be a promising 
avenue in the attempt to sensitize cancer cells to cisplatin treatment. This, however, requires the 
ultimate breakthrough in polyP research, namely the discovery of the mammalian polyP regulatory 
machineries and the development of pharmacological tools to target them efficiently and 
specifically. 
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2.5 Supplemental information 
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Supplementary Figure 2.1 Cytotoxic cisplatin treatment causes polyP foci formation in cancer cells. (A) Control images of 
HeLa cells labeled with GFP, instead of GFP-EcPPXc, after various cisplatin treatments. Signal in the GFP channel (magenta) was 
negligible, indicating a very low level of unspecific binding of the GFP-EcPPXc probe. DAPI (blue) was used to locate the cell 
nuclei. Representative images of projected z series are displayed. Scale bar: 50 μm. (B) PolyP accumulation and foci formation in 
HeLa-ATCC cells following cisplatin treatment. An overlay of GFP-EcPPXc (magenta) and DAPI (blue) signals revealed the newly 
formed polyP foci in the nucleus of cisplatin-treated cells. This phenomenon is polyP-specific, as no such changes were observed 
with GFP labeling. Representative images of projected z series are displayed. Scale bar: 50 μm. (C) Quantification of polyP foci in 
untreated HeLa cells (white bars and symbols) and cells treated with 25 μM cisplatin for 24 hours (red bars and symbols). There is 
a change in the number (top panel), area (middle panel), and fluorescence intensity (bottom panel) of polyP foci upon cisplatin 
exposure. A representative analysis is shown. Welch Two Sample t-tests were performed, and the FDR-adjusted p-values for the 
representative experiment are displayed. (D) Cisplatin-induced cell death measured by Trypan blue staining. (N = 7, mean + s.e.m., 
unpaired t-test, **: p=0.0021). (E) Apoptosis induction monitored by the increased levels of cleaved caspase-3 immunofluorescence. 
(N= 9, mean + s.e.m., unpaired t-test, *: p=0.0148). No significant changes were observed in the unspecific binding of the 
fluorescent secondary antibody alone. 
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Supplementary Figure 2.2 Cellular localization of polyP and cleaved caspase-3 after cisplatin treatment. (A and B) HeLa 
cells, untreated or treated with 25 μM cisplatin for 24 hours, were labeled with GFP and the corresponding fluorescent secondary 
antibodies for (A) NPM1 and (B) RNA Pol I stainings. An overlay of GFP (magenta) and the secondary antibody signal (cyan) is 
shown to assess the levels of unspecific binding. Nuclear DNA, illustrated by DAPI fluorescence, was used to locate the cells. 
Representative images of projected z series are displayed. Scale bar: 50 μm. (C) Co-staining using GFP-EcPPXc (magenta) and a 
cleaved caspase-3 antibody (cyan) depicted the dose- and time-dependence of apoptosis induction in HeLa cells triggered by 
cisplatin and revealed distinct localization of polyP and cleaved caspase-3 in the cells. Representative images of projected z series 
are displayed. Scale bar: 50 μm. 
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Supplementary Figure 2.3 Dose- and time-dependence of cisplatin-induced polyP response in ovarian cancer cells. (A) 
Cisplatin-sensitive ovarian cancer cell line OVCAR3 and (B) cisplatin-resistant ovarian cancer cell line OVCAR8 were treated 
with increasing concentrations of cisplatin for 8 and 24 hours and labeled with GFP-EcPPXc (magenta) to monitor the changes in 
polyP levels and distribution. Nuclear DNA was revealed by DAPI fluorescence (blue). Representative images of projected z series 
are displayed. Scale bar: 50 μm. 
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Supplementary Figure 2.4 Manipulation of intracellular polyP levels and distribution in HeLa cells. (A) Western Blotting 
analysis of doxycycline-induced FLAG-tagged ScPPX expression in the nucleus of normal HeLa cells (Control) and three 
independent clones of stably transfected HeLa cells with FLAG-tagged ScPPX (nucPPX1-3). The signal of anti-FLAG antibody is 
shown in the top panel. The Bio-Rad Mini-PROTEAN® TGX Stain-Free™ protein gel allowed visualization of the amount of cell 
lysates run on the gel (bottom panel). (B) Quantification of endogenous polyP levels in the total cell (white bar) and in the nucleus 
(black bars) following the induction of ScPPX expression. PolyP levels were normalized to the corresponding non-induced samples. 
The average and s.e.m. of 3 experiments for the wildtype control and two stable clones are shown. (The nucPPX1 clone did not 
show any effect in two biological replicates). (C) Proliferation of normal HeLa cells (black and gray) and ScPPX stable clones 
(blue and green) upon cisplatin exposure. ScPPX expression was induced by doxycycline (solid lines) and compared to the non-
induced samples (dashed lines). The average of 4 experiments and the s.e.m. are displayed (The nucPPX1 clone has been tested 
twice and showed similar results). (D) Uptake and redistribution of fluorescently labeled polyP in parallel to cisplatin treatment. 
200 μM Alexa Fluor 647-labeled polyP₃₀₀ was supplemented to HeLa cells in the absence or presence of 25 μM cisplatin for 24 
hours. The cellular localization of endogenous polyP (labeled with GFP-EcPPXc, magenta) and that of exogenous polyP (Alexa 
Fluor 647-labeled, cyan) seemed to be different. (E) Subcellular localization of polyP and transiently expressed ScPPX in HeLa 
cells. An overlay of the fluorescence signal of anti-FLAG antibody (green), mCherry-EcPPXc (red), and DAPI (blue) showed 
distinct compartmentalization of polyP and FLAG-tagged ScPPX in the nucleus of HeLa cells.
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Chapter 3 The Dynamic Rearrangement of Nucleolar Inorganic Polyphosphate Is 
Inflicted by Ribosome RNA Synthesis Stress 
3.1 Introduction 
Previous work from our lab revealed that endogenous polyphosphate (polyP) accumulates at 
distinct foci in the nucleolus of various cancer cells upon treatment with the anticancer drug 
cisplatin (127). Moreover, the extent of polyP accumulation positively correlates with the intrinsic 
cisplatin sensitivity of the cell. This earlier work also showed that upon uptake of exogenous polyP, 
selected tumor cells become sensitized to the cisplatin treatment. Taken together, these findings 
suggest that polyP is a downstream effector of cisplatin, and that alterations in polyP levels might 
be a novel strategy for cancer interventions. Yet, to explore this idea, we must first understand the 
mechanistic details as well as the physiological impact of the cisplatin-mediated polyP response in 
the mammalian cells. 
As potent chemotherapeutic agents, platinum-derived drugs, including cisplatin, inflict irreversible 
damage to the DNA, proteins, and small molecules of proliferating cells (137,139,140,163-165). 
Then, they activate apoptotic signaling pathways and incur a non-inflammatory type of cell death 
(129). 
Among the list of known cisplatin toxicities, inhibition of rRNA synthesis might be the most 
promising mechanism to engage polyP (150,154). Based on our and other’s results, a portion of 
polyP and RNA polymerase I (Pol I), the principal source of rRNA, are held in the fibrillar center 
(FC) of the nucleolus in untreated cells (38). Moreover, we found that upon cisplatin intake, both 
molecules relocate to the same nucleolar foci where they remain in the vicinity of each other (127). 
Notably, the cisplatin concentrations needed to mobilize this pair of molecules also coincide with 
those known to stall rDNA transcription (150,154). Hence, it is now tempting to speculate that 
polyP and RNA pol I physically and perhaps functionally converge in response to cisplatin stress. 
The nucleolus is a multiplex, highly dynamic assembly of over seven hundred proteins and two 
hundred RNAs (166,167). These molecules are compacted into three independent yet collaborative 
moieties: the aforementioned fibrillar component (FC), the dense fibrillar component (DFC), and 
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the granular component (GC) (148). Each of the three regions undertakes a specific task in 
ribosomal biogenesis: rDNA is transcribed at the border of FC and DFC, and the premature rRNA 
is processed throughout DFC and GC prior to entering the nucleoplasm (148). In an interphase 
nucleolus, DFC is sandwiched between FC at the interior core and GC in the outmost layer (Fig. 
3.1A). Remarkably, the boundary of each nucleolar compartment is demarcated not by a lipid 
bilayer but by the incompatible phase properties of itself and its adjacent environment (168). Phase 
separation is amenable to changes in protein concentration, ionic strength, pH, temperature, and 
so on (169). Thus, it not only allows free communications between different nucleolar 
compartments but also enables a prompt structural rearrangement of the nucleolus in reply to 
various stress stimuli. 
So far, at least three types of unconventional nucleolar morphologies have been observed (170). 
Low doses of actinomycin D (ActD), which arrest rDNA transcription, lead to the formation of a 
variety of cap structures that line up the periphery of the nucleolus (171) (Fig. 3.1B). Based on 
their constituents and appearances in the electron microscope, these cap structures are further 
categorized into dark nucleolar caps, light nucleolar caps, and fibrillar caps. More than a decade 
ago, the compositions of dark and light nucleolar caps have been elucidated with 
immunofluorescence labeling (171). As it turns out, dark nucleolar caps are dominated by 
nucleoplasmic proteins, such as fused in sarcoma (FUS) and PTB-associated splicing factor (PSF), 
while light nucleolar caps recruit a number of DFC members, including Nopp140 and fibrillarin, 
which are in charge of premature rRNA processing. The core machineries of rDNA transcription, 
represented by RNA pol I, upstream binding factor (UBF), TBP-associated factors (TAFs), and 
DNA topoisomerase I (TOP1) are temporarily stored in the fibrillar caps adjacent to the light 
nucleolar caps. Notably, this is by no means an exhaustive list of nucleolar segregates formed after 
ActD treatment. Another protein, coilin, which is a classic Cajal body marker, moves onto the 
nucleolar surface and occupies what overlaps extensively but not completely with the light 
nucleolar caps (171,172). Whether coilin belongs to a new type of nucleolar cap structure remains 
an open question. Yet, this observation signifies an unprecedentedly finetuned structure of the 
nucleolus, which remains to be fully explored. All the aforementioned caps surround the so-called 
central body originated from GC and reconfigure the nucleolus in an effort to cope with stalled 
rRNA gene transcription. 
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Figure 3.1 Structural organization of the nucleolus. Nucleolus is a multicomponent, phase-separated entity with versatile 
structural patterns adopted in different cellular environments. (A) In an interphase nucleolus, FC, DFC and GC are compacted into 
three independent layers, with FC at the innermost core and GC on the outer surface. (B) Upon RNA pol I inhibition, not only 
nucleolar proteins but also nucleoplasmic components are recruited to a series of cap structures surrounding the periphery of the 
nucleolus. Among them, dark nucleolar caps (mainly consisting of nucleoplasmic proteins), light nucleolar caps (made up of DFC 
members), and fibrillar caps (derived from FC) are the most well characterized examples. (C) When late rRNA processing is 
abolished, the intact nucleolus disappears due to a complete dissipation of GC. Consequently, FC and DFC manifest themselves as 
interspersed “beads” on a “string” of extended rDNA – a structure denoted as nucleolar necklace. (D) In the case of a mild heat 
shock, which leads to substantial protein unfolding in the nucleoplasm, nearly two hundred aggregation-prone proteins are shuttled 
to the GC compartment where they will be sorted for either refolding or degradation. Notably, the volume of the nucleolus is 
enlarged due to an enormous capacity of GC for the arriving folding intermediates. (E) Proteasome inhibition causes a different 
subset of proteins, largely substrates of ubiquitin ligases, to be deposited at the center of the nucleolus, or the so-called aggresomes. 
Rarely are nucleolar markers found in these segregates, which differs them from the structure formed by GC for the partially 
unfolded proteins described in (D). 
An alternative nucleolar conformation denoted as nucleolar necklace occurs upon inhibition of 
rRNA processing (173) (Fig. 3.1C). In this scenario, the architectures of FC and DFC appear 
normal, allowing for an unperturbed yield of premature rRNA. However, the shell-like GC region, 
which encompasses the late rRNA processing machineries dissolves.  This lifts the spatial 
confinement imposed by GC on the other two compartments, and consequently, an extended piece 
of rDNA becomes decorated with interspersed FC and DFC granules just like a string running 
through a cluster of beads. The appearance of the nucleolar necklace is typically observed in cells 
treated with 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) (173). But it is important to 
note that, as an adenosine analog, DRB has more than one cellular target, such as P-TEFb and 
casein kinase 2 (174,175), both of which are critical for RNA pol II transcription rather than rRNA 
processing. 
Most recently, the nucleolus has been identified as a reservoir for metastable proteins when cells 
are challenged with proteotoxic stress conditions, such as heat shock (176,177), proteasome 
inhibition (178) or viral infection (due to an overload of newly synthesized proteins) (179). Upon 
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heat shock, roughly two hundred partially unfolded proteins are accommodated by the GC 
compartment in a conformation that is fully competent for either Hsp70-mediated refolding or 
ubiquitination and subsequent degradation (176,177) (Fig. 3.1D). Although it is plausible that 
uncharacterized ATP-independent chaperones exist in the GC, it is more likely that the intrinsic 
folding environment of this phase-separated domain is sufficient to confer the chaperone activities 
that are necessary for this wide spectrum of clients (177). Treatment with the proteasome inhibitor 
MG132, on the other hand, leads to a massive accumulation of substrates in the so-called nucleolar 
aggresome (178,180) (Fig. 3.1E). Such inclusions appear to be devoid of nucleolar markers (178), 
clearly indicating that different types of proteotoxic insults trigger different responses in the 
nucleolus. How detrimental signals of protein quality are transmitted to the nucleolus remains an 
open question awaiting further investigation. 
In summary, the nucleolus takes advantage of phase separation to obtain the structural versatility 
required for a prompt response to diverse environmental cues. In this study, we investigated how 
nucleolar polyP responds to different stress treatments and characterized the nature of cisplatin-
induced polyP foci. Our studies showed that polyP might serve as an important signal for rRNA 
regulation, and this finding deepened our understanding about the physiological functions of 
nucleolar polyP. 
3.2 Materials and methods 
3.2.1 Reagents 
Cis-Diammineplatinum(II) dichloride (#P4394, Sigma-Aldrich) was dissolved in double distilled 
water at a stock concentration of 3 mM. Actinomycin D (ActD) (#11421, Cayman Chemical, Ann 
Arbor, MI, USA) was prepared in DMSO at a stock concentration of 5 mM. 5,6‐dichloro‐1‐β‐D‐
ribofuranosylbenzimidazole (DRB) (#D1916, Sigma-Aldrich) was dissolved in DMSO at 40 mg/ 
ml. And MG132 (#474790, Millipore Sigma) was also solubilized by DMSO to yield a 2.5 mM 
stock solution. Recombinant human TNF-α in liquid form (#PHC3015L) was purchased from 
Thermo Fisher Scientific. BV6, an IAP antagonist (#5339650001, Sigma-Aldrich), was dissolved 
in DMSO to a stock concentration of 10 mM. Z-VAD(OMe)-FMK (#sc311561, Santa Cruz 
Biotechnology, Dallas, TX, USA), a caspase inhibitor, was reconstituted in DMSO at 20 mM. All 
the reagents except cisplatin were aliquoted and stored at -20 ℃. 
A vector containing GFP-EcPPXc was generated in three steps. First, an EcPPXc fragment was 
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amplified from the pETM41-EcPPXc plasmid, which encodes the Maltose Binding Protein 
(MBP)-EcPPXc (kindly provided by Florian Freimoser; Addgene plasmid #38329; 
http://n2t.net/addgene:38329; RRID:Addgene_38329) (144). Then, EcPPXc was cloned into a 
pTEV5 vector between BamHI and NotI restriction sites downstream of mCherry. Finally, 
mCherry sequence was swapped by GFP gene cloned from pEGFP-N2 plasmid with flanking NdeI 
and BamHI sites. GFP-EcPPXc and the respective control probe, GFP, were purified as His-tagged 
proteins with Ni-NTA columns (Qiagen, Hilden, Germany). 
All reagents were obtained from Thermo Fisher Scientific (Waltham, MA, USA), Sigma-Aldrich 
(St. Louis, MO, USA), and New England Biolabs (Ipswich, MA, USA) unless stated otherwise. 
3.2.2 Cell lines and treatments 
HeLa (ATCC® CCL-2™, ATTC, Manassas, VA, USA) cells and mouse embryonic fibroblasts 
(kindly provided by Dr. Miriam Greenberg at Wayne State University) were grown in DMEM 
(#11995065, Thermo Fisher Scientific). HeLa Kyoto cells which stably overexpress FUS-GFP (a 
generous gift from Dr. S. Alberti, Dresden University of Technology) (181) were cultured in 
DMEM (#10569010, Invitrogen). All media were supplemented with 10% Fetal Bovine Serum 
(#F4135, Sigma-Aldrich) and 1% Penicillin-Streptomycin (#15140122, Thermo Fisher Scientific). 
Cells were grown in a humidified incubator at 37°C with 5% CO2. 
An approximately 80% confluent cell monolayer was detached from the flask with 0.05% Trypsin-
EDTA (#25300054, Thermo Fisher Scientific). For cytotoxicity assays, cells were plated in a 96-
well tissue culture plate (#3596, Corning, Inc., Corning, NY, USA) with 104 cells/ well. For 
immunofluorescence experiments, cells were seeded at a density of 5×104 cells/ well in a 24-well 
plate (#3526, Corning, Inc.) containing a piece of coverslip (#CLS-1760-012, Chemglass Life 
Sciences, Inc., Vineland, NJ, USA) at the bottom of each well. On the next day, spent medium was 
removed and the fully attached cells were treated with cisplatin, ActD, DRB, MG132, or a 
combination of TNF-α, BV6, and Z-VAD-FMK (TSZ) with the designated conditions. 
3.2.3 Cytotoxicity assays 
Cell viability was quantified with the WST-1 Cell Proliferation Assay Kit (#10008883, Cayman 
Chemical, Ann Arbor, Michigan, USA) with slight modifications of the manufacturer’s protocol. 
Briefly, the WST-1 Developer Reagent and the Electron Mediator Solution were first diluted to 
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their working concentrations in fresh medium. This mixture was then added to the cells after the 
supernatant was removed. Samples were incubated at 37 ℃ for 2 h to develop a stable absorbance 
signal at 450 nm wavelength which could be read by a BMG FLUOstar Omega Microplate Reader 
(Ortenberg, Germany). The average absorbance measurements of the drug treated samples were 
normalized to those of the untreated cells. 
SYTOXTM Green Nucleic Acid Stain (#S7020, Thermo Fisher Scientific) was used to assess the 
extent of cell death. Following the protocol published in (146), two identical sets of samples were 
prepared. One of them was permeabilized with 120 µM Digitonin (#D141, Sigma-Aldrich) after 
drug treatment, while the other was undisturbed. Then, 5 µM SYTOXTM Green Nucleic Acid Stain 
was added to both sets of samples and kept at 37°C for 30 min. The fluorescence of stably 
incorporated SYTOXTM Green Nucleic Acid Stain only in the membrane compromised cells was 
measured by a Tecan Infinite M1000 Microplate Reader (Männedorf, Switzerland) set to 504 nm 
excitation wavelength and 523 nm emission wavelength. The signal intensity of digitonin-treated 
samples signified the total number of cells. Therefore, the percentage of dead cells in each 
condition was represented by the ratio of the fluorescence measurement of the unpermeabilized 
replicate over that of the corresponding digitonin-treated sample. 
3.2.4 Immunofluorescence labeling 
Control and drug treated cells were fixed with freshly made 4% (v/v) Paraformaldehyde (#1578100, 
Electron Microscopy Sciences, Hatfield, PA, USA) at room temperature for 20 minutes. After three 
washes with PBS, they were permeabilized with 0.3% (v/v) Triton X-100 (#0219485480, MP 
Biomedicals, Solon, OH, USA) for 10 minutes. Triton X-100 was dissolved in blocking buffer, 
containing 1% (w/v) Bovine Serum Albumin (#A3059, Sigma-Aldrich) in PBS. After three more 
washes with PBS, cells were incubated in blocking buffer for at least 1 h to prevent nonspecific 
binding. Endogenous polyP was labeled with GFP-EcPPXc (or the respective control probe, GFP) 
at a concentration of 10 µg/ ml in blocking solution. To label nuclear proteins of interest, the 
following mouse monoclonal antibodies from Santa Cruz were used – Nopp140 (E-7) (#sc-
374033), coilin (F-7) (#sc-55594), UBF (F-9) (#sc-13125), p14 (F-12) (#sc-1661), PML (PG-M3) 
(#sc-966), and p-Histone H2A.X (Ser-139) (#sc-517348) antibodies. All these antibodies were 
used at a final concentration of 0.8 μg/ ml in blocking buffer. A rabbit polyclonal antibody for 
IP6K1 (#HPA040825, Sigma-Aldrich) was applied at 1.4 μg/ ml. A mouse anti-human G3BP 
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antibody (#611127, BD Biosciences, San Jose, CA; a generous gift from the Barmada Lab at 
University of Michigan) was used at 1 μg/ ml. Samples were double labeled with GFP-EcPPXc 
and a specific antibody for the protein of interest at 4 ℃ overnight in the dark. After that, they 
were rinsed three times with PBS and stained with compatible secondary antibodies for 2 h at room 
temperature, protected from light. Secondary antibodies from Abcam, Cambridge, United 
Kingdom, including donkey anti-mouse IgG-Alexa Fluor® 488 (#ab150105), donkey anti-mouse 
IgG-Alexa Fluor® 647 (#ab150107), and goat anti-rabbit IgG-Alexa Fluor® 647 (#ab150079) were 
used at a final concentration of 1 μg/ ml. Following three washes with PBS, cells were labeled 
with a counter stain, i.e., 1 μg/ ml DAPI (#D1306, Thermo Fisher Scientific) for 10 min. Finally, 
cells were washed with PBS three more times and mounted in Citiflour AF1 mounting medium 
(#19470, Ted Pella, Inc., Redding, CA, USA) on a microscope objective slide. 
Fluorescence imaging was performed with a Leica SP8 laser scanning confocal microscope (Leica 
GmbH, Mannheim, Germany) built on a DMI8 microscope base and via LAS X software (Leica 
GmbH). This microscope was equipped with a 100× oil objective (#11506378, Leica GmbH), a 
405 nm diode laser, and a multi-line white light laser, whose excitation wavelengths were set to 
488, 594 and 647 nm. To detect fluorescence emissions, a PMT was used for DAPI (410 to 480 
nm), and a HyD detector was used for GFP (493 to 560 nm), Alexa Fluor® 488 (493 to 560 nm), 
and Alexa Fluor® 647 (653 to 800 nm). 
3.2.5 Plasmid transfection 
To monitor the dynamics of fibrillarin and Nopp140, HeLa cells were seeded at a density of 
1.5×104 cells/ well on an 8-well NuncTM LabTekTM II Chambered Coverglass (#155409PK, 
Thermo Fisher Scientific). Twenty-four hours later, cells were transfected with a plasmid encoding 
either fibrillarin-GFP or Nopp140-GFP (generous gifts from Dr. Y. Shav-Tal, Bar-Ilan University). 
Lipofectamine 2000™ (#11668027, Thermo Fisher Scientific) was used to transfect the plasmids 
per the manufacturer’s instructions with only slight modifications. The amount of plasmid, 
Lipofectamine™ 2000, and Opti-MEM™ Reduced Serum Medium (#31985062, Thermo Fisher 
Scientific) was designated for a single transfection event. Briefly, 0.75 μl Lipofectamine™ 2000 
reagent and 0.3 μg plasmid was each dissolved in 37.5 μl Opti-MEMTM and incubated at room 
temperature for 5 min. Once combined, the reagents were mixed gently and incubated for another 
20 min to allow plasmid packaging onto the liposome. Shortly before adding the transfection 
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mixture in a dropwise manner to the cells grown on coverglass, spent medium was removed and 
replaced with 150 μl fresh medium in each well. Then, the cells were incubated at 37 ℃ for 4 h to 
take up the plasmid, followed by another medium change to get rid of superfluous copies of the 
plasmid. Overexpressed proteins were studied on the next day. 
3.2.6 Fluorescence recovery after photobleaching (FRAP) 
FRAP experiments were performed on a Leica SP8 laser scanning confocal microscope equipped 
with a 100× oil objective (with 3-fold digital zoom in), a Tokai Hit stage top incubator maintained 
at 37 ℃, a 405 nm diode laser, a multi-line white light laser set to 488 nm excitation wavelength, 
and a HyD detector capturing GFP fluorescence emission from 493 to 560 nm. A FRAP protocol 
was developed in the LAS X software (Leica GmbH) as described below. The region to be 
photobleached was defined manually using the ROI tool. To deplete the fluorescence signal as 
rapidly as possible, the power of the 405 nm diode laser (i.e., the bleaching laser) was set to 100%. 
Image acquisition rate was adjusted to 0.865 s/ frame. Each time course consisted of two frames 
taken before photobleaching, (two frames during photobleaching which were not shown in the 
final dataset), and 18 frames acquired during fluorescence recovery. 
3.3 Results 
3.3.1 Cisplatin-induced polyP foci form at the light nucleolar cap, Cajal body, and fibrillar 
cap 
To detail the molecular composition of cisplatin-induced polyP foci, we performed 
(immuno)fluorescence labeling of polyP and a list of nuclear body markers, including fused in 
sarcoma (FUS), Nopp140, UBF, p14, coilin, and promyelocytic leukemia (PML) in untreated 
HeLa cells and those treated with 40 μM cisplatin for 24 h. The distribution and the relative 
abundance of polyP were visualized with GFP-EcPPXc, a recombinant fluorescent probe that 
interacts with polyP specifically via the substrate-binding domain of Escherichia coli 
exopolyphosphatase (147). It was evident that cisplatin treatment not only reproducibly increased 
GFP-EcPPXc intensity but also caused polyP relocation to prominent foci, which had different 
sizes and shapes and appeared in different regions within the nucleus (Fig. 3.2, Fig. S3.1, and Fig. 
S3.2). Merging the signals of polyP and each of the protein markers that we used and analyzing 
their fluorescence intensity profiles in designated cellular regions, we observed three categories of 
polyP foci based on their colocalizations. PolyP colocalized 1) with Nopp140 in the light nucleolar 
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caps (Fig. 3.2A and Fig. S3.2A); 2) with coilin in the Cajal bodies (Fig. 3.2B and Fig. S3.2B); and 
3) with UBF in the fibrillar caps (Fig. 3.2C and Fig. S3.2C), respectively. 
Even in untreated cells, Nopp140 and polyP exhibited similar patterns of DFC staining, albeit with 
relatively low signal intensities (Fig. 3.2A and Fig. S3.2A). In comparison, when cisplatin was 
administered, Nopp140 readily segregated into bright, crescent-shaped foci (Fig 3.2A, arrows, and 
Fig. S3.2A) characteristic of the light nucleolar caps formed upon rDNA transcription inhibition. 
Notably, the responses of polyP to cisplatin resembled those of Nopp140, and polyP appeared to 
localize to the same structures (Fig. 3.2A, arrows, and Fig. S3.2A). Therefore, we propose that 
polyP is a previously unrecognized member of the light nucleolar caps. 
This conclusion was further corroborated by the overlap of polyP and coilin, a Cajal body marker, 
which is known to accumulate at least partially in the light nucleolar caps upon cisplatin treatment 
(171,172). Indeed, while coilin was almost exclusively detected in the Cajal bodies in the 
nucleoplasm of untreated cells, it appeared as crescent-like puncta at the periphery of the nucleolus 
in cisplatin-treated samples (Fig. 3.2B, arrows, and Fig. S3.2B). Again, GFP-EcPPXc fluorescence 
increased in these structures (Fig. 3.2B, arrows, and Fig. S3.2B), consistent with the idea that polyP 
accumulates in the light nucleolar caps upon cisplatin treatment. 
Cajal bodies, which are small, dotted and coilin-rich granules, did not seem to contain polyP unless 
the cells were stressed with cisplatin (Fig. 3.2B, arrowheads, and Fig. S3.2B). Interestingly, a 
subset of Nopp140-positive foci with similar numbers and morphology to Cajal bodies emerged 
in the nucleoplasm following cisplatin treatment (Fig. 3.2A, arrowheads, and Fig. S3.2A). Indeed, 
Nopp140 has been proposed to serve as the link between light nucleolar caps and Cajal bodies by 
physically interacting with coilin (182). Therefore, we postulate that Nopp140 together with polyP 
colocalize to Cajal bodies upon cisplatin treatment. 
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Figure 3.2 Cisplatin-triggered polyP foci colocalize with markers for light nucleolar caps, Cajal bodies, and fibrillar caps. 
Colocalization of polyP and (A) Nopp140, a light nucleolar cap marker, (B) coilin, a Cajal body marker, and (C) UBF, a fibrillar 
cap marker was assessed by immunofluorescence in either untreated HeLa cells (top row) or cells treated with 40 μM cisplatin for 
24 h (bottom row). Gray scale images from left to right depict the distribution of DNA (labeled with DAPI), polyP (labeled with 
GFP-EcPPXc) and (A) Nopp140, (B) coilin or (C) UBF (labeled with the specific primary and secondary antibodies). In cisplatin-
treated cells, typical light nucleolar caps (arrows) and Cajal bodies (arrowheads) are highlighted. An overlay of polyP (pseudo color: 
magenta) and the respective protein marker (pseudo color: cyan) is displayed in the rightmost panel with two regions (a and b) 
enlarged for more details. The corresponding fluorescence intensity plots for polyP and each protein marker can be found in Fig. 
S3.2. Representative images of projected z series are shown. Scale bar information is denoted in panel (A). 
Prompted by the finding that a minor portion of polyP resides in the FC compartment of the 
nucleolus in untreated cells (38), we set out to analyze the spatial correlation between polyP and 
UBF, a fibrillar cap marker, in the context of cisplatin stress. As it turns out, cisplatin treatment led 
to significant changes in the shapes and fluorescence intensities of UBF puncta, consistent with 
the formation of fibrillar caps (Fig. 3.2C and Fig. S3.2C). These alterations were accompanied by 
an increase of GFP-EcPPXc signal in the UBF-positive assemblies (Fig. 3.2C, arrows, and Fig. 
S3.2C). We thus concluded that cisplatin-induced polyP foci are also part of fibrillar cap structures. 
In stark contrast to Nopp140 and coilin, UBF was rarely drafted to nucleoplasmic foci, such as 
Cajal bodies (Fig. 3.2C, arrowheads, and Fig. S3.2C). 
It is worthwhile mentioning that FC and DFC are tightly associated in an interphase nucleolus. 
Therefore, it is very likely that these compartments remain proximate to each other even when the 
nucleolus is reconfigured by cisplatin. This disposition reconciles our findings that polyP exhibits 
a substantial colocalization with both light nucleolar caps and fibrillar caps, marked by Nopp140 
and UBF, respectively (Fig. 3.2, A and C; and Fig. S3.2, A and C). 
On the contrary, we were unable to associate polyP accumulation with markers for dark nucleolar 
caps (demarcated by GFP-FUS) (Fig. S3.1A and Fig. S3.2D), central body (labeled with p14) (Fig. 
S3.1B and Fig. S3.2E), or PML bodies (Fig. S3.1C and Fig. S3.2F) either before or after cisplatin 
intake. 
In summary, polyP, which is normally concentrated in the FC and DFC portions of the nucleolus, 
is selectively mobilized to the light nucleolar caps, Cajal bodies, and fibrillar caps after cisplatin 
treatment (Fig. 3.2 and Fig. S3.2). Notably, fibrillar caps and light nucleolar caps include rDNA 
transcription and processing machineries. Besides, light nucleolar cap protein Nopp140 and Cajal 
body marker coilin, which get shuffled bidirectionally in reply to cisplatin, not only 
coimmunoprecipitate with each other but also bind to RPA1, the catalytic core of RNA pol I, to 
suppress rRNA synthesis under certain stress conditions (172,183). Thereby, we propose that these 
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polyP hotspots may be genuine responses to cisplatin and/or strategies to combat this stress 
condition. 
3.3.2 Formation of polyP foci in the nucleoli and Cajal bodies is a result of RNA pol I 
inhibition 
Intrigued by the polyP deposits in nucleolar cap structures and Cajal bodies in cells challenged 
with cisplatin, we set out to unravel the molecular mechanisms underlying this phenotype. To begin 
with, we assessed the possibility that polyP was directly guided to DNA lesions. Using γ-H2AX 
as a readout for double stranded breaks (184), we confirmed the efficacy of our cisplatin treatment 
to reduce DNA stability with a massive upregulation of γ-H2AX immunofluorescence signal 
throughout the nucleus (Fig. S3.3A). However, we did not observe any consistent colocalization 
between γ-H2AX loci and polyP, suggesting that polyP was not directly associated with cisplatin-
mediated DNA damage. 
We then expanded the list of cytotoxic agents to determine how different types of cell death affect 
polyP abundance and localization. We tested a combined treatment with 10 ng/ ml TNF-α, 10 nM 
BV6 (a SMAC mimetic), and 20 μM Z-VAD-FMK (TSZ), which kills cells through necroptosis 
(185). However, this treatment did not recapitulate the polyP behavior observed upon cisplatin 
treatment despite an impairment of cell survival in embryonic mouse fibroblast (Fig. S3.3, B and 
C). Taken together, these results exclude the idea that polyP is merely a signature of dying cells. 
Instead, it appears that polyP might be actively and selectively involved in a designated cell death 
mechanism. 
Cisplatin is well known to inhibit rDNA transcription when administered at the concentrations that 
we used in our experiments (150,154,172). To investigate whether stalling rRNA synthesis is 
sufficient to mobilize polyP, we investigated the effects of ActD, a specific inhibitor of RNA pol I 
activity when used at low concentrations (186). Indeed, treatment of HeLa cells with 10 ng/ ml 
ActD for 4.5 h led to the formation of light nucleolar caps that were positive for both Nopp140 
and polyP (Fig. 3.3A, arrows, and Fig. S3.4A) as well as coilin and polyP (Fig. 3.3B, arrows, and 
Fig. S3.4B). Moreover, the polyP signal was also prevalent in the regions designated as fibrillar 
caps where UBF accumulates in response to ActD (Fig. 3.3C, arrows, and Fig. S3.4C). In addition, 
we found a large number of Cajal bodies, featured by Nopp140 and coilin to contain polyP signals 
(Fig. 3.3, A and B, arrowheads; and Fig S3.4, A and B). 
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Figure 3.3 PolyP foci appear at light nucleolar caps, Cajal bodies, and fibrillar caps upon ActD treatment. 
Immunofluorescence experiments were performed to assess the colocalizations of polyP and (A) Nopp140, a light nucleolar marker, 
(B) coilin, a Cajal body marker, and (C) UBF, a fibrillar cap marker. HeLa cells were either untreated (top row) or treated with 10 
ng/ ml ActD for 4.5 h to block rRNA transcription. Gray scale images from left to right display the patterns of DNA (labeled with 
DAPI), polyP (labeled with GFP-EcPPXc), and the respective protein marker (labeled with the specific primary and secondary 
antibodies). Typical light nucleolar caps are denoted with arrows and typical Cajal bodies are highlighted with arrowheads. 
Fluorescence images of PolyP (pseudo color: magenta) and the protein markers (pseudo color: cyan) are merged to illustrate the 
close proximity of these molecules. For each overlay, two regions (a and b) are enlarged for more details. The corresponding 
fluorescence intensity plots can be found in Fig. S3.4. Representative images of projected z series are shown. Scale bar information 
is included in panel (A). 
On the contrary, neither dark nucleolar caps marked by FUS-GFP (Fig. S3.4D and Fig. S3.5A) nor 
central bodies labeled with p14 (Fig. S3.4E and Fig. S3.5B) showed a considerable amount of 
polyP. 
In summary, by using ActD treatment, which allowed us to specifically inhibit RNA pol I activity, 
we observed a set of changes in the distribution and abundance of polyP identical to the ones 
observed with cisplatin treatment (Fig. 3.2, Fig. 3.3, Fig. S3.2, and Fig. S3.4). This result strongly 
suggests a correlation between disruption of rRNA synthesis and polyP mobilization. 
3.3.3 IP6K1 is a novel component of the light nucleolar cap 
With the advance of human protein atlas, the nucleolar proteome of HeLa cells has been 
documented in unprecedented details (https://www.proteinatlas.org/). Among the hundreds of 
nucleolar proteins, IP6K1 sparked our interest for being particularly enriched in FC and having 
been found to regulate polyP levels in yeast, Trypanosoma, and mice (120-123). Based on this 
premise, we investigated the spatial relationship between IP6K1 and polyP in the context of rRNA 
synthesis. As shown in Fig. 3.4A and Fig. 3.4B, a clear IP6K1 signal with irregular and diffuse 
pattern is visible in the nucleolus of untreated cells. Once we administered cisplatin or ActD, 
however, IP6K1 formed foci that colocalized partially with the highest levels of polyP (Fig. 3.4, A 
and B, arrows). Based on their count and morphology, we predicted that IP6K1 accumulated in 
light nucleolar caps. To test this idea, we conducted colocalization analysis of IP6K1 and Nopp140. 
IP6K1, which appeared to be enclosed in the Nopp140-positive DFC area under non stress 
conditions (as expected for a FC member) clearly segregated to the light nucleolar caps marked by 
Nopp140 upon ActD treatment (Fig. 3.4C). These results demonstrate that IP6K1 and polyP are 
found in close proximity in the nucleolus, and they are novel members of the light nucleolar caps 
under distinct rDNA stress conditions. 
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Figure 3.4 IP6K1 accumulates in the light nucleolar cap structures upon rRNA transcription inhibition. (A and B) 
Colocalization of polyP and IP6K1 was analyzed by immunofluorescence experiments in two conditions: (A) 40 µM cisplatin 
treatment for 24 h and (B) 10 ng/ ml ActD treatment for 4.5 h. Untreated HeLa cells (top rows) and treated cells (bottom rows) 
were labeled with DAPI (gray scale, left), GFP-EcPPXc (gray scale, middle), and specific primary and secondary antibodies for 
IP6K1 (gray scale, right). Typical nucleolar caps are highlighted with arrows. Fluorescence signals of polyP (pseudo color: magenta) 
and IP6K1 (pseudo color: cyan) are merged to exhibit the close proximity of the two molecules. Two regions (a and b) are enlarged 
for more details. (C) Colocalization of Nopp140, a light nucleolar cap marker, and IP6K1 was also examined by 
immunofluorescence. HeLa cells were stained with DAPI (gray scale, left), Nopp140 antibodies (gray scale, middle), and IP6K1 
antibodies (gray scale, right) either before (top row) or after (bottom row) the same ActD treatment as that in (B). Classic light 
nucleolar cap structures are pointed out by arrows. An overlay of Nopp140 (pseudo color: red) and IP6K1 (pseudo color: cyan) 
fluorescence is displayed with two regions (a and b) enlarged for a magnified view. Representative images of projected z series are 
shown. Scale bar information is included in panel (A). 
3.3.4 Light nucleolar caps are highly dynamic structures 
Given the identification of components of the light nucleolar cap, we decided to test the structural 
dynamics of this compartment using fluorescence recovery after photobleaching (FRAP). This 
approach allows us to observe the diffusion of fluorescently labeled markers in real time and 
quantify the kinetics of this event. Originally, our goal was to visualize the dynamics of polyP in 
light nucleolar caps, however, this idea was limited by the lack of polyP probes suitable for live 
cell imaging. As an alternative, we took advantage of ectopically expressed Nopp140-GFP in HeLa 
cells as a representative of the overall phase properties of light nucleolar caps. Importantly, upon 
treatment with ActD, overexpressed Nopp140-GFP segregated to the periphery of the nucleolus 
and distinct nuclear bodies (presumably Cajal bodies) in the same way as its endogenous 
counterpart (Fig. 3.5, A, D and G). We then employed a photobleaching protocol and compared 
the mobility of Nopp140 in different parts of the nucleus. We chose to focus on three regions of 
interest: 1) a spot within the light nucleolar cap (Fig. 3.5, A-C), 2) the entire light nucleolar cap 
(Fig. 3.5, D-F); and 3) the entire nuclear body (Fig. 3.5, G-I). As shown by the fluorescence time-
lapse images (Fig. 3.5, B, E and H), all three regions showed a recovery of signal intensity after 
photobleaching. When we plotted fluorescence intensity against time (Fig. 3.5, C, F and I), we 
observed a recovery rate on the timescale of seconds, consistent with earlier reports (171). Notably, 
fluorescence recovery within the nucleolar cap might be faster than the image acquisition rate 
(0.865 s/ frame), otherwise we would have observed a distinct “dark” region after photobleaching. 
Instead, it appeared that Nopp140-GFP diffusion had almost equilibrated by the time the first 
image was taken during fluorescence recovery (Fig. 3.5, B and C). This observation indicates a 
homogenous, liquid-like environment in this structure. On the contrary, recovery of Nopp140-GFP 
fluorescence across the boundaries between the light nucleolar cap and its adjacent environment, 
or between the nuclear body and the nucleoplasm was significantly slower (Fig. 3.5, E, F, H and 
I). This difference in the recovery rate likely reflects different phase properties of these sub-
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organellar regions, which create an invisible barrier for the diffusion and exchange of highly 
localized molecules. Importantly, the dynamic behaviors of Nopp140 within the light nucleolar 
cap and across the border of this compartment were fully recapitulated by fibrillarin, which was 
exclusively targeted to the light nucleolar cap upon ActD treatment (Fig. S3.6, A-F). These results 
strongly suggest that light nucleolar caps are overall highly dynamic. It is now tempting to 
speculate that polyP, a heavily negatively charged molecule just like a few known modulators of 
phase separation (187-190), might finetune the phase parameters so as to maintain a liquid-like 
state of the light nucleolar cap and nuclear bodies, preventing them from coalescing with other 
structures. 
 
Figure 3.5 Nopp140 is a dynamic member of the light nucleolar caps and other nuclear bodies. (A-C) Nopp140 is diffusive 
in the light nucleolar cap. (A) Ectopically expressed Nopp140-GFP partitioned to light nucleolar caps and other nuclear bodies 
(presumably Cajal bodies) after ActD treatment. Nucleus was outlined by a white dashed line, and the nucleolus of interest was 
highlighted by a yellow square. Scale bar: 10 μm. (B) In the nucleolus highlighted in (A), photobleaching was directed to the region 
marked by a red circle. Time-lapse images of Nopp140-GFP were acquired before photobleaching and during fluorescence recovery. 
The time interval between each frame was 0.865 s. (C) Nopp140-GFP fluorescence in the photobleached region decreased sharply 
during photobleaching but rapidly recovered afterwards. Note that fluorescence measurements were unavailable during 
photobleaching. (D-F) Nopp140 is transported to light nucleolar caps from the adjacent environment. (D) A different nucleolus 
marked by the yellow square was studied. (E) Photobleaching was performed on the entire light nucleolar cap circled in red. 
Nopp140-GFP fluorescence signal was monitored before and after photobleaching. The interval between each frame of the time-
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lapse images was 0.865 s. (F) Nopp140-GPF fluorescence in the marked region in (E) was largely depleted by photobleaching, but 
it slowly recovered post the exposure. (G-I) Nopp140-rich nuclear bodies are highly dynamic structures. (G) A smaller nuclear 
body highlighted by the yellow square was investigated for its crosstalk with the nucleoplasm. (H) An intact nuclear body, 
demarcated by a red circle, was subject to photobleaching. Time-lapse images of Nopp140-GFP fluorescence were taken before 
and after photobleaching with an interval of 0.865 s between each frame. (I) Nopp140-GFP fluorescence in the nuclear body was 
eliminated by photobleaching, whereas it gradually recovered after the treatment. 
3.3.5 Nucleolar polyP is sensitive to the inhibition of rRNA processing 
To test whether polyP redistributes also in the presence of other drugs that lead to structural 
rearrangements of the nucleolus, we treated HeLa cells with 10 μM DRB for 2 h. DRB, an 
adenosine analog and kinase inhibitor, leads to the formation of the loose nucleolar necklace (173). 
Under these stress conditions, we observed the formation of both large and small polyP foci, which 
emerged in a prompt reaction towards the DRB treatment (Fig. 3.6A). Both types of polyP 
assemblies adopted a regular, round shape, which was in stark contrast to the crescent light 
nucleolar cap structures that formed upon cisplatin or ActD treatment. Interestingly, a number of 
the small polyP foci were found in patterns that resembled the nucleolar necklace (Fig. 3.6A, 
arrowheads). Some of the larger polyP foci were adjacent to but excluded from the nucleolus which 
typically had low DAPI signals (Fig. 3.6A, arrows). As of now, we are unable to trace the origins 
of these structures without further investigating the molecular compositions of these polyP 
assemblies. It is possible that they represent an intermediate state in the transition from an intact 
nucleolus to a nucleolar necklace or a result of the unspecific effects of DRB on RNA pol II. 
On the contrary, we did not find any significant redistribution of polyP upon inactivation of the 
proteasome using MG132, which is known to deposit substrates of ubiquitin ligases at the center 
of the nucleolus denoted as “aggresome” (178,179). We tested a wide range of MG132 
concentrations, i.e., 0 to 2.5 μM, which neither triggered polyP accumulation nor relocation within 
the nucleolus (Fig. 3.6B), in spite of causing a clear defect in cell growth and survival (Fig. 3.6C). 
This result was consistent with the fact that MG132 does not interfere with the FC and DFC 
compartments (178), and it suggested that the polyP response is specific and not generally 
associated with nucleolar reorganization events. 
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Figure 3.6 A distinct type of nucleolar polyP foci occur upon the disruption of late rRNA processing but not the formation 
of nucleolar aggresomes or cytoplasmic stress granules. (A) Immunofluorescence analysis of polyP localization and levels in 
untreated HeLa cells (top row) and cells treated with 10 µM DRB for 2 h (bottom row) which inhibits late rRNA processing. DAPI 
fluorescence is an indicator for DNA and GFP-EcPPXc fluorescence is a readout for polyP. Two types of polyP foci are discernible: 
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large, round, isolated polyP foci are highlighted with arrows; and small, clustered polyP foci are pointed out by arrowheads. An 
overlay of DNA (pseudo color: gray) and polyP (pseudo color: magenta) signals is shown with two enlarged regions (a and b) for 
more details. (B) The patterns of endogenous polyP are delineated by immunofluorescence microscopy when HeLa cells were 
treated with 0, 0.1, 0.5, and 2.5 μM MG132 to block proteasomal activities. DAPI and GFP-EcPPXc were used to label DNA and 
polyP respectively. (C) The cytotoxicity of MG132 was manifested in the growth defects (measured by WST-1 assay) (top) and 
cell death (quantified by SYTOX Green assay) (bottom) in HeLa cells. MG132 conditions were the same as those in (B). (D) The 
distribution of polyP in the process of stress granule formation was monitored by immunofluorescence techniques in HeLa cells. 
Cells treated with 0.5 mM NaAsO2 for 0, 15, 30, 60, and 120 min were co-stained with GFP-EcPPXc to reveal the abundance of 
polyP (top) and specific antibodies for G3BP1 (bottom), a stress granule marker, to monitor the extent of stress granule formation. 
Representative images of projected z series are shown. Scale bar information is included in panel (A). 
Finally, we explored whether polyP incorporation is a universal character of phase-separated 
granules in mammalian cells. Here, we made use of G3BP1-positive stress granules in the 
cytoplasm (191). Whereas G3BP1 was expressed at very low levels in untreated HeLa cells, it 
formed heterogeneous, membraneless granules within 15 min of sodium arsenite (NaAsO2) 
exposure (Fig. 3.6D). We did not detect any significant polyP signals even when we prolonged the 
NaAsO2 incubation to 2 h (Fig. 3.6D). Instead, we observed a slight increase in the fluorescence 
intensity of nucleolar polyP that was concomitant with the increase in stress granules. Therefore, 
we conclude that polyP is not an essential scaffold for every phase separation-driven structure, 
although it might be influenced by the same environmental cues. 
3.4 Discussion 
3.4.1 PolyP partitions to light nucleolar caps, fibrillar caps and Cajal bodies in response to 
rRNA transcription inhibition 
In this study, we explored the mechanistic details for our previous observation that polyP 
segregates to distinct nucleolar foci in cisplatin-treated cells. Using immunofluorescence analysis 
of polyP and a range of nuclear body markers, we identified polyP foci to localize at light nucleolar 
caps, fibrillar caps, and Cajal bodies (Fig. 3.2, Fig. 3.3, Fig. S3.2 and Fig. S3.4). These structures 
share structural and functional commonalities with each other. A number of light nucleolar cap 
proteins originate from the DFC and FC, which constitute active rDNA transcription sites (148). 
Moreover, light nucleolar cap structures reveal a dynamic crosstalk with Cajal bodies by 
exchanging their proteins and RNAs  (172,182). Most importantly, however, both polyP-
containing structures have previously been found to form once RNA pol I is inhibited and rRNA 
synthesis is stalled (150,172). This result suggests that polyP is functionally related to RNA pol I 
in vivo, and it is consistent with previous studies that showed polyP to inhibit RNA Pol I activity 
in vitro (38). Yet, it is unclear if and how polyP interacts with the other proteins in these cap 
structures, and what the functional significance of this colocalization is in the context of rRNA 
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synthesis stress. 
We found that polyP associates with Nopp140, a light nucleolar cap marker. Previous work showed 
that Nopp140 is heavily phosphorylated, accounting for more than 25% of its apparent molecular 
weight and making it one of the most phosphorylated proteins in human cells (192). In fact, 
Nopp140 harbors ten serine-rich stretches with an average length of 15 residues (including 
sporadic glutamates and aspartates) joint by lysine- and proline-rich sequences (192). For a long 
time, serine was considered as the only target for phosphorylation in these segments. However, 
this paradigm has recently been shifted by the novel finding that poly acidic, serine and lysine-rich 
motifs  (PASK), which are highly abundant in Nopp140, undergo polyphosphorylation events, i.e., 
the conjugation of polyP chains to lysine residues (47,48). Compared to serine/threonine 
phosphorylation, lysine polyphosphorylation is much more efficient in maximizing the phosphate 
content of Nopp140. This feature might be particularly beneficial to human Nopp140 since 
phosphorylation is pivotal for the structure and function of this protein. When phosphorylated, 
human Nopp140 adopts an intrinsically disordered conformation which is highly resistant to heat 
even at a boiling temperature (192,193). However, once phosphorylation is abolished at low ionic 
strength, namely 0.15 M salt, Nopp140 aggregates almost instantaneously (192). The drastic 
differences in the solubility of Nopp140 suggest that phosphorylation is a prerequisite for reducing 
the aggregation propensity of this protein and keeping it soluble. Intriguingly, polyP exerts robust 
chaperone activities on a variety of clients by shielding them from heat- and oxidation-induced 
misfolding (25,26,28,29). Hence, it is tempting to hypothesize that polyphosphorylation is 
exploited to increase the structural flexibility and solubility of Nopp140. 
To test the idea that cisplatin or ActD treatment triggers the polyphosphorylation of Nopp140 in 
vivo, an established biochemical assay can be used to assess the molecular weight of Nopp140 in 
mammalian cell lysates before and after exopolyphosphatase treatment (47). In fact, SRP40, the 
yeast homologue of Nopp140, harbors two PASK-like motifs (48), consistent with the observation 
that SRP40 is phosphorylated in vivo, albeit to a much less extent than the rat and human 
counterparts (194). Therefore, it is also plausible that SRPP40 is polyphosphorylated. In this case, 
modulation of polyP levels in yeast by mutating VTC4 (the yeast PPK gene) will provide a clear 
answer. 
So far, the physiological functions of polyphosphorylation focus on the modification of subcellular 
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localization and/or enzymatic activity of the substrate (47). We wonder whether this portion of 
polyP could also exert chaperone function, a role that polyP plays in many bacteria (25,26,28,29). 
It is well-known that the nucleolar proteome faces major challenges in protein folding.  On the one 
hand, the nucleolus is extremely densely packed with proteins and RNAs (166,167), on the other 
hand, a large number of nucleolar proteins are intrinsically disordered (195). In this regard, 
covalent attachment of polyP, a universal biopolymer and primordial chaperone (25), might 
become a promising strategy to increase the solubility of nucleolar proteins within this adverse 
folding environment. Coincidentally, coilin, another nucleolar and Cajal body marker proximal to 
polyP, also features two potential PASK motifs (48), which might account for the overlapping 
fluorescence of GFP-EcPPXc and coilin antibodies (Fig. 3.2, Fig. 3.3, Fig. S3.2 and Fig. S3.4). 
Moreover, coilin like Nopp140 lacks a defined three-dimensional structure (196). It is unknown 
whether polyphosphorylation is essential to the structural dynamics of coilin yet. But if so, this 
finding will greatly strengthen the idea that polyP acts as a molecular chaperone across all 
kingdoms of life. 
From a technical standpoint, colocalization of GFP-EcPPXc fluorescence with Nopp140, coilin, 
and UBF (which contains a single PASK motif) suggests that EcPPXc-derived probes might be 
genuine reporters of polyphosphorylation in situ. This claim is consistent with our previous 
proposal that immobilized, protein-bound polyP is favored over unbound, organellar polyP (in the 
mitochondria and secretory vesicles) by the immunofluorescence detection method. Based on the 
current knowledge of polyphosphorylation, it will be necessary to test the ability of EcPPXc to 
bind   polyphosphorylated and unphosphorylated forms of Nopp140, coilin, and other known 
targets of this modification (48). To take this one step further, polyphosphorylated proteins (as well 
as stable polyP binding partners) might coimmunoprecipitate with EcPPXc-coated beads, and thus 
they could be identified by mass spectrometry. Once established, this approach will for the first 
time unveil the in vivo polyP-associated proteins in many eukaryotic organisms and provide a more 
comprehensive picture of polyP physiology. 
3.4.2 Potential roles of polyP in the regulation of RNA Pol I 
Our results suggested that the most likely trigger for polyP’s partitioning to light nucleolar caps 
and Cajal bodies is the inhibition of RNA pol I. This finding was corroborated by a low-dose ActD 
treatment, which specifically stalls rDNA transcription and elicited the same redistribution of 
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polyP as previously observed with low concentrations of cisplatin (Fig 3.2, Fig. 3.3, Fig. S3.2 and 
Fig. S3.4). As antitumor remedies, both cisplatin and ActD intercalate into DNA double helix with 
a preference for GC-rich loci (197,198). This feature renders the promoter of 45S ribosomal gene 
a primary target for either drug even when they are administered at minimal concentrations 
(150,186). Given that nucleolar polyP is mobilized by the same regimens, it is very likely that 
polyP partakes in one or more downstream events in the rRNA synthesis pathway. 
Prior to this study, the impact of polyP on the activity of RNA pol I has been determined ex vivo 
(38). When isolated nucleoli from myeloma cells were supplemented with physiological 
concentrations of exogenous polyP, the abrogation of transcriptional activity was observed (36). 
Therefore, it is conceivable that an inhibitory polyP concentration can be easily achieved in the 
segregated nucleolar compartments where polyP, RNA pol I, and other nucleolar proteins cluster 
in the presence of cisplatin or ActD (Fig. 3.2, Fig. 3.3, Fig. S3.2 and Fig. S3.4). To this date, neither 
the mechanism nor the physiological relevance of polyP-mediated inhibition of RNA pol I has 
been revealed. Here, we propose several mechanisms by which polyP may impair RNA pol I 
activities in vivo. 
UBF, which colocalizes with polyP upon cisplatin and ActD treatment, is an essential transcription 
factor that stabilizes the pre-initiation complex containing TATA box-binding protein (TBP), TBP-
associated factors (TAFs), and the RNA polymerase itself at the transcription start sites (199). Only 
when UBF is stably anchored at the upstream control element of rDNA will RNA pol I, which is 
usually in excess, be continuously recruited to the promoter region to sustain rRNA synthesis. Both 
bioinformatic predictions of PASK motifs and fluorescence colocalization of UBF and polyP 
suggest that UBF might be a target for polyphosphorylation (48). Furthermore, previous studies 
on Top1 and Nsr1, the first two polyphosphorylated proteins identified in the nucleolus of yeast, 
provided strong premises that polyphosphorylation is influential on protein localizations and 
functions (47). As such, it will be important to determine whether UBF is polyphosphorylated, and 
if so, how this modification affects the interaction between UBF and the upstream control element 
of rDNA. 
In addition to UBF, Nopp140 and coilin are physiologically relevant binding partners and 
inhibitors of RPA1 (172,183), the largest subunit and catalytic core of RNA pol I. Whereas 
Nopp140 contains ten hypothetical PASK motifs, coilin contains two. The functional levels of 
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Nopp140 must be finetuned to maximize the yield of rRNA because once overexpressed, Nopp140 
instigates a nucleolar segregation and an RNA pol I inactivation identical to those observed with 
ActD treatment (183). The same is true for an ectopic overexpression of coilin (172). Therefore, it 
will be curious to investigate the possibility that polyP interferes with rDNA transcription by 
modulating the levels of these proteins and/or their affinities for RPA1. 
3.4.3 PolyP might also respond to the inhibition of rRNA processing 
Our studies also showed that DRB, an adenosine analog which interferes with rRNA processing, 
triggers the polyP relocation to prominent nucleolar foci (Fig. 3.6A). However, in contrast to the 
distinct crescent shaped foci that form when rDNA transcription is halted, two different 
populations of round polyP assemblies appear following DRB treatment. Interestingly, several 
small polyP foci tend to cluster within a very short distance to each other, forming a pattern which 
recapitulates the so-called nucleolar necklace (173). Nucleolar necklaces are typically observed 
after DRB treatment since DRB effectively disengages the rRNA processing machinery in GC 
from the active transcription sites at the border of FC and DFC (173). Since polyP is an intrinsic 
component of FC and DFC, it is expected that the rearrangement of polyP phenocopies that of the 
nucleolar compartments. Yet, the most important evidence to support this idea would be the 
localization of FC/DFC markers to the small polyP granules, which can be monitored by 
immunofluorescence. 
Equally enigmatic are the identities of the large polyP foci, some of which are clearly excluded 
from the nucleolus (Fig. 3.6A). This observation speaks against a connection between the large 
polyP foci and rRNA synthesis. Indeed, besides disrupting rRNA processing, DRB is recognized 
for inhibiting RNA pol II (174,175). Given a moderate conservation between RNA polymerases I 
and II (with 12 identical subunits) and the fact that mediator of RNA polymerase II transcription 
subunit 1 (MED1) is among the top candidates for polyphosphorylation (48), we postulate that 
RNA Pol II might also serve as a target of polyP. 
3.4.4 IP6K1 is a novel component of the light nucleolar cap 
IP6K1 is a key enzyme of the inositol phosphate pathway, taking charge of phosphorylating the 
most abundant form of inositol phosphate in human cells, namely IP6, to form IP7 and IP8 (117). 
Both products belong to inositol polyphosphates, which not only resemble certain structural 
properties of polyP but also directly influence polyP synthesis. For instance, when KCS1, the yeast 
 65 
homolog of IP6K1, is deleted, the cells become devoid of polyP, similar to the Δvtc4 strain lacking 
the polyP producing enzyme (123). Moreover, both IP6 and IP7 boost Vtc4 enzymatic activities, 
with IP7 being a much more potent accelerator than IP6 (124,125). Other species, including 
Trypanosoma and mice, also suffer from a decrease of polyP reserve when Ip6k1 gene is knocked 
out (120-122). Although it is unlikely that IP6K1 is the mammalian PPK per se, as Ip6k1-/- mice 
retain around 50% polyP in their platelets (122), it is evident that IP6K1 is involved in polyP 
synthesis at least tangentially. 
From the Human Protein Atlas project, we became aware that IP6K1 is also located in the 
nucleolus, and we found the enzyme to colocalize with polyP under both non-stress and stress 
conditions (Fig. 3.4). Following ActD treatment, we observed the translocation of IP6K1 to the 
light nucleolar cap, coinciding with the relocation and accumulation of polyP in the same 
compartment. While we are unable to ascertain whether de novo polyP synthesis is responsible for 
this phenomenon, at a minimum, these results establish a spatial correlation between IP6K1 and 
polyP upregulation in the nucleolus. In a follow-up study, we plan to knockout/knockdown IP6K1 
in HeLa cells and compare their cisplatin- or ActD-mediated polyP response to that of the wildtype. 
This approach will provide a more straightforward answer to the question whether IP6K1 is 
responsible for polyP accumulation in the context of rRNA synthesis stress. 
3.4.5 The role of polyP in the phase separation of the nucleolus 
The nucleolus is an intricate, self-organized and phase-separated structure which retains very high 
protein motility within the same compartment and less so across the border of different 
compartments (Fig. 3.5 and Fig. S3.6). Characteristic of a phase-separated entity, the nucleolus is 
rich in charged and intrinsically disordered proteins (195). Many of them, such as fibrillarin and 
nucleolin, are capable of forming phase-separated droplets by themselves provided with the 
appropriate buffer conditions in vitro (168). Yet, to form an intact nucleolus in the cellular 
environment requires a multitude of regulations. By far, RNA and ATP are the most well-
established regulators of phase separation (187-190). Their working mechanisms rely, at least 
partially, on their abundant negative charges, which interact with the positively charged residues 
enriched in the phase-separating nucleolar proteins. This notion leads us to propose that polyP, a 
similarly negatively charged and phosphate-rich molecule endogenous to the nucleolus, may 
contribute to the nucleolar phase separation process in vivo. An encouraging finding in Citrobacter 
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freundii supports this idea by showing that the phase separation behavior of an engineered substrate, 
+36GFP, was greatly affected by nutrient deprivation conditions, which are known to  alter cellular 
polyP content (200). The same group reconstituted +36GFP coacervates in vitro and revealed a 
polyP chain length-dependent trait of this process (200), similar to other types of polyP protein 
interactions (25,26,84).  It is intriguing whether this aspect of polyP activity has been preserved in 
the evolution of miscellaneous phase-separated compartments in the mammalian species. To 
answer this question, one must develop a feasible tool to either up- or down-regulate polyP levels 
(e.g., in the nucleolus) and analyze the corresponding kinetic parameters of local proteins using 
the FRAP technique. This proposal again alludes to the paramount importance of discovering the 
polyphosphate kinase(s) and polyphosphatases in mammalian cells. 
3.5 Outlook 
We are confident that this study together with the abovementioned follow-up experiments will 
deepen our understanding of polyP and ribosome biogenesis. In addition to the emerging evidence 
which lays the foundation of polyphosphorylation in the late ribosome assembly (48), these 
experiments will reveal the role of polyP and polyphosphorylation in the de novo synthesis and 
processing of premature rRNA transcripts. By prioritizing Nopp140, coilin, and UBF among 
hundreds of candidates to be polyphosphorylated in vivo, we conceptualize novel mechanisms to 
leverage RNA pol I activities. Furthermore, we propose to engineer EcPPXc-related tools to 
visualize and/or purify polyphosphorylated molecules from a cellular origin. 
The ultimate transition from the description of polyP distributions in response to stress to the 
mechanistic understanding of polyP’s role in the physiology of the eukaryotic cell, however, relies 
on the development of a robust and reliable polyP manipulation paradigm. Whereas this endeavor 
is greatly hindered by the unknown polyphosphate kinase(s) and polyphosphatase(s), it may be 
achieved by ectopically expressing E. coli or yeast polyP-metabolizing enzymes in an 
organelle/compartment of interest. Based on previous experiences from us and others, the success 
of this strategy seems to depend on the locations where these enzymes are targeted to (18,48,50,60). 
Alternatively, an endogenous nucleolar protein and potential polyP modifier, namely IP6K1, may 
be genetically ablated to indirectly affect polyP levels. However, the outcome of this approach will 
inevitably be confounded by inositol polyphosphates throughout the cell and therefore become 
hard to be interpreted. As far as we know, neither upregulation nor downregulation of polyP in the 
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nucleolus specifically has been reported so far. Therefore, this might be a niche for exploring polyP 
and ribosomal biogenesis through trial and error. 
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3.6 Supplemental information 
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Supplementary Figure 3.1 Cisplatin-induced polyP foci are distinct from dark nucleolar caps, central bodies, and PML 
bodies. Colocalization of polyP and (A) FUS, a dark nucleolar cap marker, was monitored by labeling polyP with mCherry-EcPPXc 
in a stable FUS-GFP-overexpressing HeLa Kyoto cell line. Partitioning of polyP and FUS was evident both before (top row) and 
after (bottom row) a 25 µM cisplatin treatment for 24 h. From left to right are signals of DNA (revealed by DAPI), polyP (revealed 
by mCherry-EcPPXc), and endogenously expressed FUS-GFP. PolyP (pseudo color: magenta) and FUS-GFP (pseudo color: cyan) 
fluorescence signals are merged and two regions (a and b) are enlarged for more details. Colocalizations of polyP and (B) the central 
body marker, p14(ARF) and (C) the PML body marker, PML were also examined by immunofluorescence. Untreated HeLa cells 
(top row) and cells treated with 40 µM cisplatin for 24 h (bottom row) were labeled with GFP-EcPPXc and the respective primary 
and secondary antibodies for the protein markers. DNA, polyP, and (B) p14(ARF) or (C) PML signals are shown from left to right. 
The rightmost image is an overlay of polyP (pseudo color: magenta) and the respective protein marker (pseudo color: cyan). Two 
regions (a and b) are enlarged for a detailed view. The corresponding fluorescence intensity plots can be found in Fig. S3.2. 
Representative images of projected z series are shown. Scale bar information is denoted in panel (A).  
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Supplementary Figure 3.2 Colocalization analysis of polyP and nuclear markers in cisplatin-treated cells with fluorescence 
intensity plots. The spatial correlation of polyP and (A) Nopp140, (B) coilin, (C) UBF, (D) FUS-GFP, (E) p14 or (F) PML was 
analyzed by measuring the fluorescence intensities of GFP-EcPPXc (or mCherry-EcPPXc) and the designated protein marker at the 
same positions in the nucleus. On the left of each panel, fluorescence images of untreated HeLa cells (top) and cells treated with 
40 μM cisplatin for 24 h (bottom) are shown to visualize the distributions of polyP (pseudo color: magenta) and the respective 
nuclear marker (pseudo color: cyan). Positions of interest are defined by a yellow dashed line. On the right is the alignment of the 
fluorescence intensities of polyP (magenta) and the nuclear marker (cyan) at each position along the yellow dashed line (shown as 
the distance from the starting point). Each peak represents a punctum of polyP and/or the nuclear marker. The height of the peak is 
proportional to the signal intensity before and after cisplatin treatment, whereas the width of the peak indicates the size of the 
punctum. An overlapped peak is a signature of the colocalization of polyP and the corresponding nuclear marker. 
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Supplementary Figure 3.3 PolyP foci are not a direct readout of DNA damage or cell death. (A) Immunofluorescence labeling 
of polyP and γ-H2AX, a reporter for DNA double stranded breaks, was performed in untreated HeLa cells (top row) and cells 
treated with 40 μM cisplatin for 24 h (bottom row). The distributions of DNA (gray scale, left), polyP (gray scale, middle), and γ-
H2AX (gray scale, right) were depicted by DAPI, GFP-EcPPXc, and specific primary and secondary antibodies for γ-H2AX. 
Overlaying polyP (pseudo color: magenta) and γ-H2AX (pseudo color: cyan) signals, it is evident that these two molecules belong 
to distinct nuclear compartments after cisplatin treatment. For each merged image, two regions (a and b) are enlarged for a more 
detailed view. Representative images of projected z series are shown. Scale bars are shown on the images. (B) Survival rates of 
mouse embryonic fibroblasts treated with 10 ng/ ml TNF-α, 10 nM BV6 (a SMAC mimetic), and 20 μM Z-VAD-FMK (denoted as 
TSZ) were measured by SYTOX Green assay. (C) The corresponding time lapse analysis of polyP levels and distributions after 0, 
3, and 6 h TSZ treatment was conducted via fluorescence labeling of polyP with GFP-EcPPXc. 
 72 
 
Supplementary Figure 3.4 Colocalization analysis of polyP and nuclear markers in ActD-treated cells using fluorescence 
intensity plots. The spatial correlation of polyP and (A) Nopp140, (B) coilin, (C) UBF, (D) FUS-GFP or (E) p14 was examined 
by plotting the fluorescence intensities of GFP-EcPPXc/mCherry-EcPPXc and the designated protein marker at the same positions 
in the nucleus. On the left side of each panel are fluorescence images of untreated HeLa cells (top) and cells treated with 10 ng/ ml 
ActD for 4.5 h (bottom), showing the overlay of polyP (pseudo color: magenta) and nuclear marker (pseudo color: cyan) signals. 
A series of positions are selected by a yellow dashed line. On the right side are fluorescence intensity plots of polyP (magenta) and 
the nuclear marker (cyan) at different positions along the yellow dashed line (shown as their distances from the starting point). 
Each peak signifies a punctum of polyP and/or the nuclear marker. The height of the peak reflects the signal intensity before and 
after ActD treatment, and the width of the peak measures the size of the structure. Overlapped peaks are indications of the 
colocalizations of polyP and selected nuclear markers. 
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Supplementary Figure 3.5 PolyP foci formed upon ActD treatment are excluded from dark nucleolar caps and central bodies. 
(A) Colocalization study of polyP and FUS, a dark nucleolar cap marker, was conducted using immunofluorescence method. 
Untreated HeLa Kyoto cells (top row) and cells treated with 10 ng/ ml ActD for 4.5 h (bottom row) were labeled with DAPI (gray 
scale, left) and GFP-EcPPXc (gray scale, middle). FUS-GFP (gray scale, right) was stably overexpressed in the cells. An overlay 
of polyP (pseudo color: magenta) and FUS-GFP (pseudo color: cyan) fluorescence is displayed with two regions (a and b) enlarged 
for a closer view. (B) Colocalization analysis of polyP and p14(ARF), a central body marker, was also examined in untreated HeLa 
cells (top row) and cells treated with the same ActD condition (bottom row). Gray scale images from left to right depict the patterns 
of DNA (stained with DAPI), polyP (stained with GFP-EcPPXc), and p14(ARF) (stained with the specific primary and secondary 
antibodies). PolyP (pseudo color: magenta) and p14(ARF) (pseudo color: cyan) signals are merged to show the partition of the two 
molecules. Two regions (a and b) are enlarged for more details. The corresponding fluorescence intensity plots can be found in Fig. 
S3.4. Representative images of projected z series are shown. Scale bar information is included in panel (A) 
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Supplementary Figure 3.6 Fibrillarin-GFP is highly dynamic in the light nucleolar cap and communicates with the 
surrounding environment. (A-C) FRAP analysis of fibrillarin-GFP within the light nucleolar cap. (A) Overexpressed fibrillarin-
GFP was targeted to light nucleolar caps upon ActD treatment in HeLa cells. Two nuclei were outlined by white dashed lines and 
the nucleolus of interest was highlighted by a yellow square. (B) In the same nucleolus as the one highlighted in (A), photobleaching 
was limited to the region with the red border, and time-lapse images of fibrillarin-GFP fluorescence were taken with a time interval 
of 0.865 s. The first two images were taken prior to photobleaching, and the following 18 images were taken during fluorescence 
recovery. (C) Fibrillarin-GFP fluorescence intensity in the photobleached area was plotted against time. Note that measurements 
were unavailable during photobleaching. (D-F) FRAP analysis of fibrillarin-GFP between light nucleolar caps and their adjacent 
environment. (D) The same cells (outlined by white dashed lines) and the same nucleolus (highlighted by the yellow square) were 
studied. (E) The entire nucleolar cap circled in red was subject to photobleaching, and time-lapse images of fibrillarin-GFP were 
acquired with a time interval of 0.865 s. Two images were taken before photobleaching, followed by 18 images taken after 
photobleaching. (F) Fibrillarin-GFP fluorescence intensity in the designated nucleolar cap decreased due to photobleaching and 
gradually recovered after photobleaching. Fluorescence intensity measurements were unavailable during photobleaching.
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Chapter 4 Identification of Polyphosphate Regulatory Genes in Mammalian Cells 
4.1 Introduction 
Despite the high conservation of inorganic polyphosphate (polyP) (2), very little is known about 
the mechanisms by which it is synthesized and/or degraded in the vast majority of species. Ever 
since polyP aroused the attention of biologists in the 19th century, the field took the greatest leaps 
when the bona fide polyphosphate kinases (PPKs) were discovered, first in Escherichia coli (7) 
and later on in Saccharomyces cerevisiae (62). A lack of sequence homology between E. coli ppk1, 
yeast vacuolar transport chaperone 4 (VTC4), and any mammalian genes eliminates a 
bioinformatic approach to identify PPK genes in the human genome. Hence, coming up with 
alternative strategies is a prerequisite for solving the most intriguing puzzle in the field, namely 
how mammalian cells manage their polyP reserve. 
By far the most successful attempts at identifying polyP synthesizing machineries utilized a 
combination of biochemical and genetic methods (7,62). 
To isolate E. coli PPK1 from cell lysate, the Kornberg team combined a series of protein 
purification techniques with a highly sensitive, radioactivity-based PPK activity assay (7,201). 
This strategy allowed them to enrich PPK activity by nearly 60,000-fold with a concomitant 
20,000-fold purification of the enzyme. Notably, a similar experimental setup led to the discovery 
of D. discoideum PPK2, whose in vitro polyP-synthesizing activity was corroborated by the same 
assay (114). However, the in vivo activity of this enzyme is still under debate (89). A commonality 
between E. coli PPK1 and D. discoideum PPK2 is their structural rigidity, which survived 
extensive purification procedures using sonication, detergents, salts, affinity binding, and etc. This 
feature together with a reliable specific activity assay are the core premises for uncovering an 
enzyme of interest with a biochemical approach. Undoubtedly, this path had been taken, in fact, as 
the first attempt to find the mammalian PPK (36,105). However, those early endeavors were futile 
as PPK activity was readily lost upon cell lysis. This dilemma brought about a prevalent view that 
mammalian PPK might reside in the lipid bilayers and/or utilize an electrochemical gradient across 
the membrane as an indispensable energy supply (202). 
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The identification of Vtc4 was an unintended result of  a genome-wide microarray analysis of 
phosphate metabolism genes in S. cerevisiae (62). Unlike E. coli, which accumulates polyP under 
oxidative stress with a less than two-fold upregulation of ppk transcripts (34), yeast elicits a similar 
response under phosphate limitation conditions yet with a surge of VTC4 mRNA (62). In retrospect, 
Vtc4 would not have been discovered had researchers not identified an environmental cue that 
triggered a change in polyP levels. Hence, conceptually, establishing an analogous scenario in 
other organisms whose genetic backgrounds are well documented and easily manipulated in a high 
throughput manner might pave the way to unveiling novel PPK genes, particularly those in mice 
and humans. 
Another limiting factor in identifying the polyP machinery in mammalian systems is the 
quantitation of polyP levels. In a biochemical approach, three main steps, namely polyP extraction 
(with phenol chloroform), conversion to ATP (by E. coli PPK1), and ATP detection (with a 
luciferase assay) must be carefully executed to gauge the concentrations of intracellular polyP 
(203). Nonetheless, a few drawbacks are intrinsic to this workflow, including the preference of 
PPK1 for long chain polyP and the incomplete sample recovery rate. A second category of polyP 
detection tools are less quantitative yet uniquely suited to resolve the chain length distribution of 
polyP in a biological sample. This goal is achieved by combining gel electrophoresis with a 
negative staining of polyP with DAPI whose fluorescence signal gets rapidly photobleached under 
UV (204). However, a recent study challenges the specificity of this approach, especially for short 
chain polyP, by exhibiting an identical UV-sensitive feature of DAPI-IP7 fluorescence (205). The 
same problem concerns in situ polyP visualization with DAPI staining because not only polyP but 
also inositol pyrophosphates and RNA induce a signature red-shift of the excitation and emission 
profile of the dye (37,206,207). Apart from DAPI, JC-D7 and JC-D8 are the only polyP reporters 
designed for live cell imaging (40). Both chemicals, albeit less promiscuous than DAPI, bind to 
polyP with much weaker affinity. This caveat might account for a limited application of these tools 
to engineered models where polyP is overrepresented (208). 
In contrast, a wealth of knowledge on the subcellular localization of polyP was driven by the 
development of different variants of the inactive polyP binding domain of E. coli 
exopolyphosphatase (EcPPXc), which revealed polyP in the vacuoles of yeast (147), cell walls of 
algae and fungi (144,209), acidocalcisome-like granules of animal eggs (210,211) and mast cells 
(39), and nucleoli of mammalian cells (38). The high sensitivity and specificity of EcPPXc for 
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polyP was verified by competition assays (147) and follow-up studies using subcellular 
fractionation and biochemical quantification. Ideally, an enzymatic digestion of polyP in the 
samples prior to EcPPXc labeling would provide the ultimate proof for the precision of this probe. 
However, this trial failed in practice possibly due to a tight association of polyP with other 
macromolecules, such as RNA (38), which appears to shield the polymer from being shortened at 
the ends. Thereby, alternative routes must be taken to corroborate the previous findings and 
uncover the full potential of EcPPXc-related probes for characterizing the regulation of polyP in 
mammalian cells. 
In this study, we assessed and confirmed the fidelity of EcPPXc with E. coli strains undergoing 
nutrient starvation, a condition known to induce polyP accumulation in bacteria (5,212). We then 
conducted a genome-wide siRNA screen in HeLa cells treated with cisplatin and labeled with 
mCherry-EcPPXc to search for genuine polyP regulators in the human genome. In the primary 
screen, we identified a list of 115 candidates for the human PPK genes, whose knockdowns 
resulted in more than 70% decrease in polyP levels after cisplatin treatment. We followed up on 
validating 36 of them and found a few potential polyP-related genes, i.e. GRIN3B, P2RY1, 
ATP5F1E, PANK4, and AP3M1 to be of particular interest. Furthermore, we revealed a potential 
connection between inositol phosphate metabolism and polyP levels. Lastly, we discovered a 
subset of genes involved in DNA damage repair, the ubiquitin-proteasome system, and cell cycle 
progression to be essential for combating cisplatin stress in HeLa cells. 
4.2 Materials and methods 
4.2.1 Reagents 
A vector containing mCherry-EcPPXc was generated as previously reported (127). Briefly, we used 
the pETM41-EcPPXc plasmid, which encodes the Maltose Binding Protein (MBP)-EcPPXc 
(kindly provided by Florian Freimoser; Addgene plasmid #38329; http://n2t.net/addgene:38329; 
RRID:Addgene_38329) (144) as a template to amplify the EcPPXc fragment by PCR. Next, this 
fragment was inserted between the BamHI and NotI recognition sites downstream of the mCherry-
coding sequence in a pTEV5 vector. mCherry-EcPPXc protein and the corresponding control, 
mCherry, were His-tagged and therefore could be purified with Ni-NTA columns (Qiagen, Hilden, 
Germany). All reagents used for cloning and protein purification were obtained from Thermo 
Fisher Scientific (Waltham, MA, USA), Sigma-Aldrich (St. Louis, MO, USA), and New England 
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Biolabs (Ipswich, MA, USA) unless mentioned otherwise. 
4.2.2 Nutrient shift treatment of E. coli 
The following amino acid and phosphate limitation protocol was adapted from (28). Briefly, E. 
coli strains with two different genetic backgrounds, wild-type (MG1655) and Δppk1Δppx1, were 
cultured in lysogeny broth (LB) at 37 ℃ overnight. Then, cells were diluted in potassium 
morpholinoprepanesulfonate (MOPS) buffer (#M2101, Teknova, Hollister, CA, USA) 
supplemented with 0.2% glucose, 100 μM potassium phosphate, and 10 μM thiamine to OD600= 
0.1 and cultured at 37 ℃ until mid-log phase (OD600= 0.4 to 0.8). After that, cells were pelleted 
with centrifugation, and supernatant was discarded. 
4.2.3 Immunofluorescence labeling and visualization of polyP in E. coli 
Following nutrient downshift, the cell pellet was resuspended in freshly prepared 4% (v/v) 
Paraformaldehyde (#1578100, Electron Microscopy Sciences, Hatfield, PA, USA) and fixed for 
20 min in a thermomixer set at room temperature, 500 rpm. Then, cells were spun down at 16,100 
g for 1 min in a tabletop centrifuge, and paraformaldehyde was transferred to a hazardous waste 
container. Next, the cell pellet was rinsed with PBS for three times (by completely resuspending 
the cells and spinning them down). To penetrate the plasma membrane, cells were resuspended in 
a permeabilization buffer containing 0.3% Triton X-100 (#0219485480, MP Biomedicals, Solon, 
OH, USA) and 1% Bovine Serum Albumin (#A3059, Sigma-Aldrich) in PBS. Samples were 
incubated in the thermomixer using the same settings. Ten minutes later, cells were subject to 
another round of three PBS washes and subsequently blocked with 1% bovine serum albumin 
dissolved in PBS for 1 h. To label polyP, blocking buffer was replaced with 10 μg/ ml mCherry-
EcPPXc solution, and cells were incubated at 4 ℃, 500 rpm overnight. Hereon, samples should be 
shielded from light as much as possible. A final round of three PBS washes were performed to 
remove superfluous dye. Lastly, cell resuspension in PBS was mounted between a piece of 
coverslip and a microscope glass slide. 
Differential interference contrast (DIC) images and mCherry fluorescence images were acquired 
immediately after sample preparation. The image acquisition platform was constructed with an 
Olympus BX61 upright microscope (Olympus, Center Valley, PA, USA) carrying a 40× objective, 
a Photometrics Coolsnap HQ2 cooled CCD camera equipped with a quad filter set (DAPI/ FITC/ 
TRITC/ CY-5), and an X-Cite® exacte mercury lamp whose illumination intensity was held 
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consistent with a feedback loop. 
4.2.4 High throughput siRNA screens for polyP regulatory genes 
4.2.4.1 Cell line 
HeLa (ATCC® CCL-2™, ATTC, Manassas, VA, USA) cells were grown in DMEM (#11995065, 
Thermo Fisher Scientific) supplemented with 10% Fetal Bovine Serum (#F4135, Sigma-Aldrich) 
and 1% Penicillin-Streptomycin (#15140122, Thermo Fisher Scientific). Cells were cultured at 
37°C with 5% CO2 until they reached ~ 80% confluent and were then detached from the flask 
using 0.05% Trypsin-EDTA (Thermo Fisher Scientific). 
4.2.4.2 Genome-wide human siRNA libraries 
The primary screen for human PPK genes was carried out using the Dharmacon siGENOME 
SMARTPool® human siRNA library (Dharmacon, Inc., Lafayette, CO, USA) purchased by and 
cataloged at the Life Science Institute, University of Michigan. In total,18,110 genes and loci were 
targeted, each by a mixture of four siRNA duplexes to minimize the off-target effect. The 
lyophilized siRNAs were dissolved in siRNA buffer (#B002000UB100, Dharmacon, Inc.) to a 
concentration of 0.5 μM and stored at -80 ℃ in 384-well plates. In the primary screen, three out 
of sixty-seven siRNA stock plates were assayed at a time. Afterwards, all the hits were 
cherrypicked from the original siRNA stock plates, transferred to a new 384-well plate and retested 
in the same assay to generate a list of candidates. 
Two validation screens for 36 promising candidates were performed with custom siRNA stock 
plates prepared with ON-TARGETplus SMARTpool® siRNAs and individual siGENOME 
siRNAs by Dharmacon, Inc. 
To silence ATP5F1E, we used newly purchased siGENOME SMARTpool® siRNA (#M-012330-
00), individual siGENOME siRNAs (#D-012330-01, #D-012330-02, #D-012330-03, and #D-
012330-04), ON-TARGETplus SMARTpool® siRNA (#L-012330-02), and individual ON-
TARGETplus SMARTpool® siRNAs (#J-012330-17, #J-012330-18, #J-012330-19, and #J-
012330-20), all from Dharmacon, Inc. To knockdown ATP5PB, we used siGENOME 
SMARTpool® siRNA (#M-015956-01) and ON-TARGETplus SMARTpool® siRNA (#L-015956-
01). 
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4.2.4.3 Reverse transfection of siRNA 
The siRNA stock solutions were thawed at 4 ℃ overnight. A BioMek FX fluid handling robot 
(Beckman Coulter, Brea, CA, USA) equipped with sterile, RNase-free pipet tips (#B98224, 
Beckman Coulter) was utilized to transfer 2.4 μl (equivalent to 1.2 picomoles) siRNA from the 
siRNA stock plates to three identical 384-well black tissue culture plates with clear bottom 
(#6007460, PerkinElmer, Waltham, MA, USA). The transfection agent, Lipofectamine™ 
RNAiMax (#13778075, Thermo Fisher Scientific) was diluted in the Opti-MEM™ Reduced 
Serum Medium (#31985062, Thermo Fisher Scientific) at a ratio of 1: 110 and incubated at room 
temperature for 5 min. Then, a Multidrop Combi Dispenser (Thermo Fisher Scientific) with sterile 
tubing was employed to add 8 μl transfection mixture to each well. siRNAs and Lipofectamine™ 
RNAiMax were allowed to assemble at room temperature for 20 min. In the meantime, HeLa cells 
were trypsinized and resuspended in growth medium to a density of 6.7×104 cells/ ml. After adding 
30 μl cell suspension (or 2,000 cells) to each well with the Multidrop dispenser, the cells were 
grown for three days to allow for an efficient knockdown of the target gene or locus. In parallel, a 
non-targeting siRNA (#D0012061305, Dharmacon, Inc.), which lacks any matched sequences in 
the human transcriptome, was applied to the positive and negative controls. 
4.2.4.4 Cisplatin treatment 
Cis-Diammineplatinum(II) dichloride (#P4394, Sigma-Aldrich) was solubilized in double distilled 
water at a stock concentration of 3 mM. Following siRNA transfection and knockdown, spent 
medium was removed from the 384-well plates, and 0.4 mM cisplatin prepared in fresh growth 
medium was administered to the cells, with the only exception that one set of control (i.e., the 
positive control) was left untreated, mimicking the scenario where there was no polyP 
accumulation. Cisplatin treatment typically lasted for 24 h. 
4.2.4.5 Immunofluorescence labeling 
An adapted immunofluorescence protocol for high throughput screening was developed to 
visualize intracellular polyP levels. Briefly, cisplatin-containing medium was removed by covering 
the plates with thick, absorbent materials, inverting the plates and gently shaking them (so that any 
cisplatin contaminated materials could be disposed easily). Immediately afterwards, 30 μl freshly 
prepared 4% (v/v) paraformaldehyde was dispensed to each well by the Multidrop dispenser. The 
cells were fixed at room temperature in the dark for 20 min. Following a similar procedure as that 
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used for cisplatin, paraformaldehyde was removed from the plates, and the cells were rinsed three 
times with PBS using the Multidrop dispenser. Then, cellular membranes were penetrated with 30 
μl permeabilization buffer, which contained 0.3% Triton X-100 and 1% bovine serum albumin 
dissolved in PBS. After a 10 min incubation at room temperature, Triton X-100 was discarded and 
the cells were again rinsed with PBS for three times. To decrease the background noise caused by 
nonspecific binding, the cells were blocked with 1% bovine serum albumin in PBS (i.e., blocking 
buffer) for at least 1 h at room temperature. Later on, mCherry-EcPPXc working solution was 
prepared at a concentration of 10 μg/ ml in prechilled blocking buffer. Each well was filled with 
50 μl mCherry-EcPPXc and kept at 4 ℃ overnight, protected from light. On the next day, after 
rinsing away mCherry-EcPPXc with PBS for three times, the cells were incubated with 1 μg/ ml 
DAPI (#D1306, Thermo Fisher Scientific) for 5 min in the dark, which served as a counter stain. 
As soon as three final rinses with PBS were completed, and each well was filled with 50 μl PBS, 
the plates were sealed with black films and kept in the cold room, typically for 0 to 4.5 h, until the 
designated imaging sessions. 
It is important to note that both cisplatin and paraformaldehyde were considered as hazardous 
chemicals. Therefore, all the reagents and materials that had been contaminated during sample 
preparation should be dealt with complying the local rules. 
4.2.4.6 Image acquisition 
A set of three plates, namely technical triplicates of the same siRNA transfection, were equilibrated 
to room temperature and loaded sequentially by the CRS Catalyst Express Robot Arm (Thermo 
Fisher Scientific) onto the automated ImageXpress Micro XLS Imager (Molecular Devices, San 
Jose, CA, USA). Fluorescence images were captured with the CFI Plan Fluor ELWD (extralong 
working distance) DM 20×C lens (Nikon, Minato City, Tokyo, Japan). Fluorophores were excited 
by the SOLA SE 2 Light Engine® (Lumencor, Inc., Beaverton, OR, USA). Specific excitation and 
emission wavelengths were set by a filter cube, which alternated between TxRed channel (for 
detecting mCherry-EcPPXc) with 900 ms exposure time for cisplatin-treated samples and 1.5 s for 
untreated samples, and DAPI channel with 50 ms exposure time. In each well, five different 
positions were sampled to expand the number of cells and average out random noises. To obtain 
the best focus, manual adjustment for the post-laser offset was performed for each channel, 
followed by autofocus calibrated using the first three wells on the plate. 
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4.2.4.7 Image analysis 
Fluorescence images were analyzed with the Multi-Wavelength Cell Scoring Application Module 
of the MetaXpress® Software (Molecular Devices). For the DAPI channel, a detection limit (i.e., 
fluorescence intensity above local background) and an estimated nucleus size were set to determine 
the number as well as the location of all the nuclei in the image. For the mCherry-EcPPXc channel, 
a detection limit and an estimated cell size were defined to identify the cells. Then, mCherry-
EcPPXc fluorescence intensity was measured either for the entire cell or only for the nucleus (using 
the spatial information from the corresponding DAPI channel). A sorting criterion was created for 
the mCherry-EcPPXc channel to highlight “cisplatin responsive cells” or cells accumulating 8.5 to 
12 times as much polyP as the steady state level. The percentage of cisplatin responsive cells was 
calculated and served as the chief parameter for hit identification. 
All the measurements, except cell count, were normalized to the internal controls on the same 384-
well plate. The score of positive control was set to 0, and that of negative control was set to 100. 
Sample scores were calculated using the following formula: 100× [(sample value) − (positive 
control value)]/ [(negative control value) − (positive control value)]. Notably, normalized sample 
scores positively correlated with polyP content. Data storage, analysis, and hit identification were 
assisted by the MScreen platform (213) built in-house at the Center for Chemical Genomics, 
University of Michigan. 
4.2.5 Quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
qRT-PCR analyses were performed to evaluate the knockdown efficiencies of ATP5F1E and 
ATP5PB siRNAs, with the non-targeting siRNA serving as the negative control. 
For siRNA transfection, 4.8 picomoles of siRNA was added to a 96-well tissue culture plate (#3596, 
Corning, Inc., Corning, NY, USA). Then, we prepared transfection reagent by diluting 
Lipofectamine™ RNAiMax in the Opti-MEM™ reduced serum medium by 110-fold. After 5 min 
incubation at room temperature, 32 μl transfection mixture was added to the siRNA, followed by 
another incubation for 20 min. Lastly, HeLa cells were seeded at a density of 8,000 cells/ well and 
incubated at 37 ℃ with 5% CO2 for 72 h. To collect samples, spent medium was removed from 
the plate, and 20 μl/ well TRIzol™ reagent (#15596026, Thermo Fisher Scientific) was used to 
lyse the cells immediately. Usually, cell lysates from 8 identical wells transfected with the same 
siRNA were combined to scale up the amount of material. Samples could be stored at -80 ℃ if 
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necessary. 
To extract total RNA from the cell lysate, we added 50 μl chloroform (#C2432, Sigma-Aldrich) to 
150 μl cell lysate (thawed at room temperature). After a brief vortex for 30 s, we left the sample 
unperturbed until the aqueous phase and the organic phase started to reappear, which usually took 
3 min. Then, a prolonged centrifugation was carried out at 12,000 rpm, 4 ℃ for 10 min to ensure 
a complete separation of the two phases. The aqueous layer was transferred to a clean, RNase-free 
Eppendorf tube and extracted with chloroform once more, following the same procedure described 
above. RNA concentration was measured with a NanoDrop™ 2000 spectrophotometer (Thermo 
Fisher Scientific). 
cDNA was synthesized with the Radiant™ cDNA Synthesis Kit (#QC1125, Alkali Scientific, Inc., 
Lauderdale, FL, USA) per the manufacturer’s instructions. Briefly, we set up two reactions in 
parallel: 1) a reverse transcription reaction with cDNA synthesis mix, reverse transcriptase, and 
total cellular RNA (4 pg to 4 μg) and 2) a control reaction in which reverse transcriptase was 
substituted by DNase/RNase-free water (#10977015, Thermo Fisher Scientific). Both reactions 
were run at 42 ℃ for 30 min, prior to heat denaturation of the reverse transcriptase at 85 ℃ for 10 
min. 
The following primer sequences were designed for amplifying ATP5F1E cDNA: 5’-
GTGGCCTACTGGAGACAGG-3’ (forward primer) and 5’-GGAGTATCGGATGTAGCTGAGT-
3’ (reverse primer). As an internal control, HSP90 cDNA was amplified with 5’-
GAAATCTGTAGAACCCAAATTTCAA-3’ (forward primer) and 5’-
TCTTTGGATACCTAATGCGACA-3’ (reverse primer). The efficiencies of ATP5F1E and HSP90 
primer pairs were 81.2% and 89.3%, respectively. 
Each qRT-PCR reaction was set up with 5 ng cDNA, 200 ng/ μl forward primer, 200 ng/ μl reverse 
primer, and 10 μl EvaGreen qPCR 2× Mastermix-ROX (#BEQPCR-R, MIDSCI, St. Louis, MO, 
USA) in a total volume of 20 μl. Technical triplicates were set up for each sample. Reactions were 
performed in the MasterCycler® ep realplex 4 Real-Time PCR system (Eppendorf, Hamburg, 
Germany) using the recommended program for EvaGreen qPCR Mastermix. cDNA was first 
denatured at 95 ℃ for 10 min, and then, it underwent 40 cycles of amplification (95 ℃ for 15 s 
and 60 ℃ for 1 min). Threshold cycle (Ct) was calculated by the MasterCycler® ep realplex 
software. 
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4.2.6 Western blotting 
Knockdown efficiencies of GAPDH, ATP5F1E, and ATP5PB siRNAs were also assessed by 
western blotting. 
Reverse transfection and knockdown procedures were the same as those described earlier in 
section 4.2.5. To harvest cells, spent medium was removed from the 96-well plate before 10 μl 
lysis buffer was added to each well. Lysis buffer contained 140 mM Tris (pH 8), 2 mM MgCl2, 4% 
sodium dodecyl sulfate (SDS), 50 mM 1,4-dithiothreitol (DTT), 5M urea, and ≥ 250 units/ ml 
Benzonase® Nuclease (#E1014, Millipore Sigma). To scale up the amount of material, cell lysates 
of 8 identical wells transfected with the same siRNA were pooled. Samples could be stored at -
80 ℃ if necessary. 
Protein concentrations were measured by the Bio-Rad DC Protein Assay Kit (#500-0112, Bio-Rad, 
Hercules, CA, USA). Briefly, we prepared a set of protein standards, namely 0, 0.1, 0.2, 0.4, and 
0.8 mg/ ml bovine serum albumin and made three serial dilutions of each cell lysate by 2, 4, and 
8-fold. Then, we transferred 5 μl of sample to each well of a 96-well plate, where technical 
triplicates were set up for each sample. Every ml of Reagent A was supplemented with 20 μl 
Reagent S, and then, 25 μl mixture was added to each well. After adding 200 μl Reagent B, the 
solutions were mixed by pipetting and incubated at room temperature for 15 min. Absorbance 
reading at 750 nm wavelength was measured in a BMG FLUOstar Omega microplate reader 
(Ortenberg, Germany). Protein concentration was calculated based on the standard curve and the 
mean value of technical triplicates for each sample. Using this information, we adjusted all the 
samples to the same protein concentration in lysis buffer. 
For gel electrophoresis, cell lysates were mixed with 5× SDS-PAGE sample loading buffer and 
boiled at 95 ℃ for 5 min. Then, GAPDH knockdown samples were loaded onto Any kD™ Mini-
PROTEAN® TGX Stain-Free™ Protein Gel (#4568124, Bio-Rad), whereas ATP5F1E and 
ATP5PB knockdown samples were loaded onto 4-20% Mini-PROTEAN® TGX™ Precast Protein 
Gel (#4561096, Bio-Rad). Electrophoresis was conducted at 160 V until the protein of interest was 
expected to reach the middle of the gel. 
For GAPDH knockdown samples, the Stain-Free™ gel was photoactivated by UV in the 
ChemiDoc Imaging System (Bio-Rad), which enabled visualizing the tryptophan fluorescence of 
total proteins. Then, we used a Tran-Blot Turbo Transfer Pack (#1704156, Bio-Rad) and the Trans-
 85 
Blot Turbo Blotting Apparatus (Bio-Rad) to transfer proteins from the gel to the PVDF membrane. 
An image of successfully transferred proteins was taken, which served as loading control. For 
ATP5F1E and ATP5PB knockdown samples, proteins were transferred directly after gel 
electrophoresis to PVDF membranes in the same way. 
Membranes were blocked with 5% non-fat milk dissolved in TBST buffer for 1 h. Then, they were 
incubated with designated antibodies (prepared in blocking buffer) for the protein of interest. To 
label GAPDH, an anti-GAPDH antibody (#G9545, Millipore Sigma) was used at 500 ng/ ml, and 
to label mitochondrial FoF1-ATPase ε subunit, an anti-ATP5E antibody (A-11) (#sc-393695, Santa 
Cruz Biotechnology, Inc., Dallas, TX, USA) was used at 5 μg/ ml. Incubation with primary 
antibodies was carried out at  4 ℃ overnight with constant, gentle agitation. Then, primary 
antibodies were removed, and the membranes were rinsed with TBST buffer for three times. 
For the GAPDH knockdown samples, the membrane was incubated with 80 ng/ ml Goat anti-
Rabbit IgG (H+L) secondary antibody conjugated to horseradish peroxidase (HRP) (#31460, 
Thermo Fisher Scientific) for 2 h at room temperature. Three TBST washes and two PBS washes 
were then used to remove unbound antibodies. SuperSignal™ West Pico PLUS Chemiluminescent 
Substrate (#34580, Thermo Fisher Scientific) was directly applied to the membrane, and 
chemiluminescence signal was detected by the ChemiDoc Imaging System (Bio-Rad). For the 
ATP5F1E and ATP5PB knockdown samples, the membrane was incubated with 67 ng/ ml IRDye® 
680LT Goat anti-Mouse secondary antibody (#926-68021, LI-COR Biosciences, Lincoln, NE, 
USA) for the mitochondrial FoF1-ATPase ε subunit and 67 ng/ ml IRDye® 800CW Goat anti-Rabbit 
secondary antibody (#925-32211, LI-COR Biosciences) for GAPDH, the loading control, 
respectively. Secondary antibodies were prepared in Odyssey® Blocking Buffer (TBS) (#927-
50000, LI-COR Biosciences) supplemented with 0.01% SDS and 0.2% Tween 20. The membrane 
was kept in the dark during the 1 h incubation period, before fluorescence signals were detected 
using the LI-COR Odyssey® CLx Imaging System (LI-COR Biosciences). 
4.2.7 Immunofluorescence labeling and confocal microscopy 
We visualized PANK4 and polyP in cisplatin-treated cells with confocal microscopy. Briefly, HeLa 
cells were seeded at a density of 5×104 cells/ well in a 24-well tissue culture plate (#3526, Corning, 
Inc., Corning, NY, USA) with a piece of coverslip placed at the bottom (#CLS-1760-012, 
Chemglass Life Sciences, Inc., Vineland, NJ, USA). Cells were cultured at 37 ℃ with 5% CO2. 
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On the next day, cells were treated with 40 μM cisplatin for 24 h. Fixation, permeabilization, and 
blocking procedures were the same as those described in section 4.2.4.5, except for volume 
adjustments for 24-well plate and manual liquid handling using P1000 pipettes (Eppendorf, 
Hamburg, Germany) instead of Multidrop dispensers. To label PANK4 and polyP, samples were 
incubated with 4 μg/ ml anti-PANK antibody (#SAB1411043, Sigma-Aldrich) and 10 μg/ ml GFP-
EcPPXc (prepared in blocking buffer) at 4 ℃ overnight, protected from light. To visualize PANK4 
signal, a goat anti-rabbit IgG Alexa Fluor® 647 secondary antibody (#ab150079, Abcam, 
Cambridge, United Kingdom) was supplemented to the PBS-washed samples at 1 μg/ ml and 
incubated at room temperature for 2 h, protected from light. Unbound antibodies were removed by 
PBS, and samples were stained with 1 μg/ ml DAPI for 5 min. Finally, PBS-washed samples were 
mounted in Citiflour AF1 mounting medium (#19470, Ted Pella, Inc., Redding, CA, USA) on 
microscope objective slides. Note that a set of controls for non-specific signals were prepared using 
GFP and goat anti-rabbit IgG Alexa Fluor® 647 alone. 
Fluorescence images were acquired by a Leica SP8 laser scanning confocal microscope (Leica 
GmbH, Mannheim Germany) built on a DMI8 microscope base using LAS X software, 100× oil 
objective (#11506378, Leica GmbH) and a 405 nm diode laser, in addition to a multi-line white 
light laser, set to 488, 594, and 647 nm excitation wavelengths. Spectral detection using a PMT 
from 410 to 480 nm was utilized for DAPI, a HyD detector from 493 to 560 nm for GFP and GFP-
EcPPXc, and a HyD detector from 653 to 800 nm for Alexa Fluor® 647. 
4.3 Results 
4.3.1 Visualization of polyP accumulation in nutrient shifted bacteria using the mCherry-
EcPPXc probe 
To test whether mCherry-EcPPXc signal intensities and endogenous polyP levels correlate, we 
conducted immunofluorescence labeling of polyP in E. coli. In this organism, polyP accumulation 
is stimulated simply by shifting the cells from an nutrient rich environment to a minimal medium, 
which contains no amino acids and less than 10% of the normal amount of phosphate (5,23,28). 
Furthermore, it was feasible to genetically manipulate the polyP operon comprised of ppk (the gene 
encoding polyphosphate kinase 1) and ppx (the gene encoding exopolyphosphatase) (21,109). 
As shown in Fig. 4.1, polyP accumulation phenotype was fully recapitulated by the mCherry-
EcPPXc probe. The rod-like shapes of both wild-type and ΔppkΔppx strains under normal 
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conditions changed into a nearly spherical morphology upon nutrient shift, indicative of an 
efficient growth arrest. Yet, polyP labeling was distinctly different in these strains.  Specifically, 
wild-type cells exhibited a remarkable increase in the mCherry-EcPPXc signal (but not mCherry 
signal) following nutrient starvation. However, mCherry-EcPPXc fluorescence remained 
undetectable in nutrient-shifted ΔppkΔppx cells, which lacked the polyP synthesizing capacity. 
These results further supported the conclusion that staining with mCherry-EcPPXc serves as a 
reliable readout for endogenous polyP. 
 
Figure 4.1 Immunofluorescence labeling of polyP by mCherry-EcPPXc in nutrient shifted E. coli cells. Wild-type and 
ΔppkΔppx E. coli strains were grown either under normal condition or in a nutrient deprived environment. Then, cells were labeled 
with mCherry-EcPPXc (or the control probe, mCherry) to monitor the levels of polyP. For the immunofluorescence images, 
brightness and contrast were adjusted on the same scale. The number and the morphology of untreated cells and nutrient starved 
cells can be visualized in the phase contrast (PC) images at the bottom. Scale bar: 10 μm. 
4.3.2 A genome-wide siRNA screen for polyP regulators in the human genome 
Having shown that mCherry-EcPPXc provides a reliable labeling system for endogenous polyP, 
we set out to establish an unbiased high throughput screening platform for polyP related genes in 
HeLa cells. This approach exploited the capacity of 384-well plates (laid out in Fig. 4.2A) to batch-
process the procedures of HeLa cell culture, siRNA reverse transfection, a three-day knockdown, 
cisplatin treatment, immunofluorescence labeling with mCherry-EcPPXc, high content imaging, 
and data analysis (Fig. 4.2B). 
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Figure 4.2 Workflow of a genome-wide siRNA screen for mammalian PPK genes in cisplatin-treated HeLa cells using 
mCherry-EcPPXc immunofluorescence labeling. (A) Layout of a typical 384-well plate, which tested 280 different targets (Row 
B to O and Column 3 to 22) and contained 14 positive controls (Row B to O, column 2), 14 negative controls (Row B to O, column 
23), and 76 unlabeled wells to avoid the edge effect of the plate. Positive controls (i.e., without cisplatin treatment and hence no 
upregulation of polyP) and negative controls (treated with 0.4 mM cisplatin and hence upregulation of polyP) were transfected with 
non-targeting siRNA. Four wells, B3, B4, C3, and C4 (outlined in bold) were taken as examples to explain the workflow in Fig. 
4.2B. Notably, during image acquisition, 5 different fields of view were obtained for each well, and their mean value was reported 
as the final result. (B) The workflow of the primary screen in HeLa cells involved reverse transfection of a Dharmacon siGENOME 
SMARTpool® siRNA library, a three-day knockdown followed by the exposure of the cells to 0.4 mM cisplatin for 24 h, 
immunofluorescence labeling of polyP with mCherry-EcPPXc, automated image acquisition, and data analysis. Four different 
parameters were deduced from the fluorescence images (i-iv), of which the percentage of cisplatin responding cells was used as 
the primary criterion for hit identification. For each 384-well plate, a range from 0 to 100 was defined using the values of the 
positive control and the negative control, respectively. Any target, which scored less than 30 in at least two out of three repetitions 
after cisplatin treatment qualified as candidates for potential PPK and/or genes for the upregulation of polyP. 
To survey as many genes as possible, we screened a Dharmacon siGENOME siRNA library, which 
targeted 18,110 loci with four siRNA duplexes (denoted as SMARTpool®) for each site to 
maximize their on-target effect. Knockdown efficiency was assessed by Western blotting analysis 
of a gene encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Fig. S4.1A). 
Quantitation of the GAPDH signals over those of total cell lysates in the siRNA-targeted cells 
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estimated a knockdown efficiency of 85% to 90%. 
Limited by the lack of known polyP regulatory machineries, we devised an arbitrary dynamic range 
of mCherry-EcPPXc signals. Cells transfected with non-targeting siRNA without cisplatin 
treatment served as the positive control, that is, cells without an upregulation of polyP. Conversely, 
cells transfected with non-targeting siRNA and exposed to cisplatin served as the negative control 
since they fully upregulated polyP levels (Fig. 4.2A). 
Quantitative data were extrapolated from the fluorescence images displaying mCherry-EcPPXc 
fluorescence and analyzed for the following parameters: 1) percentage of cisplatin responsive cells; 
2) average mCherry-EcPPXc intensity in the nucleus; 3) average mCherry-EcPPXc intensity in the 
whole cell; and 4) cell number. Notably, the percentage of cisplatin responsive cells was designated 
to reflect the reproducible variations in the polyP levels of individual HeLa cells after cisplatin 
treatment (also discussed in Chapter 2).  Only cells accumulating 8 to 12.5-fold more polyP than 
what was detected at basal level were classified as responsive ones (typically 25-40% of cells of 
the entire population). Compared to the other two parameters, i.e., average mCherry-EcPPXc 
intensity in the nucleus or that in the whole cell, which typically varied by 1.5 to 2-fold between 
the positive and negative controls, the percentage of cisplatin responding cells generated a much 
wider window from 0% (for the positive control) to up to 40% (for the negative control). Thus, the 
latter was chosen as the primary parameter for hit identification. 
Limited by the number of 384-well plates we could handle in each experiment, we divided the 
primary screen into 23 independent assays performed on different days. In each assay, we set up 
technical triplicates on three different plates for every siRNA tested. Therefore, to normalize 
measurements obtained from different plates (bearing internal positive and negative controls), the 
value of positive control was set to 0 and that of negative control was set to 100. This value 
positively correlated with mCherry-EcPPXc fluorescence intensities, hence polyP levels. Any 
knockdowns scoring no more than 30 in at least two out of three technical replicates were classified 
as candidates for genes upregulating mammalian polyP levels. This criterion yielded 405 hits in 
total, however, only 115 of them (listed in Table 4.1) were validated when the siRNAs were 
retested in the same assay to minimize random noises. This reckoned the final hit rate at 0.64% for 
the primary screen. 
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Table 4.1 Candidates for genes upregulating polyP levels in HeLa cells upon cisplatin treatment 
Ranka Gene ID Gene symbolb Name 
Scorec 
Primary 
screen Validation 
1 116444 GRIN3B glutamate ionotropic receptor NMDA type subunit 3B 1.0 4.0 
2 9480 ONECUT2 one cut homeobox 2 2.7 2.5 
3 146540 ZNF785 zinc finger protein 785 1.1 4.6 
4 5031 P2RY6 pyrimidinergic receptor P2Y6 2.5 7.7 
5 3208 HPCA hippocalcin 2.3 11.0 
6 120 ADD3 adducin 3 4.7 8.6 
7 6757 SSX2 SSX family member 2 10.1 3.7 
8 337880 KRTAP11-1 keratin associated protein 11-1 12.2 3.3 
9 54496 PRMT7 protein arginine methyltransferase 7 6.5 9.7 
10 90167 FRMD7 FERM domain containing 7 10.0 6.5 
11 1432 MAPK14 mitogen-activated protein kinase 14 4.9 11.7 
12 55806 HR HR, lysine demethylase and nuclear receptor corepressor 11.4 5.4 
13 10809 STARD10 StAR related lipid transfer domain containing 10 10.4 7.5 
14 3052 HCCS holocytochrome c synthase 6.4 12.5 
15 442117 GALNTL6 polypeptide N-acetylgalactosaminyltransferase like 6 5.4 14.3 
16 57085 AGTRAP angiotensin II receptor associated protein 9.8 10.3 
17 79796 ALG9 ALG9 alpha-1,2-mannosyltransferase 9.4 10.8 
18 90187 EMILIN3 elastin microfibril interfacer 3 7.6 12.7 
19 29952 DPP7 dipeptidyl peptidase 7 3.6 18.2 
20 6358 CCL14 C-C motif chemokine ligand 14 13.7 10.7 
21 6001 RGS10 regulator of G protein signaling 10 15.8 9.0 
22 5028 P2RY1 purinergic receptor P2Y1 15.4 10.2 
23 8452 CUL3 cullin 3 3.4 22.2 
24 8851 CDK5R1 cyclin dependent kinase 5 regulatory subunit 1 7.2 19.2 
25 514 ATP5F1E ATP synthase F1 subunit epsilon 22.5 4.1 
26 7251 TSG101 tumor susceptibility 101 13.5 13.4 
27 84934 RITA1 RBPJ interacting and tubulin associated 1 5.3 22.5 
28 2810 SFN stratifin 2.2 26.6 
29 23433 RHOQ ras homolog family member Q 19.8 9.2 
30 9827 RGP1 RGP1 homolog, RAB6A GEF complex partner 1 9.7 19.9 
31 286077 FAM83H family with sequence similarity 83 member H 19.1 10.9 
32 5158 PDE6B phosphodiesterase 6B 7.1 23.1 
33 133482 SLCO6A1 solute carrier organic anion transporter family member 6A1 7.0 23.6 
34 221938 MMD2 monocyte to macrophage differentiation associated 2 13.0 18.3 
35 51506 UFC1 ubiquitin-fold modifier conjugating enzyme 1 9.7 22.1 
36 5428 POLG DNA polymerase gamma, catalytic subunit 16.3 15.8 
37 219473 OR8K3 olfactory receptor family 8 subfamily K member 3 (gene/pseudogene) 26.5 6.5 
38 10146 G3BP1 G3BP stress granule assembly factor 1 8.0 25.2 
 
a Candidates are ranked by the average score of the primary screen and the retest (validation) in the order from low to high. 
b Official NCBI gene symbols are listed in this table for those entries with more than one commonly used gene symbols. 
c The mean score of three technical replicates is reported here. Scores are normalized on a scale of 0 to 100 defined by the 
positive and negative control, respectively. 
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Ranka Gene ID Gene symbolb Name 
Scorec 
Primary 
screen Validation 
39 7052 TGM2 transglutaminase 2 6.0 27.2 
40 55229 PANK4 pantothenate kinase 4 26.8 6.5 
41d 100652781 SNX29BP1 sorting nexin 29 pseudogene 1 18.0 15.3 
42 4495 MT1G metallothionein 1G 25.8 7.9 
43 339345 NANOS2 nanos C2HC-type zinc finger 2 13.5 21.0 
44 85316 BAGE5 BAGE family member 5 7.4 27.4 
45 64780 MICAL1 microtubule associated monooxygenase, calponin and LIM domain containing 1 19.3 16.0 
46 285527 FRYL FRY like transcription coactivator 11.1 24.3 
47 83695 RHNO1 RAD9-HUS1-RAD1 interacting nuclear orphan 1 8.7 26.8 
48 80323 CCDC68 coiled-coil domain containing 68 27.2 8.8 
49 652919 RGPD7 RANBP2-like and GRIP domain containing 7 6.5 29.9 
50 148870 CCDC27 coiled-coil domain containing 27 6.6 30.3 
51 9140 ATG12 autophagy related 12 18.3 19.1 
52 9284 NPIPA1 nuclear pore complex interacting protein family member A1 16.0 21.7 
53 401994 OR14I1 olfactory receptor family 14 subfamily I member 1 30.9 7.1 
54 340351 AGBL3 ATP/GTP binding protein like 3 15.1 23.4 
55 222894 FERD3L Fer3 like bHLH transcription factor 19.3 19.5 
56 28970 C11orf54 chromosome 11 open reading frame 54 21.0 18.0 
57 391123 VSIG8 V-set and immunoglobulin domain containing 8 23.6 15.9 
58 88455 ANKRD13 ankyrin repeat domain 13A 27.0 12.9 
59 51239 ANKRD39 ankyrin repeat domain 39 16.9 23.4 
60 26261 FBXO24 F-box protein 24 30.3 10.1 
61 11047 ADRM1 adhesion regulating molecule 1 23.8 16.7 
62 3939 LDHA lactate dehydrogenase A 24.8 15.7 
63 6461 SHB SH2 domain containing adaptor protein B 22.3 18.8 
64 390874 ONECUT3 one cut homeobox 3 29.1 11.5 
65 201292 TRIM65 tripartite motif containing 65 13.4 27.2 
66 286319 TUSC1 tumor suppressor candidate 1 20.0 21.0 
67 441108 IRF1-AS1 IRF1 antisense RNA 1 25.4 16.1 
68 9688 NUP93 nucleoporin 93 20.8 20.8 
69 3167 HMX2 H6 family homeobox 2 13.9 27.8 
70 26985 AP3M1 adaptor related protein complex 3 subunit mu 1 26.5 15.7 
71 8883 NAE1 NEDD8 activating enzyme E1 subunit 1 17.4 25.7 
72 23151 GRAMD4 GRAM domain containing 4 18.4 25.1 
73 56915 EXOSC5 exosome component 5 26.1 17.4 
74 91526 ANKRD44 ankyrin repeat domain 44 20.9 22.7 
75 8354 HIST1H3I histone cluster 1 H3 family member i 18.7 25.1 
76 131583 FAM43A family with sequence similarity 43 member A 16.0 28.3 
77 2764 GMFB glia maturation factor beta 18.2 26.3 
78 9342 SNAP29 synaptosome associated protein 29 22.9 21.9 
79 378832 COL18A1-AS1 COL18A1 antisense RNA 1 20.7 24.2 
80 50807 ASAP1 ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 17.5 27.5 
81 115201 ATG4A autophagy related 4A cysteine peptidase 21.1 24.0 
82 312 ANXA13 annexin A13 14.8 30.6 
 
d This entry is the replacement of LOC400509 (Gene ID: 400509) according to NCBI. 
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Ranka Gene ID Gene symbolb Name 
Scorec 
Primary 
screen Validation 
83 4637 MYL6 myosin light chain 6 29.4 16.1 
84 54455 FBXO42 F-box protein 42 18.2 27.6 
85 51778 MYOZ2 myozenin 2 29.4 17.9 
86 63970 P53AIP1 tumor protein p53 regulated apoptosis inducing protein 1 23.2 24.2 
87 4065 LY75 lymphocyte antigen 75 22.1 25.8 
88 2700 GJA3 gap junction protein alpha 3 27.3 20.7 
89 56891 LGALS14 galectin 14 26.8 21.6 
90 10215 OLIG2 oligodendrocyte transcription factor 2 21.0 28.4 
91 4131 MAP1B microtubule associated protein 1B 28.5 20.9 
92 440699 LRRC52 leucine rich repeat containing 52 20.9 30.0 
93 154790 CLEC2L C-type lectin domain family 2 member L 26.1 24.9 
94 84924 ZNF566 zinc finger protein 566 24.6 26.6 
95 10417 SPON2 spondin 2 21.2 30.2 
96 29091 STXBP6 syntaxin binding protein 6 24.2 27.3 
97e 221262 CCDC162P coiled-coil domain containing 162, pseudogene 26.8 25.5 
98 55196 RESF1 retroelement silencing factor 1 29.3 23.7 
99 440 ASNS asparagine synthetase (glutamine-hydrolyzing) 26.0 27.1 
100 57542 KLHL42 kelch like family member 42 24.0 29.5 
101 401265 KLHL31 kelch like family member 31 25.4 28.0 
102 84923 FAM104A family with sequence similarity 104 member A 31.6 21.9 
103 148979 GLIS1 GLIS family zinc finger 1 25.7 27.8 
104 360023 ZBTB41 zinc finger and BTB domain containing 41 24.1 29.6 
105 285440 CYP4V2 cytochrome P450 family 4 subfamily V member 2 21.6 33.3 
106 81622 UNC93B1 unc-93 homolog B1, TLR signaling regulator 22.9 32.2 
107 7761 ZNF214 zinc finger protein 214 36.6 18.6 
108 1836 SLC26A2 solute carrier family 26 member 2 25.3 31.2 
109 119032 BORCS7 BLOC-1 related complex subunit 7 27.8 29.5 
110 140453 MUC17 mucin 17, cell surface associated 29.1 28.1 
111 391189 OR11L1 olfactory receptor family 11 subfamily L member 1 30.4 28.0 
112 9927 MFN2 mitofusin 2 32.7 25.9 
113 30848 CTAG2 cancer/testis antigen 2 28.5 30.7 
114 79990 PLEKHH3 pleckstrin homology, MyTH4 and FERM domain containing H3 29.8 30.3 
115 1446 CSN1S1 casein alpha s1 30.5 30.4 
To ensure that the above candidates were not skewed by our choice of using cisplatin 
responsiveness as the chief parameter for hit identification, we ranked the 18,110 targets based on 
their average mCherry-EcPPXc fluorescence intensities in the nucleus. When the raw 
measurements were normalized to the positive and negative controls on a scale of 0 to 100, 98 
knocked down genes scored 30 or less in at least two technical replicates (Table S4.1). Importantly, 
84 of them were scored as hits, based on their proportions of cisplatin responsive cells. In addition 
 
e This entry is the replacement of FLJ37396 (Gene ID: 285754) according to NCBI. 
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to giving us more candidate genes (405 vs. 98 before validation), the calculation of cisplatin 
responsiveness rather than nuclear mCherry-EcPPXc signal was also more consistent judged by 
the standard deviation values (Table S4.1), further justifying our use of cisplatin responding cells 
as primary scoring parameter. Nevertheless, we routinely cross-examined different parameters to 
reach as rigorous conclusions as possible. 
In the course of data analysis, we also made an intriguing discovery that RNAi itself might affect 
the extent of polyP accumulation following cisplatin treatment. This finding became clear once we 
calculated the average score of all the targets and found it to be 140 and the median to be 146 (Fig. 
4.3A). These scores were 40% higher than the score of the negative control, which indicated the 
amount of polyP found in cisplatin-treated cells exposed to non-targeting siRNA. Consistently, the 
mean score of mCherry-EcPPXc fluorescence intensity in the nucleus of the whole population also 
exceeded the negative control by 63% (Fig. 4.3B). However, no such difference existed for cell 
count, an indirect measurement of cisplatin sensitivity (Fig. 4.3C). Therefore, RNAi might 
specifically affect polyP regulation rather than cell survival. It is conceivable that the differences 
in polyP levels emerged from the downstream events of mRNA binding to the antisense strand of 
the siRNA duplex. Yet, without further experiments, we are unable to ascribe the source of this 
additional polyP accumulation to an activated RNAi machinery, a general stress response in reply 
to the loss of a functional protein, or other factors. Nonetheless, this difference in polyP levels 
rendered our candidates even more significant than previously considered. 
 
Figure 4.3 Distributions of three major parameters of the primary screen. For each target, (A) the score of the percentage of 
cisplatin responsive cells, (B) the score of nuclear mCherry-EcPPXc fluorescence intensity, and (C) cell count are shown in violin 
plots. The percentage of cisplatin responsive cells and the nuclear mCherry-EcPPXc intensity are normalized to the positive control 
(Pos. ctrl) and the negative control (Neg. ctrl), whose scores were set to 0 and 100, respectively. The hit identification criterion, i.e., 
scoring below 30 for the percentage of cisplatin responsive cells, is highlighted by a red line in (A). Cell count value for the non-
targeting siRNA control (NT ctrl) is indicated by a dashed line in (C). Means and standard deviations are reported in the graphs. 
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To validate the 115 hits and investigate whether the respective siRNAs also affect the steady state 
polyP levels, we determined the baseline of polyP content in cells transfected with the 115 siRNAs 
without cisplatin supplement. Cells containing the non-targeting siRNA were labeled with either 
mCherry or mCherry-EcPPXc to set a new dynamic range of polyP signals from 0 to 100. Any 
knockdowns, whose mCherry-EcPPXc brightness scored below 100 were indictive of impaired 
polyP synthesis compared to the non-targeting siRNA control. Indeed, 98.3% of the candidate 
siRNAs belonged to this category, and the mean score of the whole group was 71.7, reflecting an 
average of nearly 30% decrease in basal polyP concentrations (Fig. 4.4A). 
 
Figure 4.4 Frequency distribution analysis of basal polyP levels and fold increase of polyP concentrations upon cisplatin 
treatment in the candidates of the primary screen. (A) The scores of basal polyP levels for the 115 candidates clustered below 
100. This result indicates lesser amounts of polyP in these samples compared to the non-targeting siRNA control. (B) The relative 
fold change of polyP concentrations before and after cisplatin treatment in cells transfected with 115 candidate siRNAs had an 
average of 0.76. The fold increase in polyP levels of a knockdown sample was normalized to that of the non-targeting siRNA 
control, set at 1. Overall, 112 targets, with a relative fold change value below 1, showed lower ability to enrich polyP than the non-
targeting siRNA control. 
Next, we evaluated the fold change of polyP levels upon cisplatin administration by normalizing 
the mCherry-EcPPXc fluorescence signals of cisplatin-treated cells to those of untreated cells 
targeted by the same siRNA sequence. Presumably, this quantitation was more accurate because it 
took into account the dissimilar basal polyP concentrations due to the knockdown of different 
targets. When we plotted the frequency distribution of the fold change values of all 115 candidates 
(relative to the fold change of non-targeting siRNA control, set at 1), we obtained a population 
with an average of 0.76 (Fig. 4.4B). In fact, only 4 hits (which scored above 1) overtook the non-
targeting siRNA control in causing a cisplatin-mediated polyP spike. Taken together, these results 
testified for the selectivity of our original hit identification parameter for potential PPK genes and 
prompted us to further scrutinize the candidates from the primary screen (Table 4.1). 
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4.3.3 Validation of PPK candidate genes using ON-TARGETplus SMARTpool® siRNAs 
An inevitable challenge of RNAi is the potency of off-target effects caused by each siRNA duplex. 
Besides recognizing its complimentary mRNA target, the seed sequence, which refers to the 2nd to 
the 7th or the 2nd to the 8th positions in the anti-sense strand is inadvertently guided to the 3’UTR 
of many different mRNA species (214). Due to the promiscuous regulatory functions of the 3’UTR, 
it is impractical to decipher the mis-targeted sites more often than not. We therefore decided to 
conduct a secondary screening for selected candidates using an alternative ON-TARGETplus 
SMARTpool® siRNA library and testing for its effects on cisplatin-induced polyP accumulation. 
As an essential premise, we confirmed the knockdown efficiencies of both sets of siRNAs for one 
representative target, ATP5F1E, with qRT-PCR and western blotting analyses. On the mRNA level, 
99.4% and 97.2% of the ATP5F1E mRNA copies were silenced by ATP5F1E specific oligos 
provided by the ON-TARGETplus and the siGENOME libraries, respectively (Fig. S4.1B). 
Although three out of four siRNA duplexes differed in sequence between the two SMARTpool® 
siRNA preparations, their efficacies tied in quadruple biological samples. For a different purpose, 
we also assessed the influence of ATP5PB silencing on the expression levels of ATP5F1E gene. 
Although we found a slight increase in the ATP5F1E mRNA level, it was not statistically 
significant. Therefore, we considered ATP5PB siRNA to serve as an additional control to the 
default non-targeting siRNA. Consistent with the qRT-PCR results, cells transfected with 
ATP5F1E siRNA from either library showed a nearly 75% loss of the mitochondrial ATP synthase 
ε subunit in three independent Western blotting assays (Fig. S4.1C). Although we cannot rule out 
other potential differences between these two libraries, we regarded the ON-TARGETplus 
SMARTpool® siRNAs as an adequate substitution for the siGENOME SMARTpool® siRNAs that 
we used in our primary screen. 
In a proof-of-concept study, we then focused on a subset of 36 candidate genes and analyzed their 
steady-state and cisplatin-induced polyP accumulation upon RNAi using the following parameters: 
1) proportion of cisplatin responsive cells (also the chief criterion to be considered for hit 
validation); 2) fold change of polyP levels before and after cisplatin treatment; 3) polyP levels of 
cisplatin-treated cells; and 4) basal polyP levels. Results from three to five independent 
experiments were summarized in Table 4.2 and Table 4.3.  
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Table 4.2 Percentage of cisplatin responding cells in selected candidates transfected with ON-TARGETplus SMARTpool® 
siRNAs 
Rank Gene ID Gene Symbolf Score
g SDh Rank Gene ID Gene Symbol Score SD 
1 7251 TSG101 57.25 11.23 19 1432 MAPK14 123.11 18.05 
2 133482 SLCO6A1 58.08 16.83 20 337880 KRTAP11-1 124.29 25.21 
3 29952 DPP7 59.17 23.01 21 5031 P2RY6 127.78 9.40 
4 5428 POLG 65.30 14.69 22 5158 PDE6B 129.41 34.09 
5 116444 GRIN3B 70.04 14.49 23 401994 OR14I1 130.08 13.13 
6 9480 ONECUT2 71.84 14.54 24 3208 HPCA 135.00 22.96 
7 57085 AGTRAP 76.70 23.11 25 64780 MICAL1 135.38 17.38 
8 8851 CDK5R1 79.15 28.47 26 90187 EMILIN3 140.38 30.47 
9 339345 NANOS2 86.41 8.42 27 6757 SSX2 140.67 7.26 
10 9140 ATG12 93.01 15.67 28 79796 ALG9 141.66 22.58 
11 55806 HR 93.19 15.55 29 84934 RITA1 145.79 24.92 
12 10809 STARD10 100.47 12.80 30 8883 NAE1 148.61 34.61 
13 90167 FRMD7 107.17 27.65 31 514 ATP5F1E 151.98 31.90 
14 55229 PANK4 108.90 41.79 32 6001 RGS10 161.11 27.28 
15 146540 ZNF785 110.99 11.76 33 10146 G3BP1 188.26 25.24 
16 5028 P2RY1 114.44 27.84 34 54496 PRMT7 188.60 32.34 
17 3052 HCCS 118.06 18.67 35 6358 CCL14 209.59 46.72 
18 23433 RHOQ 120.75 20.95 36 120 ADD3 228.36 27.34 
To our great surprise, none of the candidates scored 30 or less when their fractions of cisplatin 
responsive cells were normalized to the corresponding value of the non-targeting siRNA control 
(which was set to 100) (Table 4.2). Furthermore, the relative fold change of polyP signals before 
and after cisplatin exposure appeared to make 89% of the hits more proficient at increasing their 
polyP levels compared to the non-targeting siRNA control (Table 4.3). Ranking these candidates 
by the fold change of polyP levels was akin to ranking them by cisplatin responsiveness. Based on 
this analysis, we found that only basal polyP concentrations followed our prediction and scored 
between 70 and 100 (after normalization) for all the candidates tested (Table 4.3). At a minimum, 
this observation signified an attenuated polyP synthesizing activity caused by perturbing a 
candidate gene in an otherwise unstressed cell.  
 
f Official NCBI gene symbols are listed in this table for those entries with more than one commonly used gene symbols. 
g The mean score of five biological replicates is reported here. Scores are normalized on a scale of 0 to 100 defined by the 
positive control and the negative control, respectively. 
h SD stands for the standard deviation of the mean for five biological replicates. 
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Table 4.3 PolyP content before and after cisplatin treatment and the respective fold change in selected candidates targeted 
by ON-TARGETplus SMARTpool® siRNAs 
Ranki Gene ID Gene symbolj Relative fold change 
Score 
(mCherry-EcPPXc 
signal in the nucleus 
after cisplatin 
treatment) 
Score 
(mCherry-EcPPXc 
signal in the nucleus at 
basal level) 
Mean SDk Mean SDl Mean SDm 
1 7251 TSG101 0.90 0.06 68.63 4.69 87.71 10.15 
2 9480 ONECUT2 0.91 0.03 82.77 11.61 85.83 8.34 
3 29952 DPP7 0.94 0.13 72.89 15.36 77.42 8.97 
4 133482 SLCO6A1 0.95 0.13 76.27 8.99 90.83 15.88 
5 5428 POLG 1.01 0.08 71.61 10.19 75.38 8.54 
6 9140 ATG12 1.05 0.08 92.83 11.65 87.13 18.96 
7 116444 GRIN3B 1.06 0.13 89.07 8.61 85.81 6.88 
8 90167 FRMD7 1.07 0.02 102.35 12.77 97.70 9.12 
9 57085 AGTRAP 1.08 0.02 83.69 12.36 75.15 13.35 
10 339345 NANOS2 1.09 0.07 91.45 4.76 80.46 10.74 
11 146540 ZNF785 1.09 0.10 105.81 5.66 95.78 6.40 
12 55806 HR 1.09 0.04 89.13 10.25 79.53 6.99 
13 8851 CDK5R1 1.10 0.16 82.75 13.82 70.55 9.75 
14 337880 KRTAP11-1 1.11 0.12 117.67 15.90 92.57 8.94 
15 10809 STARD10 1.13 0.12 95.57 5.10 80.93 15.75 
16 5028 P2RY1 1.16 0.03 104.03 14.61 84.41 7.99 
17 55229 PANK4 1.16 0.15 98.01 24.91 80.18 12.50 
18 23433 RHOQ 1.18 0.13 107.23 8.88 86.58 16.05 
19 401994 OR14I1 1.19 0.09 117.12 8.82 97.41 9.24 
20 5031 P2RY6 1.23 0.14 118.95 7.99 91.93 13.68 
21 64780 MICAL1 1.27 0.12 121.07 10.23 82.04 19.11 
22 1432 MAPK14 1.28 0.06 117.19 13.66 82.24 14.14 
23 3052 HCCS 1.28 0.20 110.57 13.23 75.53 8.39 
24 90187 EMILIN3 1.32 0.03 133.23 18.00 84.30 11.32 
25 6001 RGS10 1.33 0.13 135.40 16.63 91.29 9.81 
26 79796 ALG9 1.34 0.06 126.75 11.93 81.68 13.59 
27 5158 PDE6B 1.34 0.12 115.61 16.83 77.02 12.39 
28 8883 NAE1 1.37 0.25 136.93 18.54 84.46 12.04 
29 6757 SSX2 1.37 0.24 124.37 12.45 74.88 11.31 
30 3208 HPCA 1.38 0.10 123.87 14.11 74.26 7.58 
31 84934 RITA1 1.39 0.16 137.03 13.29 83.23 11.34 
32 514 ATP5E 1.40 0.21 113.33 46.53 84.83 8.88 
33 10146 G3BP1 1.57 0.11 163.28 18.16 86.93 7.24 
34 54497 PRMT7 1.69 0.18 183.47 32.36 93.69 7.60 
35 6358 CCL14 1.85 0.15 190.21 44.04 82.13 13.87 
36 120 ADD3 2.04 0.17 208.71 24.88 76.41 10.88 
These results suggested that our validation results might be unintentionally skewed by systemic 
differences between the two libraries. Notably, we only altered the source of target siRNAs but not 
the non-targeting siRNA. While our intention was to simplify the comparisons between primary 
 
i Candidates are ranked by their fold change values in an order from low to high. 
j Official NCBI gene symbols were listed in this table for those entries with more than one commonly used gene symbols. 
k SD stands for standard deviation of the mean for three independent measurements of fold change. 
l SD stands for standard deviation of the mean for five independent measurements of nuclear mCherry-EcPPXc fluorescence 
intensity after cisplatin treatment. 
m SD stands for standard deviation of the mean for four independent measurements of nuclear mCherry-EcPPXc signal at basal 
level. 
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and validation screens, we neglected the potential impact of different chemical modifications of 
siGENOME and ON-TARGETplus siRNAs on the behaviors of endogenous polyP. Presumably, 
another confounding factor was the effective concentrations of the two siRNA libraries. Although 
the siGENOME SMARTpool® library had been carefully maintained at a core facility, its stability 
might have been compromised after a few freezing-and-thawing cycles. 
4.3.4 Explorations of ATP5F1E and PANK4 siRNAs 
Despite our inability to validate any of the hits with the secondary screen, we nevertheless decided 
to follow up on a few select targets, which could be relevant players in the cisplatin-triggered polyP 
reaction. One of these genes was ATP5F1E, which encodes the ε subunit of the mitochondrial ATP 
synthase. First and foremost, the ε subunit is the only subunit that is unique to the mitochondrial 
FoF1-ATPase (215). This feature implies a novel function and/or regulation of this multicomplex 
compared to its bacterial and chloroplast equivalents. Coincidentally, mitochondrial FoF1-ATPase 
was recognized for overseeing polyP levels in this organelle, but the underlying mechanism 
remains unknown to this date (115,116). Provided with the phenotype (from the primary screen) 
that polyP production was impeded by the knockdown of ATP5F1E, we explored whether this 
gene might serve as the missing link between polyP and mitochondrial FoF1-ATPase activity. 
To test this hypothesis, we inspected the effect of each individual ATP5F1E siRNA derived from 
the siGENOME SMARTpool® collection (#1 to #4) and the ON-TARGETplus SMARTpool® 
collection (#17 to #20) on polyP accumulation in cisplatin-treated cells. Our rationale was that 
although SMARTpool® siRNAs were designed to minimize the off-target effects of each individual 
component, their combinatory effects might be biased towards a few very potent siRNAs rather 
than representing the majority of the population. 
Using qRT-PCR analysis, we verified the efficacies of all the individual and SMARTpool® siRNAs 
to alter the mRNA levels of ATP5F1E (Fig. 4.5A, left panel). Notably, one oligo sequence was 
shared by the siGENOME collection (#1) and the ON-TARGETplus collection (#20). This would 
allow us to assess the systematic errors between the two libraries (likely due to differential 
chemical modifications). It was obvious that all the ATP5F1E siRNAs had remarkable and almost 
identical knockdown efficiencies. Nevertheless, the cells treated with the various ATP5F1E 
siRNAs lowered, maintained or even surpassed the polyP content of the non-targeting siRNA 
control (Fig. 4.5B). In fact, only two out of seven individual siRNA variants (#1 and #4) were more 
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potent in disrupting the cisplatin-induced polyP response than the non-targeting siRNA control, 
whose score was set to 100. Two additional constructs (#17 and #19) resulted in less polyP 
accumulation than the average of the 18,110 targets, whose mean score approximated to 140. The 
phenotype of a SMARTpool® siRNA indeed reflected the summed outcomes of all four individual 
components, especially the ones with the strongest impact. It was likely for this reason that the 
siGENOME SMARTpool® reagent with two apparent outliers (#2 and #3) was even more robust 
in lowering polyP levels than the ON-TARGETplus equivalent whose values were dominated by 
a single siRNA (#18). 
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Figure 4.5 Validation of ATP5F1E with individual siRNAs from the siGENOME and the ON-TARGETplus libraries. (A) 
The knockdown efficiencies (left panel) and the scores of cisplatin responsiveness (right panel) of all the individual and 
SMARTpool® ATP5F1E siRNAs are presented in the heatmaps. The expression levels of ATP5F1E are almost identical in all the 
samples, but the extent of polyP accumulation under cisplatin stress is vastly different. siRNA #1 and #20 have the same sequence. 
(B) Representative images of mCherry-EcPPXc labeling (pseudo color: red) and DAPI staining (pseudo color: blue) in cisplatin-
treated cells are displayed. Cells were transfected with individual and SMARTpool® ATP5F1E siRNAs from either library. Cells 
transfected with non-targeting siRNA before and after cisplatin exposure served as the positive control and the negative control, 
respectively. The score of cisplatin responsive cells for each sample is indicated in the image. 
These results still did not suffice to conclude that ATP5F1E is a candidate for the human PPK gene. 
Nevertheless, they encouraged us to conduct polyP measurements in knockout models of this non-
essential gene in the near future. It is intriguing to figure out whether mitochondrial FoF1-ATPase 
had been reconfigured into a dual functional engine for ATP and polyP synthesis with the ε subunit 
serving as the molecular coordinator of these two functions. 
In addition to retesting ATP5F1E, this set of experiments also addressed two technical issues 
concerning the primary and the validation screens using different siRNA libraries. Earlier, we 
suspected that the unique chemical modifications on the siRNA strands might be the reason for the 
different effects of the siGENOME and the ON-TARGETplus SMARTpool® siRNAs. However, 
since we observed a comparable knockdown efficiency as well as polyP content in cisplatin-treated 
cells harboring either siRNA #1 or #20, we can likely exclude this possibility. Besides, the 
siGENOME SMARTpool® reagents used in this assay were newly purchased rather than 
cherrypicked from the core facility, which also circumvented the potential problem of lower 
effective concentrations of the siGENOME SMARTpool® siRNAs caused by freezing-and-
thawing cycles. 
In addition to the ε subunit of the FoF1-ATPase, we also considered pantothenate kinase 4 (PANK4), 
the one and only kinase on the list, as potential candidate worthy of following up. PANK4 consists 
of two domains: a putative pantothenate kinase domain at the N terminus and a phosphatase 
domain at the C terminus. However, ‘PANK4’ is actually a misnomer since this enzyme cannot 
synthesize 4’-phosphopantothenate from pantothenate due to the lack of the conserved catalytic 
residues (216). To the best of our knowledge, the specific activity of PANK4 has not been 
characterized so far. 
We therefore decided to monitor the distribution of PANK4 with immunofluorescence labeling in 
cisplatin-treated cells. Surprisingly, we observed an enhanced signal of PANK4 in cells stressed 
with 40 μM cisplatin, which was 10-fold less that what was used in the high throughput screens 
(Fig. 4.6). However, PANK4 did not appear to co-localize with polyP in either untreated or 
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cisplatin-treated cells, except for a few very bright foci in the nucleolus (Fig. 4.6, arrows). Based 
on these preliminary results, we decide to raise cisplatin concentrations and scrutinize the spatial 
relationship of these two molecules in the follow-up experiments. 
 
Figure 4.6 PANK4 upregulation in cisplatin-treated cells. Colocalization study of polyP and PANK4 was performed in untreated 
HeLa cells (top row) and cells treated with 40 μM cisplatin for 24 h (bottom row). Gray scale images from left to right depict the 
patterns of DNA, polyP (stained with GFP-EcPPXc), and PANK4 (labeled with specific primary and secondary antibodies). PolyP 
(pseudo color: magenta) and PANK4 (pseudo color: cyan) signals are merged to show the partition of the two molecules. Two 
regions (a and b) are enlarged for more details. Representative images of projected z series are shown. Scale bar information is 
shown on the images. 
4.3.5 Validation of PPK candidate genes with individual siGENOME siRNAs 
We also applied our validation strategy for ATP5F1E to the remaining 35 candidates selected from 
the primary screen and retested with the ON-TARGET SMARTpool® siRNAs as described in 
section 4.3.3. Here, we targeted each candidate with four individual siRNAs from the siGENOME 
library and determined how many of them could reduce the polyP accumulation mediated by 
cisplatin. 
Similar to what we observed for ATP5F1E, not every siRNA affected the polyP-related phenotypes 
to the same extent (Fig. 4.7). When we analyzed the proportion of cisplatin responsive cells, we 
classified the 35 candidates into five groups (I to V) based on the number of siRNAs which scored 
below the mean of the entire 18,110 targets in the primary screening, i.e., 140. This analysis put 
RITA1 and KRTAP11-1 at the top of the list with all 4 siRNAs qualified for this criterion (group I). 
The majority of the candidates clustered in groups II and III with one and two siRNA outliers, 
respectively. Both ATP5F1E and PANK4 belonged to this population. For those genes in categories 
 102 
IV and V, it was much more perplexing to interpret the inverse outcomes of the siGENOME 
individual siRNAs and the corresponding siGENOME SMARTpool® form. It was likely that those 
hits suffered from stronger off-target effects and therefore ought to be considered with more 
caution. 
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Figure 4.7 Effects of individual siGENOME siRNAs on the polyP content of selected candidates after cisplatin treatment. 
Each candidate was targeted by four individual siRNAs (#1 to #4) from the siGENOME collection. The scores of cisplatin 
responsiveness are presented in a heatmap. Overall, these candidates can be classified into five groups (I to V) based on the number 
of siRNAs that scored below 140 (the mean value of all the targets from the primary screening). Within each group, hits are ranked 
by the average scores of the four individual siRNAs. 
4.3.6 Potential candidates for genes that downregulate polyP 
Apart from revealing potential human PPK and other genes involved in polyP upregulation, our 
screening also shed light on the mechanisms by which polyP may be downregulated in mammalian 
cells. Focusing on the mCherry-EcPPXc signal in the nucleus, we identified 79 knockdown 
samples which accumulated at least three times as much polyP as the mean of the entire library, or 
nearly five times as much as the non-targeting siRNA control (Table 4.4). Notably, we ranked the 
targets by their scores of nuclear mCherry-EcPPXc fluorescence intensities rather than the scores 
of cisplatin responding cells because the former parameter showed a much wider dynamic range 
for targets with substantially elevated scores (Fig. 4.3, A and B). Nevertheless, we observed an 
average of a 2.2-fold increase in the percentage of cisplatin responsive cells in this subset of 
candidates compared to the non-targeting siRNA control, or a 1.6-fold increase compared to the 
mean of the 18,110 targets in total (Table 4.4). 
Table 4.4 Potential candidates for genes responsible for polyP downregulation 
Rank
n 
Gene 
ID 
Gene 
Symbolo 
Score 
(Nuclear 
mCherry-
EcPPXc 
signal) 
Score 
(% of 
cisplatin 
responsive 
cells) 
Rank Gene ID 
Gene 
Symbol 
Score 
(Nuclear 
mCherry-
EcPPXc 
signal) 
Score 
(% of 
cisplatin 
responsive 
cells) 
1 90231 KIAA2013 840.2 243.5 41 81602 CDADC1 539.4 235.8 
2 2560 GABRB1 788.6 227.3 42 6755 SSTR5 538.4 244.5 
3 53827 FXYD5 763.5 226.1 43 6794 STK11 536.5 221.2 
4 56604 TUBB7P 748.6 191.2 44 344905 ATP13A5 531.7 219.0 
5 79883 PODNL1 722.8 243.8 45 7755 ZNF205 531.2 206.8 
6 491 ATP2B2 718.6 207.1 46 4293 MAP3K9 530.8 220.6 
7 9651 PLCH2 716.8 226.1 47 160857 CCDC122 527.0 224.7 
8 260425 MAGI3 673.6 217.3 48 84445 LZTS2 525.5 232.9 
9 5429 POLH 662.1 180.4 49 1742 DLG4 525.0 248.5 
10 8464 SUPT3H 660.6 184.2 50 3791 KDR 524.2 213.9 
11 6667 SP1 651.9 224.0 51 1118 CHIT1 523.8 239.1 
12 138639 PTPDC1 649.2 226.4 52 26240 FAM50B 522.4 287.6 
13 4908 NTF3 618.4 178.8 53 862 RUNX1T1 522.3 190.6 
14 9928 KIF14 613.8 224.6 54 11113 CIT 521.6 212.1 
15 64419 MTMR14 602.1 222.0 55 5529 PPP2R5E 521.0 219.9 
16 158055 C9orf163 598.2 99.5 56 2203 FBP1 519.9 219.3 
17 11318 GPR182 587.4 246.7 57 10753 CAPN9 519.3 223.4 
18 773 CACNA1A 585.7 232.6 58 1945 EFNA4 519.0 241.6 
19 1198 CLK3 582.5 220.7 59 1340 COX6B1 518.2 201.9 
 
n The candidates are ranked by their scores of nuclear mCherry-EcPPXc fluorescence intensities in an order from high to low. 
o Official NCBI gene symbols are listed in this table for those entries with more than one commonly used gene symbols. 
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Rank
n 
Gene 
ID 
Gene 
Symbolo 
Score 
(Nuclear 
mCherry-
EcPPXc 
signal) 
Score 
(% of 
cisplatin 
responsive 
cells) 
Rank Gene ID 
Gene 
Symbol 
Score 
(Nuclear 
mCherry-
EcPPXc 
signal) 
Score 
(% of 
cisplatin 
responsive 
cells) 
20 1850 DUSP8 577.7 225.8 60 2532 ACKR1 517.7 245.6 
21 843 CASP10 573.5 230.1 61 53 ACP2 513.3 217.6 
22 3631 INPP4A 565.3 223.7 62 1580 CYP4B1 512.5 204.3 
23 5347 PLK1 565.1 175.8 63 1601 DAB2 512.1 216.6 
24 8844 KSR1 564.8 239.6 64 5159 PDGFRB 510.9 211.5 
25 7031 TFF1 561.2 186.3 65 51305 KCNK9 510.7 229.4 
26 165829 GPR156 559.5 226.5 66 95681 CEP41 508.6 166.9 
27 1437 CSF2 556.9 184.2 67 403313 PLPP6 505.0 230.2 
28 4161 MC5R 556.5 250.3 68 23636 NUP62 504.6 199.6 
29 56623 INPP5E 555.5 218.8 69 766 CA7 504.6 220.6 
30 1314 COPA 555.0 211.2 70 1847 DUSP5 503.6 228.9 
31 2268 FGR 553.4 216.7 71 5747 PTK2 502.1 243.4 
32 4356 MPP3 553.3 212.2 72 8031 NCOA4 500.7 203.2 
33 9973 CCS 551.3 210.5 73 6790 AURKA 500.3 207.9 
34 659 BMPR2 548.9 199.8 74 4923 NTSR1 497.5 248.4 
35 4140 MARK3 548.6 230.6 75 10434 LYPLA1 497.1 236.4 
36 5297 PI4KA 547.2 241.2 76 54826 GIN1 495.2 203.3 
37 92370 PXYLP1 546.6 219.7 77 8560 DEGS1 494.4. 204.4 
38 6204 RPS10 544.0 178.3 78 5901 RAN 493.2 238.2 
39 2538 G6PC 543.7 212 79 23414 ZFPM2 492.0 200.8 
40 118471 PRAP1 542.1 196.9      
To further understand the biological meanings behind these candidates, we ran a gene ontology 
enrichment analysis (http://geneontology.org/) to decipher the biological processes that were 
significantly overrepresented by these genes. In the end, we revealed ten such biological processes 
(not including the ones with higher hierarchies in the gene ontology structure; e.g., positive 
regulation of cytokinesis (GO:0032467) is a branch of regulation of cytokinesis (GO:0032465), 
which was also significantly overrepresented but not included in this figure) (Fig. 4.8). Strikingly, 
three biological processes were related to inositol phosphate and phosphatidylinositol. In particular, 
several enzymes directly involved in the phosphorylation and dephosphorylation of the inositol 
moiety were now proposed to negatively influence polyP levels in response to cisplatin. These 
enzymes included 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase eta-2 (PLCH2), 
inositol polyphosphate 4-phosphatase type I A (INPP4A), phosphatidylinositol polyphosphate 5-
phosphatase type IV (INPP5E), and phosphatidylinositol 4-kinase alpha (PI4KA). At this point, 
we cannot rule of the possibility that polyP is a previously uncharacterized substrate of certain 
phosphatidylinositol phosphatases. However, it appears more likely to us that polyP regulation is 
partially entwined with phosphatidylinositol and inositol phosphate metabolism. This notion is 
consistent with previous findings that loss of inositol hexakisphosphate kinase 1 (IP6K1) activity 
in several model organisms, including yeast, Trypanosoma, and mice, led to a 50-100% inhibition 
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of polyP synthesis (120-123). Yet, it is Vtc4 – not Ip6k1 – that catalyzes the polyP elongation 
reaction in the unicellular eukaryotes, and we did not identify IP6K1 as a candidate for human 
PPK genes in our screens either. As for other biological processes, such as the positive regulation 
of cytokinesis and the MAPK cascade, they might be crucial to sensing and signaling cisplatin 
stress, which acts on the upstream of polyP synthesis. 
 
Figure 4.8 Biological processes overrepresented by the potential candidates that downregulate polyP. A PANTHER 
Overrepresentation Test using the GO biological process complete annotation dataset revealed ten biological processes to be 
significantly overrepresented by the 79 candidate genes for polyP downregulation. Fold enrichment of each biological process was 
shown in the graph, and the genes in each category were listed in the corresponding column. 
4.3.7 Potential candidates for the regulation of cisplatin sensitivity in HeLa cells 
In the previous sections, we focused exclusively on the polyP-related phenotypes in the primary 
screen. However, another important aspect of this study concerned the cisplatin sensitivities of the 
18,110 targets. We decided to use cell count as a rough estimation of cisplatin toxicity. For the non-
targeting siRNA control, we observed an 88% cell loss (from 1170.9 cells to 143.8 cells) after 24 
hours of cisplatin treatment. In parallel, the cell numbers of cisplatin-treated knockdown samples 
varied from 0.1 to 799.4 with an average of 146.0 (Fig. 4.3C). This value was almost identical to 
that of the non-targeting siRNA control, which led us to believe that the non-targeting siRNA serve 
as an appropriate reference in this case. 
In the initial experimental setup, we did not determine the cell count or polyP levels before cisplatin 
treatment. Hence, we decided to sort the targets by their absolute cell numbers after cisplatin 
exposure and focused on the 108 targets with 1/30 or fewer cells than the non-targeting siRNA 
control. 
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Table 4.5 Potential candidates for the regulation of cisplatin toxicity 
Rank Gene ID Gene Symbol Cell count Rank Gene ID Gene Symbol Cell count 
1 7884 SLBP 0.1  55 7415 VCP 3.2  
2 5430 POLR2A 0.5  56 1308 COL17A1 3.2  
3 93611 FBXO44 0.5  57 3084 NRG1 3.2  
4 79624 ARMT1 0.7  58 200159 C1orf100 3.2  
5 6651 SON 0.9  59 6272 SORT1 3.3  
6 389118 CDHR4 1.1  60 401665 OR51T1 3.3  
7 2519 FUCA2 1.1  61 7844 RNF103 3.4  
8 10482 NXF1 1.1  62 2567 GABRG3 3.4  
9 7314 UBB 1.2  63 3765 KCNJ9 3.5  
10 1212 CLTB 1.3  64 23263 MCF2L 3.5  
11 84448 ABLIM2 1.3  65 55362 C6ORF110 3.5  
12 5683 PSMA2 1.4  66 336 APOA2 3.5  
13 51676 ASB2 1.4  67 1622 DBI 3.5  
14 157574 FBXO16 1.5  68 7364 UGT2B7 3.5  
15 11269 DDX19 1.6  69 1654 DDX3X 3.5  
16 22974 TPX2 1.6  70 3249 HPN 3.6  
17 80852 GRIP2 1.8  71 9861 PSMD6 3.6  
18 151648 SGO1 1.8  72 91074 ANKRD30A 3.7  
19 255488 IBRDC2 1.8  73 130814 C2ORF22 3.7  
20 342357 ZKSCAN2 1.9  74 64326 COP1 3.7  
21 57621 ZBTB2 1.9  75 160857 CCDC122 3.7  
22 5768 QSOX1 1.9  76 3782 KCNN3 3.9  
23 4605 MYBL2 1.9  77 84304 NUDT22 3.9  
24 10155 TRIM28 2.0  78 9348 NDST3 3.9  
25 2629 GBA 2.1  79 390212 GPR152 3.9  
26 123879 DCUN1D3 2.1  80 5149 PDE6H 3.9  
27 891 CCNB1 2.1  81 9640 ZNF592 3.9  
28 56891 LGALS14 2.2  82 1278 COL1A2 4.1  
29 5435 POLR2F 2.2  83 7515 XRCC1 4.1  
30 4702 NDUFA8 2.2  84 6299 SALL1 4.1  
31 159296 NKX2-3 2.3  85 81853 TMEM14B 4.1  
32 23450 SF3B3 2.3  86 387 RHOA 4.1  
33 3744 KCNA10 2.4  87 9034 CCRL2 4.1  
34 5347 PLK1 2.4  88 139793 PAGE3 4.2  
35 5901 RAN 2.5  89 26539 OR10H1 4.2  
36 30837 SOCS7 2.5  90 5053 PAH 4.3  
37 131669 UROC1 2.5  91 55790 CHGN 4.3  
38 55734 ZFP64 2.5  92 401190 RGS7BP 4.3  
39 3118 HLA-DQA2 2.5  93 8988 HSPB3 4.3  
40 10741 RBBP9 2.5  94 245812 CNPY4 4.4  
41 11073 TOPBP1 2.5  95 7423 VEGFB 4.5  
42 1192 CLIC1 2.6  96 3992 FADS1 4.5  
43 27246 RNF115 2.7  97 374877 TEX45 4.5  
44 11331 PHB2 2.7  98 442867 BPY2B 4.5  
45 3183 HNRPC 2.8  99 2561 GABRB2 4.5  
46 91544 UBXN11 2.8  100 643365 LINC00452 4.5  
47 6693 SPN 2.8  101 5087 PBX1 4.5  
48 10204 NUTF2 2.9  102 2206 MS4A2 4.5  
49 1161 CKN1 2.9  103 79883 PODNL1 4.5  
50 140625 ARPM2 2.9  104 84056 KATNAL1 4.5  
51 158055 C9orf163 2.9  105 1981 EIF4G1 4.6  
52 10720 UGT2B11 3.1  106 7458 WBSCR1 4.7  
53 203076 C8orf74 3.1  107 25832 NBPF14 4.7  
54 57582 KCNT1 3.1 108 147381 CBLN2 4.7 
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Through a gene ontology enrichment analysis, we identified several biological processes to be 
significantly overrepresented by this subset of genes (Fig. 4.9). In particular, we found 
transcription-coupled nucleotide-excision repair, proteasomal ubiquitin-dependent protein 
catabolism, and mitotic cell cycle phase transitions to be highly enriched (>11.5-fold). These 
results were fully consistent with the notion that cisplatin toxicity is largely incurred by DNA 
damage, and that cell survival likely requires a cell cycle arrest for DNA damage repair. In the 
meantime, genes responsible for ubiquitination and proteasomal degradation were also 
significantly overrepresented, which indicates severe protein damage caused by cisplatin. We 
postulate that all these processes have come into play to minimize the detrimental consequences 
of cisplatin on the cells.
 108 
 
Figure 4.9 A gene ontology enrichment analysis of targets involved in the regulation of cisplatin sensitivity. 108 knockdown samples were selected from the primary screen for 
having fewer than 4.8 cells (i.e., 1/30 of the number of cells in the non-targeting siRNA control) after cisplatin treatment. They were subject to a PANTHER Overrepresentation Test 
using the GO biological process complete annotation dataset. Listed here are all the significantly overrepresented categories and their respective fold changes. Terms with the same 
color belong to the same branch of the hierarchical gene ontology structure. Specific genes identified for each category are listed in the designated column.
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4.4 Discussion 
4.4.1 An siRNA screen designed for identifying human PPK genes 
The most important purpose of this study was to identify the potential regulators of polyP levels 
in humans, especially the polyphosphate kinase(s). To achieve this goal, we used an siGENOME 
SMARTpool® siRNA library to target 18,110 mRNAs in the transcriptome of HeLa cells and 
monitored the cisplatin-induced polyP response with mCherry-EcPPXc fluorescence. 
For data analysis, we designed four parameters to describe the phenotypes we observed: 1) 
percentage of cisplatin responsive cells; 2) polyP concentration in the nucleus; 3) polyP 
concentration in the whole cell; and 4) cell count. All the measurements, except cell numbers, were 
normalized on a scale of 0 to 100, defined by the positive control and the negative control, 
respectively. The proportion of cisplatin responsive cells was chosen as the chief parameter for hit 
identification because the widest dynamic range could be attained from this measurement. 
Consistently, calculations of cisplatin responsiveness and nuclear mCherry-EcPPXc fluorescence 
yielded a similar subset of hits (Table 4.1 and Table S4.1). 
After the primary screen, we analyzed the overall distributions of polyP-related phenotypes and 
cell count for all the 18,110 targets (Fig. 4.3). As it turns out, the mean scores of cisplatin 
responsiveness as well as nuclear mCherry-EcPPXc signal for the 18,110 targets exceeded those 
of the non-targeting siRNA control. This observation raised an intriguing possibility that polyP 
levels might increase in response to the execution of RNAi by the RNA-induced silencing complex 
(RISC). At this point, we are unable to establish a direct interaction between polyP and RISC. 
However, there are several mechanisms which might explain our observation. RISC and 
exogenous siRNA oligos are sequestered in the cytoplasmic GW bodies (or processing bodies, P-
bodies), and the structural integrity of GW bodies is an important premise for the efficiency of 
RNAi (217).  GW bodies are formed by phase-phase separation just like the nucleoli. In a previous 
study, we characterized polyP as a nucleolar component, which appeared highly dynamic under 
rRNA synthesis stress (127). Therefore, we wonder whether polyP is also enriched in the GW 
bodies and partakes in RNAi. Alternatively, polyP upregulation might be a general stress response 
to the perturbation of a functional protein by RNAi. After all, polyP is considered as a 
cytoprotective agent under many stressful conditions (1). In either case, a 40% difference in the 
mean polyP content of the knockdown samples and that of the non-targeting siRNA control 
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prompted us to reestablish proper reference values for the polyP-related phenotypes. Notably, this 
adjustment was not necessary for the cell count parameter, suggesting that cisplatin sensitivity was 
not altered by RNAi per se. 
To generate a list of potential candidates for human PPK genes, we set an arbitrary cutoff at the 
score of 30 for the measurement of cisplatin responding cells. When we took into consideration 
the mean score of the whole siRNA library, this criterion only selected those candidates with less 
than 21.4% of the ability to enrich polyP after cisplatin treatment. We were able to identify 405 
hits after screening 201 plates in 23 independent assays. However, only 115 of them were validated 
with the same siRNA and the same experimental setup in an assay combining all the hits together 
(Table 4.1). This outcome informed us of substantial variations from experiment to experiment. 
We would ascribe this result to the random noises of cell conditions, effective cisplatin 
concentrations, transfection efficiencies, and/or immunofluorescence labeling. 
Focusing on the 115 candidates, we evaluated their basal polyP levels and the fold changes of 
nuclear mCherry-EcPPXc signals upon cisplatin treatment (Fig 4.4). Overall, these candidates had 
28.3% less polyP than the non-targeting siRNA control under normal growth condition (Fig. 4.4A). 
Due to the limitation of our experimental setup, we could not calculate the mean score of basal 
polyP levels for all the targets involved in the primary screening. Hence, we could not estimate the 
relative change of this parameter for the 115 candidates against the entire library. Still, our results 
supported a role of the corresponding genes in making ample polyP to sustain the most 
fundamental cellular activities. Furthermore, this subset of candidates also exhibited a reduced fold 
increase in the mCherry-EcPPXc fluorescence intensity following cisplatin supplement (Fig. 4.4B). 
The ratiometric measurement of polyP signals with and without cisplatin seemed to be dominated 
by the post-cisplatin measurements. This might be due to an individualized response of each 
knockdown sample to cisplatin, which greatly expanded the dynamic range of this parameter. In 
summary, analyses of basal polyP levels as well as the amplitude of cisplatin-mediated polyP 
response confirmed a severe impairment of polyP regulation in this subset of candidates. 
4.4.2 Validation of the potential candidates for human PPK genes 
RNAi remains a powerful tool to study gene expression, yet, its outcome is often confounded by 
inadvertent off-target effects. Therefore, we decided to further scrutinize our candidates with 1) 
ON-TARGETplus SMARTpool® siRNAs and 2) individual siRNAs derived from the siGENOME 
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SMARTpool® library. The former aimed at discriminating the on-target and off-target effects by 
modifying siRNA sequences, while the latter took advantage of numbers to tell the major (on-
target) and minor (off-target) effects apart. 
The results of the validation screens were quite perplexing. First and foremost, we could not 
reproduce the > 70% reduction of cisplatin responding cells for any of the 36 targets tested in a 
pioneer study using ON-TARGETplus SMARTpool® siRNAs (Table 4.2). This issue was not due 
to insufficient knockdown efficiencies (Fig. S4.1) or systematic errors between the siGENOME 
and ON-TARGETplus libraries (Fig. 4.5, ATP5F1E siRNA #1 and #20). In the worst-case scenario, 
this meant a 100% false positive rate for this subset of hits, raising doubts about the validity of the 
primary screen. However, it is also possible that the combinatory effect of ON-TARGETplus 
SMARTpool® siRNAs might be skewed by a few individual components with very potent 
phenotypes. At a minimum, this was the case for ATP5F1E, where a single siRNA (#18) with a 
surge of polyP dominated all three others with varying degrees of polyP reduction (in relative to 
the mean score of the 18,110 targets) (Fig. 4.5). We are fully aware that these results are inadequate 
to verify the role of ATP5F1E in polyP synthesis. Still, it encourages us to follow up on a few top 
hits in this pioneer study and determine the consequence of knocking down the corresponding 
genes with individual ON-TARGETplus siRNAs. 
Along the same line, we compared individual siRNAs from the siGENOME library to their 
corresponding SMARTpool® formats. Again, using the average score of the whole population as a 
reference, we classified the majority of the 36 candidates into groups with two, three, and four 
individual siRNAs qualified for a polyP reduction (Fig. 4.7). Assuming that the majority of 
individual siRNAs were guided to their specific mRNA targets, and that mistargeting events were 
only sporadic, our results tend to suggest that many of these genes are promising candidates for 
the upregulation of polyP in mammalian cells. 
4.4.3 Evaluation of the candidates for human PPK genes 
To prioritize the most promising candidates, we considered the three types of screens that we 
conducted for the subset of 36 targets: 1) a genome-wide screen with siGENOME SMARTpool® 
siRNAs and a validation screen with the same reagent; 2) a validation screen with ON-
TARGETplus SMARTpool® siRNAs; and 3) a validation screen with individual siGENOME 
siRNAs. The rankings of the hits differed, sometimes dramatically, from one screen to another 
 112 
(Table 4.1, Table 4.2, Fig. 4.7), and it was not trivial to weigh the reliability of each approach given 
their respective strengths and drawbacks. 
Yet, simply considering all the screens equally, we noticed GRIN3B at the top of each list. This 
gene encodes GluN3B, a subunit of the unconventional N-methyl-D-aspartate (NMDA) type 
glutamate receptor, which can be excited by glycine alone and is relatively impermeable to Ca2+ 
(218). The spatial and temporal expression patters of this protein have been characterized in the 
brain, and its malfunction is a risk factor for schizophrenia (218-221). Intriguingly, polyP has been 
shown to modulate NMDA receptors, presumably those with low Ca2+ permeability in the dentate 
gyrus of the hippocampus (222). This finding now creates a biologically relevant context for our 
hypothesis that GluN3B might in turn control polyP metabolism in a yet unknown manner. 
Furthermore, our discovery reminded us of a dormant notion in the field that “because polyP 
synthesis from Pi in the medium bypasses intracellular Pi and ATP pools, a direct involvement of 
energy sources in cell membranes…should be considered” (202). Given our limited understanding 
of GluN3B and polyP, we cannot conceive a model of polyP synthesis by GluN3B directly. 
However, this protein indicates the potential importance of plasma membrane proteins in the 
regulation and/or synthesis of polyP. 
Apart from referencing the hit rankings, we also conducted extensive literature searches to seek 
polyP-related information for the hits. Indeed, we were able to establish at least tangential 
connections between polyP and a handful of candidates. Such examples included P2RY1, which 
encodes the best characterized polyP receptor in the astrocytes and endothelial cells (42,77), and 
P2RY6, which belongs to the same family of purinergic receptors. In fact, much of polyP’s 
signaling properties depend on P2Y1. Either a genetic or a pharmaceutic perturbation of this 
receptor dampens polyP-mediated signaling cascades (42,77,222). Notably, P2Y1 underpins the 
cytoprotective function of polyP against mitochondrial membrane depolarization incurred by an 
overflow of glutamate in the cortical neurons (222). Therefore, a connection between GRIN3B and 
P2RY1 appears likely. Another intriguing candidate, AP3M1 (ranked 70th in the primary screen) 
encodes the mu-1 subunit of the adaptor-related protein complex 3 (AP-3). Previous studies in 
Trypanosoma and Leishmania have established the critical importance of the AP-3 complex in the 
enrichment of polyP in the acidocalcisomes, presumably by overseeing the protein trafficking to 
this organelle (223,224). Genetic mutations in several subunits of the AP-3 complex lead to 
Hermansky-Pudlak syndrome (225,226) in humans, a rare disease associated with the lack of 
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platelet dense granules – the most prominent intracellular polyP storage. These findings suggest 
that AP3M1 might be a novel member of the acidocalcisome-related polyP machinery. 
From the perspective of polyP synthesis, we were most excited about identifying ATP5F1E, which 
encodes the ε subunit of mitochondrial FoF1-ATPase. This small protein (7 kDa) in the central stalk 
of the F1 catalytic domain has no structural equivalent in the bacterial or chloroplast ATP synthases 
(215). Moreover, previous studies recording polyP-DAPI fluorescence in either intact cells or 
isolated mitochondria have alluded to a causal relation between the activity of FoF1-ATPase and 
the concentration of mitochondrial polyP (115,116). Joint together, these findings created a perfect 
niche for our hypothesis that the ε subunit adapts the mitochondrial FoF1-ATPase into a dual 
functional engine for both ATP and polyP synthesis. As a consequence, we performed the most 
extensive validation experiments for this candidate. To summarize, we were able to achieve 
varying degrees of polyP depletion by targeting this gene with four out of seven uniquely designed 
siRNAs (with #1 and #20 sharing the same sequence) (Fig. 4.5). And the outcomes of the 
siGENOME SMARTpool® and the ON-TARGETplus SMARTpool® collections hinged on their 
respective siRNA compositions (Fig. 4.5). Contrary to our expectation, we were unable to conclude 
that ATP5F1E is a true candidate for human PPK genes. But we will now attempt to recapitulate 
the phenotype of ATP5F1E knockdown with a complete gene knockout. 
Prompted by the notion that ATP is the universal substrate for all polyP synthesizing machineries 
known to date, we paid attention to another candidate, PANK4, which encodes the only kinase on 
the list. PANK4 appealed to us for several reasons. Primarily, both PANK4 and polyP were 
upregulated by a low dose of cisplatin (40 μM) (Fig. 4.6), and PANK4 knockdown obstructed polyP 
accumulation in cisplatin-treated cells. Moreover, this protein harbors a kinase domain and a 
phosphatase domain whose enzymatic activities remain yet uncharacterized. For follow-up 
experiments, we will test a higher dose of cisplatin for recruiting PANK4 and polyP to colocalize 
in the same hotspots, and we will corroborate the phenotype of PANK4 knockdown cells with either 
an siRNA-resistant PANK4 variant or a PANK4 knockout model. Even in the worst-case scenario 
that PANK4 and polyP are completely irrelevant, our discovery that PANK4 is part of the cisplatin 
response might still shed light on the function of this protein. 
Our experimental design does not allow us to distinguish polyP synthesizing machines from 
cisplatin sensors. Instead, any impairment in the transmission of cisplatin signal from outside the 
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cell to the PPK enzyme will manifest a similar phenotype as an impairment in the enzyme itself. 
For example, one of the top hits, tumor susceptibility gene 101 (TSG101) encodes a component of 
the endosomal sorting complexes required for transport-I (ESCRT-I) machinery. While this protein 
is largely recognized for multivesicular body formation, membrane abscission, and budding of 
viral particles (227), it is also proclaimed to be an essential gene for cell proliferation and 
prognostic marker for certain types of cancers (228). Other candidates, such as MAPK14, P53AIP1, 
MT1G might also be more closely related to cisplatin rather than polyP (Table 4.1). 
4.4.4 Potential candidates for the downregulation of polyP 
Conceivably, not only polyP synthesis but also polyP degradation is critical to maintaining the 
homeostasis of such an energetic and multifunctional polymer. Therefore, we also focused on 
genes whose knockdowns led to an enormous accumulation of polyP in cisplatin-treated cells. As 
it turns out, 79 candidates had more than three times the mean polyP level of the whole library or 
five times the value of the non-targeting siRNA control (Table 4.4). Many of them participated in 
distinct biological processes revealed by gene ontology enrichment analysis (Fig. 4.8). Three out 
of ten such biological processes raised our attention: 1) inositol phosphate metabolism (with a 17-
fold enrichment); 2) positive regulation of phosphatidylinositol 3-kinase signaling (with a 14-fold 
enrichment); and 3) phosphatidylinositol metabolism (with a more than 8-fold enrichment). In our 
opinion, these results strongly suggest the roles of inositol phosphates in controlling polyP 
production and/or utilization. In fact, IP6K1, which catalyzes the formation of highly 
phosphorylated inositol phosphate species (including IP7 and IP8) from IP6, has been found to 
maintain the steady-state polyP levels in yeast, Trypanosoma, and mice (120-123). In yeast cells, 
IP6, IP7, and IP8 are novel binding partners of the SPX domain of Vtc4 (124,125), the bona fide 
polyP synthesizing machinery. Association of inositol phosphates with the SPX domain enhances 
Vtc4 enzymatic activity, with IP8 and IP7 being significantly more potent than IP6. Therefore, this 
model explains how IP6K1 might influence intracellular polyP concentrations without mediating 
polyP elongation per se. Given that no VTC4 homologue exists in the mouse genome, it is 
intriguing how IP6K1 could elicit a similar effect on polyP production in vertebrates. It is tempting 
to speculate that mammalian PPK enzyme(s) might also harbor an inositol phosphate-sensitive 
domain which confer the regulatory effects of different inositol phosphate species. Along the same 
line, we propose that several candidates for the downregulation of polyP, such as PLCH2, INPP4A 
and INPP5E, might not catalyze the depolymerization of polyP chains, but rather modify the 
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cellular inositol phosphate levels and compositions, which causes an alteration of polyP abundance 
in the cell. 
4.4.5 Potential mechanisms for the regulation of cisplatin sensitivity 
Since our screens exploited the power of cisplatin to mobilize polyP, we also expected to find 
genes responsible for sensing and combatting cisplatin stress. Here, we utilized the number of 
remaining cells after drug treatment (and immunofluorescence labeling) as a rough estimation of 
cisplatin resistance. Certainly, this parameter was oversimplified in more than one aspect. In 
essence, it measured the combined cytotoxicity of abnormal gene expression (as a result of RNAi) 
and cisplatin-related cellular damages. This factor became important for those genes either 
beneficial or harmful to cell growth and proliferation. Moreover, we could not ascertain the fate of 
the remaining cells without a sophisticated analysis of different cell death markers. It was 
inconceivable that any cells could have survived such a high dose of cisplatin (0.4 mM) for 24 h. 
However, different samples might have followed different cell death pathways, leaving the 
remaining cells in a broad spectrum of different numbers and morphologies. 
Taking into consideration the abovementioned caveats, we decided to focus on the targets with the 
least number of cells, namely fewer than 4.8 (or 1/30 of the number for the non-targeting siRNA 
control). This criterion yielded 108 candidates (Table 4.5) with a clear pattern of gene ontology 
enrichment (Fig. 4.9). 
The transcription-associated nucleotide excision repair mechanism (represented by POLR2A, UBB, 
POLR2F, CKN1, and XRCC1) was most overrepresented due to the formation of DNA-cisplatin 
adducts. It is conceivable that cells become sensitized to cisplatin when DNA damages remain 
unrepaired. This result also inferred that DNA remains the most vulnerable target when the drug 
was administered at high concentrations. Meanwhile, it was also likely that deletion of POLR2A 
and POLR2F may disrupt cellular homeostasis independently of cisplatin. The former gene 
encodes RPB1, the largest subunit of RNA polymerase II (Pol II), and the latter encodes RPABC2, 
a universal component of Pol I, Pol II, and Pol III. Hence, POLR2A and POLR2F knockdowns 
might alter the gene expression landscape of the cell, and it is crucial to determine the toxicity of 
this aspect alone. In a highly speculative way, this finding also reminded us of our previous finding 
on polyP and Pol I during cisplatin-mediated apoptosis (127). Given that polyP and Pol I are 
sequestered in the vicinity of each other under cisplatin stress, it is intriguing whether a similar 
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spatial (and maybe functional) relation exists among polyP and other RNA polymerases. After all, 
polyP and bacterial RNA polymerase are binding partners of each other (32). 
Another distinct biological process overrepresented by this subset of genes was the positive 
regulation of proteasomal ubiquitin-dependent protein catabolism. As part of the protein quality 
control network, the ubiquitin-proteasome system mitigates the burden of misfolded proteins by 
rapidly decomposing its substrates with the energy of ATP. Interestingly, the expression of 
proteasome subunits is stimulated by cisplatin, possibly to compensate for the inhibition of 
proteasomal activities by the same drug (229,230). In fact, synergistic effects of cisplatin and 
proteasome inhibitors have been observed in HeLa cells and bladder cancer cells, where these 
drugs amplify apoptotic signals by altering the concentrations of pro- and anti-apoptotic proteins 
(231,232). These findings support our observation that proteasomal perturbation by RNAi renders 
HeLa cells more susceptible to cisplatin. And we believe that our screens have likely provided 
valuable targets for understanding as well as optimizing the current platinum-based cancer 
therapies. 
As expected, cell cycle progression was another prominent biological process overrepresented by 
this subset of candidates. We attributed this phenomenon to the overwhelming DNA damages 
which likely activated the corresponding cell cycle checkpoints. 
In summary, although our approach to estimate cisplatin resistance by the number of remaining 
cells was far from perfect, it shed light on the mechanisms of cisplatin toxicity with coherent 
evidence from the literature. For those hits of interest, we strongly suggest reassessing their 
cisplatin sensitivities by detecting classic cell death markers before and after cisplatin treatment. 
Then, either a genetic or a pharmaceutical intervention of the selected gene can be tested for 
triggering cancer cell death synergistically with cisplatin. Furthermore, encouraged by our findings 
on the potential sensitizers of cisplatin toxicity, we are now confident to explore the other extreme 
– knockdown samples conferring remarkable cisplatin resistance. We believe that these endeavors 
are equally important to our study as finding the human polyP regulators. 
4.5 Outlook  
In this study, we completed a genome-wide siRNA screen for polyP regulatory genes in humans. 
After a pioneer validation experiment, we sorted out a few candidates of interest: GRIN3B, P2RY1, 
ATP5F1E, PANK4, and AP3M1 for upregulating polyP levels. Meanwhile, we proposed a tight 
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connection between inositol phosphate metabolism and polyP regulation. In the follow-up 
experiments, we plan to use CRISPR to genetically manipulate these genes of interest and 
reexamine their cisplatin-induced polyP accumulation phenotypes. We believe that this work is of 
great importance because the discovery of genuine polyP regulators in humans will create 
unprecedented opportunities for characterizing the physiological functions of this polymer. 
In parallel, we appreciated the potential of our screens to uncover the intracellular targets and 
effectors of cisplatin. Focusing on the cisplatin sensitizers, we identified a list of knockdown 
samples involved in nucleotide excision repair, the ubiquitin-proteasome system, and cell cycle 
progression. Since the current platinum-based chemotherapies are challenged by two outstanding 
problems: side effects and drug resistance, it might be fruitful to explore the synergistic effects of 
cisplatin and a cellular target to trigger cancer cell death more effectively. 
4.6 Supplemental information 
Supplementary Table 4.1 Candidates for genes upregulating polyP levels based on the average fluorescence intensities of 
mCherry-EcPPXc in the nucleus 
Ranka Gene ID Gene symbolb 
Score 
(mCherry-EcPPXc fluorescence 
intensity in the nucleus) 
Score 
(Percentage of cisplatin 
responsive cells) 
Mean SD Mean SD 
1 7884 SLBP -43.43 35.38 17.67 24.84 
2 50508 NOX3 -9.20 3.02 20.63 3.22 
3 90187 EMILIN3 -2.03 2.10 7.63 0.82 
4 1233c CCR4 1.70 14.12 31.57 4.59 
5 51700 CYB5R2 1.87 9.76 21.03 3.07 
6 9344 TAOK2 3.77 19.49 17.77 7.41 
7 29952 DPP7 3.80 2.86 3.60 0.28 
8 10215 OLIG2 4.80 15.61 20.97 10.67 
9 6358 CCL14 6.83 4.24 13.67 1.37 
10 146540 ZNF785 8.27 4.22 1.07 0.19 
11 3052 HCCS 8.90 1.70 6.37 1.88 
12 1432 MAPK14 9.27 7.72 4.90 3.21 
13 55561 CDC42BPG 9.30 9.84 39.00 6.19 
14 8569 MKNK1 10.03 9.23 15.87 6.49 
15 5031 P2RY6 10.57 12.74 2.47 2.87 
16 2296 FOXC1 11.67 2.82 5.30 2.08 
17 646 BNC1 11.77 10.36 6.23 2.15 
18 8452 CUL3 12.03 4.15 3.43 0.56 
19 116444 GRIN3B 13.03 3.52 0.97 0.46 
20 2016 EMX1 13.80 37.76 15.03 6.14 
21 5188 GATB 13.90 14.37 12.00 12.16 
22 10941 UGT2A1 14.30 3.42 5.93 3.09 
 
a Candidates are ranked based on the score of mCherry-EcPPXc fluorescence intensity in the nucleus. 
b Official NCBI gene symbols are listed in this table for those entries with more than one commonly used gene symbols 
c Entries shadowed in gray are assigned as candidates based on their average mCherry-EcPPXc fluorescence intensities in the 
nuclei but not the percentage of cisplatin responding cells. 
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Ranka Gene ID Gene symbolb 
Score 
(mCherry-EcPPXc fluorescence 
intensity in the nucleus) 
Score 
(Percentage of cisplatin 
responsive cells) 
Mean SD Mean SD 
23 9655 SOCS5 14.43 3.29 5.13 3.08 
24 3617 IMPG1 15.27 1.39 3.67 1.27 
25 22998 LIMCH1 15.40 7.38 5.33 1.87 
26 79796 ALG9 15.50 1.53 9.43 6.18 
27 7251 TSG101 16.03 6.17 13.53 0.82 
28 9140 ATG12 16.67 4.65 18.27 4.37 
29 25819 NOCT 17.13 3.95 3.97 1.33 
30 100506658d OCLN 17.47 9.52 23.73 6.74 
31 378832 COL18A1-AS1 18.23 16.31 20.70 5.20 
32 337880 KRTAP11-1 18.37 2.22 12.20 1.77 
33 7067 THRA 18.53 2.58 2.90 1.92 
34 3761 KCNJ4 20.10 2.70 3.33 0.39 
35 84844 PHF5A 20.20 6.93 12.77 5.92 
36 9480 ONECUT2 20.33 0.94 2.70 1.31 
37 2515 ADAM2 20.40 3.40 9.27 2.11 
38 27199 OXGR1 20.67 3.40 14.63 1.16 
39 56140 PCDHA8 20.70 2.50 7.97 0.74 
40 57639 CCDC146 22.00 2.41 3.43 1.04 
41 1743 DLST 22.43 3.07 2.17 0.78 
42 55806 HR 22.80 4.92 11.37 1.76 
43 8851 CDK5R1 22.90 17.26 7.17 1.07 
44 2302 FOXJ1 23.10 1.31 9.10 1.82 
45 3479 IGF1 23.30 2.46 7.20 4.63 
46 157574 FBXO16 23.37 21.00 49.33 20.02 
47 11185 INMT 23.43 3.48 4.33 1.39 
48 120 ADD3 23.63 3.03 4.73 3.82 
49 8883 NAE1 24.00 2.78 17.37 3.11 
50 9361 LONP1 24.60 3.76 6.97 3.07 
51 153579 BTNL9 24.83 3.58 16.50 4.73 
52 3249 HPN 25.00 18.08 11.67 9.59 
53 11094 CACFD1 25.00 3.47 11.80 3.37 
54 54708 MARCHF5 25.03 4.29 8.17 5.76 
55 1660 DHX9 25.20 3.98 18.07 5.38 
56 6757 SSX2 25.30 2.57 10.10 2.12 
57 81603 TRIM8 25.37 8.10 25.53 4.72 
58 11216 AKAP10 25.67 7.55 50.43 7.86 
59 85316 BAGE5 26.43 1.82 7.37 0.17 
60 54496 PRMT7 26.57 4.11 6.50 4.82 
61 5158 PDE6B 26.77 5.20 7.07 2.28 
62 7743 ZNF189 26.93 2.60 16.23 1.35 
63 222546 RFX6 27.07 3.36 20.17 6.50 
64 23492 CBX7 27.30 9.18 55..30 24.39 
65 4825 NKX6-1 27.43 2.71 15.33 1.73 
66 2862 MLNR 27.73 1.05 34.90 1.43 
67 339345 NANOS2 27.77 4.64 13.50 2.99 
68 151306 GPBAR1 28.13 12.21 24.37 8.78 
69 4879 NPPB 28.27 8.68 29.97 1.23 
70 3748 KCNC3 28.43 2.53 9.23 2.95 
71 7706 TRIM25 28.53 2.29 10.63 3.84 
72 1024 CDK8 28.60 12.14 26.70 3.14 
73 2564 GABRE 28.60 2.30 14.73 3.09 
74 56891 LGALS14 28.87 18.57 26.83 25.14 
 
d This entry is the replacement of OCLN (Gene ID: 4950) according to NCBI. 
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Ranka Gene ID Gene symbolb 
Score 
(mCherry-EcPPXc fluorescence 
intensity in the nucleus) 
Score 
(Percentage of cisplatin 
responsive cells) 
Mean SD Mean SD 
75 91683 SYT12 28.97 1.44 5.53 1.30 
76 84073 MYCBPAP 29.00 3.51 15.47 0.94 
77 115708 TRMT61A 30.07 5.12 21.60 0.73 
78 64780 MICAL1 30.43 11.31 19.33 1.44 
79 201255 LRRC45 30.53 1.96 163.33 7.36 
80 133482 SLCO6A1 30.57 5.47 7.00 2.63 
81 2810 SFN 30.67 2.66 2.23 0.74 
82 84934 RITA1 30.77 2.35 5.30 0.86 
83 285527 FRYL 31.17 4.91 11.07 5.86 
84 390598 SKOR1 31.67 8.49 130.23 4.11 
85 81622 UNC93B1 31.70 11.03 22.93 3.50 
86 5973 RENBP 31.87 14.87 16.43 10.15 
87 6001 RGS10 32.53 4.46 15.83 6.80 
88 154881 KCTD7 32.67 5.38 12.10 2.45 
89 114789 SLC25A25 33.20 24.78 39.73 21.74 
90 159296 NKX2-3 33.60 25.10 69.07 36.39 
91 8520 HAT1 35.53 15.05 37.00 8.77 
92 1612 DAPK1 36.23 51.09 24.90 7.86 
93 5683 PSMA2 38.73 104.14 46.07 52.86 
94 123879 DCUN1D3 40.73 28.97 48.33 17.35 
95 3705 ITPK1 41.40 56.80 94.33 22.08 
96 143471 PSMA8 53.10 42.36 14.97 6.34 
97 472 ATM 59.00 57.81 26.93 6.66 
98 389118 CDHR4 64.40 75.12 77.43 58.67 
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Supplementary Figure 4.1 Assessment of the knockdown efficiencies of siGENOME and ON-TARGETplus SMARTpool® 
siRNAs by qRT-PCR and Western blotting analyses. (A) A dose-dependent reduction of GAPDH protein levels in HeLa cells 
was caused by reverse transfection with 15 and 30 nM GAPDH specific siRNAs but not the non-targeting siRNAs from the 
siGENOME SMARTpool® library. Results from three biological replicates (separated by blue dashed lines) are shown. The top 
panel is an overlay of the chemiluminescence signals of GAPDH antibodies and the colorimetric signals of the protein ladder. 
GAPDH has a molecular weight of 36 kDa. The bottom panel is a visualization of the enhanced tryptophan fluorescence of the 
total cell lysate. (B) Quantitation of ATP5F1E mRNA levels by qRT-PCR reported a knockdown efficiency of 99.4% and 97.2% 
for ATP5F1E specific siRNAs from the ON-TARGETplus and the siGENOME SMARTpool® libraries, respectively. In contrast, 
siRNAs designated for the ATP5PB gene which encodes subunit b of the FoF1-ATPase slightly increased the expression level of 
ATP5F1E. All the measurements were normalized to the ATP5F1E mRNA concentrations in cells treated with non-targeting siRNA. 
Statistical analysis of four biological replicates was performed using repeated-measures one-way ANOVA and Sidak’s multiple 
comparisons test, which rendered the differences between the two types of ATP5F1E siRNAs not significant. (C) An efficient 
knockdown of the mitochondrial ATP synthase ε subunit was achieved by siGENOME and ON-TARGETplus SMARTpool® 
siRNAs targeting the ATP5F1E gene. Non-targeting siRNAs and ATP5PB siRNAs retained and slightly increased the expression 
levels of the ε subunit, respectively. These observations are consistent among three biological replicates. The ε subunit (7 kDa) and 
GAPDH (36 kDa) were detected with designated primary antibodies and secondary antibodies conjugated with IRDye® 680LT (for 
the ε subunit) and IRDye® 800CW (for GAPDH). GAPDH served as a loading control. 
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